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SUMMARY
The circadian variation in 5-hydroxytryptamine (5-HT) concentrations in brain 
tissue appear to result from circadian rhythms in both synthesis and release of the 
transmitter. The release of 5-HT is affected by many factors, including the activity of the 
terminal 5-HT autoreceptor which, in the rat brain, corresponds to the 5-HT.jg binding 
site. The results presented in this thesis show that this terminal 5-HT autoreceptor in the 
rat cerebral cortex and hippocampus does not display a circadian variation in its 
sensitivity. In the guinea-pig brain, the terminal 5-HT autoreceptor corresponds to the 5- 
HT.jp binding site. This receptor was also devoid of any circadian variation in its 
sensitivity.
The release of 5-HT can be modulated by the a/p/^-adrenoceptor located on 5-HT 
nerve terminals. The sensitivity of this receptor, when examined over 24-hours, did not 
reveal any significant circadian variation.
The somadendritic 5 -H T ^  autoreceptor modulates the firing rate of 5-HT neurones 
and, consequently, the synthesis and the release of 5-HT in terminal-containing regions. 
The ability of this receptor to regulate 5-HT synthesis, when examined at mid-light and at 
mid-dark, did not display any differences in sensitivity.
Radio-ligand binding studies in the cerebral cortex did not reveal any significant 
circadian variation in either the total number of binding sites or the affinity of [^H]5-HT 
binding to the 5-HT.j binding site. Competition studies, using 8 -OH-DPAT, suggest that the 
number of 5 -H T ^  binding sites, corresponding to a postsynaptic receptor in this region, is 
unchanged during the light : dark cycle. Examination of [3 H]ketanserin binding to the 5- 
HT2  binding site in the rat frontal cortex, at mid-light and mid-dark, did not reveal any 
significant differences.
It is concluded that the circadian variation in the release of 5-HT is not the result of 
a corresponding rhythm in the sensitivity of the terminal or the somadendritic 5-HT 
autoreceptor, but rather that they would be susceptible to, and capable of passing on, any 
circadian rhythm in the level of stimulus applied to them.
INTRODUCTION
1 INTRODUCTION
5-hydroxytryptamine (5-HT, serotonin) is a neurotransmitter in the central 
nervous system (CNS). Many aspects of its physiology vary over 24 hours. For 
example, a marked circadian variation in 5-HT concentrations is reported in several 
regions of the rat brain, values being higher during the light phase. In contrast, the 
synthesis and release of 5-HT are greater during the dark phase. Several studies have 
been carried out to identify the cause of this variation, which is discussed in the following 
sections, however, the sensitivity of the terminal- or the somadendritic-5-HT 
autoreceptor has not been investigated over 24 hours, these receptors are in a prominent 
position for regulating the activity of 5-HT neurones. In addition, receptors for other 
neurotransmitters have been identified on 5-HT nerve terminals, these receptors are 
capable of regulating the release of 5-HT. An example of such a receptor is the alpha2 - 
adrenoceptor, its sensitivity was also measured over 24 hours. In this way it is hoped to 
obtain some understanding of the contribution of these receptors, to the rhythm in the 
release and synthesis of 5-HT.
Radio-ligand binding studies were also performed during the light : dark cycle, to 
Investigate for circadian changes in the affinity or the number of 5-HT-j and 5 -HT2  binding 
sites.
It is the purpose of this introduction to give readers sufficient background in the 
published work in these areas, and thus allow them to evaluate the data presented in this 
thesis and the conclusions drawn from them.
1.1 CIRCADIAN RHYTHMS
The yearly rotation of the earth around the sun is responsible for the changes in 
seasons. Similarly, its rotation on its axis once every 24 hours determines the day-night 
cycle to which we are all exposed. Animals and plants have evolved over millions of years 
using these rhythms to regulate aspects of their physiology, biochemistry and behaviour, 
with periods ranging from milliseconds to several years.
Rhythms which approximate to a period of 24 hours are termed "circadian", in 
addition to these a variety of other rhythms exist. Rhythms with periods of less than 24 
hours are termed ultradian {e.g. electrical activity in the brain), while those with periods 
much greater than 24 hours are termed infradian (e.g. the menstrual cycle), and those 
with periods of about one year are termed circannual (e.g. hibernation). It is not known 
whether all these rhythms are driven by the same oscillator as circadian rhythms.
This section is a brief introduction to circadian rhythms and their characteristics, 
and the reader is referred to comprehensive reviews elsewhere (Rusak and Zucker, 1979 ; 
Meijer and Reitveld, 1989).
1.1.1  Characteristics of circadian rhvthms
Rhythms function to enable plants and animals to anticipate future events. A 
circadian rhythm (from the latin : circa *= about ; diem *  day) has been defined as "an 
oscillation in a biochemical, physiological or behavioural function which under conditions in 
nature has a period of exactly 24 hours, in phase with the environmental light and 
darkness, but which continues to oscillate under constant but permissive conditions of light 
and temperature, with a period of approximately but usually not exactly 24 hours" 
(Sweeney, 1975). The ability of circadian rhythms to persist under constant conditions, 
Le. to free-run, suggests that they are endogenously generated. These rhythms are in no 
way fixed, but responsive to alterations of their time cues, resulting in phase shifts. 
Consequently, they will synchronise, or entrain, to an external time cue, so long as the
„  1 f,-', '-A \
period of the cue is close to 24 hours (Aschoff, 1978).
For animals, the natural environment provides a multitude of time cues which
function to synchronise rhythms. However, in the laboratory where the majority of time 
cues can be controlled, the light-dark cycle is considered to be the most important 
(Pittendrigh, 1981).
Ostensibly therefore, circadian rhythms are a feature of the adaptation of an 
organism to its environment. They function as homeostatic regulators of internal events 
and also extrinsic behaviours. They enable organisms to anticipate with some certainty 
recurring events and thus adapt appropriately.
1 . 1 . 2  Neural control of circadian rhvthms
In mammals, the location of the endogenous rhythm generator remained largely 
hypothetical until 1967 when, using lesioning techniques, Richter (1967) discovered that 
localized lesions of the ventral hypothalamus caused the complete loss of free-running 
circadian rhythmicity. The precise area of the hypothalamus remained unknown for 
another 5 years, when further lesioning studies identified a structure in the anterior 
hypothalamus which was essential for circadian rhythmicity of adrenal corticosterone 
secretion (Moore and Eichler, 1972) and of drinking and locomotor activity (Stephan and 
Zucker, 1972).
The ability of the endogenous rhythm generator to be entrained by an external 
light-dark cycle suggested the existence of a neural connection between this generator and 
optic pathways of the retina. However, lesioning of the primary and accessory optic 
pathways (Chase et al. 1969 ; Moore and Eichler, 1972 ; Stephan and Zucker, 1972) failed 
to abolish entrapment, but it did lead investigators to the suprachiasmatic nuclei (SCN) of 
the hypothalamus. Subsequent autoradiographic studies in search of a neural connection 
revealed a direct bilateral neural pathway originating in the retina and terminating in the 
SCN (Hendrickson et al., 1972). This pathway was named the retinohypothaiamic tract 
(RHT). A second visual pathway is now known to link the retina to the SCN. This pathway 
is an indirect one, first supplying the ventral lateral geniculate nuclei (vLGN) and the 
intergeniculate leaflet (IGL), which subsequently send axons to the SCN (Swanson et al., 
1974 ; Pickard, 1985). This projection is called the geniculohypothalamic tract (GHT). 
Further experiments have shown the SCN to drive a great number of circadian rhythms in
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rodents, i.e. sleep-wake cycle, locomotor activity, food intake, water intake, body 
temperature, adrenal corticosterone secretion and the rhythm in pineal melatonin (Rusak 
and Zucker, 1979 ; Moore and Eichler, 1972 ; Stephan and Zucker, 1972 ; Rosenwasser and 
Adler, 1986).
Transplantation studies of the SCN have reported the period of the circadian cycle 
of transplanted grafts to be maintained (Ralph et al., 1990), thus conclusively proving 
that the SCN functions as a pacemaker and not just as a relay station or an oscillator. This 
finding is supported by the ability of surgically isolated SCN to retain electrical activity, 
while their removal abolished various circadian rhythms in rodents (Rusak and Zucker, 
1979).
The SCN while functioning as the primary pacemaker is not the only rhythm 
generator in the central nervous system. Prolonged exposure to constant conditions or the 
bilateral lesioning of the SCN can induce a dissociation of free-running rhythms into two 
components. This phenomenon is known as "internal desynchronization" or "splitting". 
Examples of such phenomena include the bilateral lesioning of the SCN in the squirrel 
monkey which resulted in a loss of the circadian drinking rhythm but not the circadian body 
temperature rhythm (Fuller et al., 1981). Similarly, humans in isolation, under constant 
conditions, have shown their free-running rhythms to split into two components, one group 
coupled to the sleep-wake cycle, and the other to the core body temperature (Aschoff, 
1965 ; Wever, 1979 ; Czeisler et al., 1980). Splitting is considered to expose two 
underlying circadian oscillators which have become out of phase with each other. The 
location of these secondary oscillators and their respective properties remain to be 
determined.
While secondary oscillators are observed during splitting, it is likely that they are 
not autonomous. Their innate rhythms are considered to be damped so that they may be 
driven by the primary pacemaker of the SCN (Turek, 1985).
1 . 1 . 3  Organization of the circadian pacemaker
The SCN receive two neural inputs from the retina, as already described, directly
via the RHT and indirectly via the vLGN and the IGL. It also receives inputs from the 
ventral subiculum and septal nuclei (Pickard, 1982), the periaqueductal grey, the 
paraventricular nucleus, the mid-brain, the retrochiasmatic area, the paraventricular 
thalamic nucleus and other hypothalamic areas (Moore, 1983) and a prominent projection 
from both the median and dorsal raphe nuclei (Dahlstrom and Fuxe, 1964 ; Azmitia and 
Segal, 1978).
The SCN projects efferent pathways to the majority of areas from which it 
receives inputs. However, two efferent pathways of the SCN terminate in areas from 
which arise, afferents to the SCN : one is the raphe (Bons et a!., 1983); and the other is 
the IGL (Watts et al. 1987). These feedback loops are considered to allow the SCN to 
adjust its own inputs.
1 . 1 . 4  Pharmacological control of circadian rhvthms
In order to establish the nature of the circadian pacemaker in the SCN, several 
studies have been conducted to identify potential neurotransmitters associated with its 
function. While little is known about these putative neurotransmitters, several 
neurotransmitters have been identified and their manipulation has revealed valuable 
information about their potential role in the functioning of the SCN.
Transmitters located inside the SCN include vasopressin and neurophysin 
(Sofroniew and Weindl, 1978), somatostatin (Moore, 1983), gastrin-releasing peptide; 
bombesin (Roth et al., 1982), vasoactive intestinal peptide (Card et al., 1981), and 
corticotrophin-releasing factor (Palkovits ef al., 1983). The SCN also contain significant
quantities of gamma-aminobutyric acid (GABA) and its synthetic enzyme glutamic acid 
decarboxylase (Perry et al., 1971), suggesting that it is probably synthesized there. 5- 
hydroxytryptamine (5-HT) is also found in the SCN (Fuxe, 1965), together with its 
synthesizing enzyme, tryptophan hydroxylase (Brownstein et al., 1975) and its 
metabolizing enzyme, monoamine oxidase (Saavedra et al., 1974), as is the 
neurotransmitter acetylcholine (Murakami et al., 1984), its synthesizing enzyme, choline 
acetyltransferase (Brownstein et al., 1975) and nicotinic cholinergic receptors (Segal et 
al., 1978).
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Neurotransmitters located outside the SCN and which may act on the SCN include, 
5-HT (Fuxe, 1965 ; Kiss et al.t 1984) which is thought to originate from efferents of the 
raphe and, neuropeptide Y, which is gaining recognition as the primary neurotransmitter of 
the GHT (Harrington et al., 1985). In contrast, glutamate and aspartate are considered 
to be the neurotransmitters of the RHT, as they are released upon electrical stimulation of 
the optic nerve (Liou et al., 1986).
Other neurotransmitters detected in axons of the SCN include dopamine, 
noradrenaline and adrenaline (Van den pol and Tsujimoto, 1985). However, they do not 
appear to be located selectively either inside or outside the SCN (Van den pol and 
Tsujimoto, 1985). The reader is referred elsewhere to a more comprehensive list of the 
neurotransmitters located inside and outside the SCN (Van den pol and Tsujimoto, 1985).
Selective transection of the GHT, or its associated nuclei, does not impair the 
ability of light to activate or suppress the SCN (Groos and Meijer, 1985). In contrast, 
selective transection or damage of the RHT is not possible, without risk of damage to the
optic tract, which runs in close proximity.
Considerable evidence suggests that acetylcholine may be involved in relaying the 
information about the light-dark cycle to the SCN. Intraventricular administration of 
carbachol (a cholinergic receptor agonist) causes a small phase shift in blinded mice (Zatz 
and Herkenham, 1981), this effect is similar to that produced by light pulses. Also, light
is reported to decrease the enzyme activity of N-acetyltransferase in the pineal gland; this
effect is likely to be mediated by the RHT and the SCN (Rusak and Zucker, 1979), since 
carbachol injection close to the SCN resembles the effect of light, whilst an injection of 
alpha-bungarotoxin (nicotinic cholinergic receptor antagonist) prevents the effect of 
carbachol (Zatz and Brownstein, 1979). It is likely that carbachol is acting via nicotinic 
cholinergic receptors at the level of the SCN. In addition, the iontophoretic application of 
acetylcholine to the SCN produced excitation of 80% of SCN cells (Nishino and Koizumi, 
1977). Although the above results suggest that acetylcholine may be the transmitter of 
the RHT, the SCN proved unresponsive to several other cholinergic agents but was inhibited 
by antagonists of excitatory amino acids (Cahill and Menaker, 1987).
Experiments monitoring the release of glutamate and aspartate from nerve 
terminals in the SCN showed their release to be effected by stimulation of the optic nerve 
(Liou et al., 1986). In addition, the iontophoretic application of glutamate onto cells of the 
SCN, produces excitation (Nishino and Koizumi, 1977) and a phase shift, which resembles 
that of dark pulses (Meijer et al., 1988). It is therefore probable that glutamate and 
aspartate serve as neurotransmitters of the RHT.
Studies employing benzodiazepines have proved useful in establishing the role 
played by the inhibitory neurotransmitter GABA; triazolam, a short acting benzodiazepine, 
produces phase shifts in locomotor activity. However, the similarity of its phase- 
response curves obtained during light and dark suggests that GABA may not be involved 
with the relaying of photic information to the SCN (Turek and Losee-Olson, 1986). 
Moreover, the phase shifting effect of triazolam is unaltered in animals that have been 
blinded (associated with a degenerated RHT) or pinealectomized (Van Reeth et al., 1987). 
These findings suggest that the phase shifting effect of triazolam and probably GABA is not 
mediated by the RHT.
The depletion of brain serotonin using p-chlorophenylalanine (PCPA) has shown free 
running circadian rhythms in locomotor activity to disappear and then reappear after 7 
days with an altered phase (Honma et al., 1979). A tryptophan-free diet is associated 
with a marked reduction in brain 5-HT concentration, and a disturbance of the sleep-wake 
balance (Lanoir et al., 1981). However, circadian rhythms in locomotor activity (Block 
and Zucker, 1976) and prolactin levels (Dunn et al., 1980) are capable of persisting 
following raphe lesioning. In addition, transection of the raphe afferents of the SCN, which 
would be expected to have similar effects to lesioning of the raphe nuclei, was found not to 
alter entrained or free-running rhythms (Inouye and Kawamura, 1980). In contrast, the 
iontophoretic application of 5-HT or the electrical stimulation of the raphe nuclei inhibits 
the firing of SCN cells (Groos et al., 1983). These findings suggest that the raphe nuclei 
are not primarily involved in the generation or entrainment to a particular light : dark 
cycle but that they are able to modulate the expression of circadian rhythms. In addition, 
the raphe nuclei receive retinal afferents (Foote et al., 1978), it is thought that these 
afferents are not in themselves involved in the acclimatization to a particular light dark
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cycle but contribute to the generation and modulation of a coherent circadian rhythm.
In vivo voltammetry has recently demonstrated the existence of a circadian 
variation in extracellular concentrations of 5-hydroxyindoleacetic acid (5-HIAA) (Faradji 
et al., 1983 ; Martin and Marsden, 1985), in the SCN of the rat. 5-HIAA is the major 
metabolite of 5-HT and is reported to be a good indicator of changes in 5-HT released 
(Sharp et al., 1984). These findings imply that extracellular 5-HT concentrations are 
higher during the dark period, when the animals are most active, suggesting that the 
release of 5-HT into the synaptic cleft is greater at this time (Martin and Marsden, 1985 ; 
Kalen et al., 1989). Electrophysiological studies have shown the firing rate of 5-HT 
neurones to be higher during the dark phase, when the animals are active, and this may 
account for the greater 5-HT release at this time (McGinty and Harper, 1976 ; Trulson and 
Jacobs, 1979). In contrast, the firing rate of the SCN is at its lowest during the dark 
phase (Inouye and Kawamura, 1980). Meijer and Groos (1988) demonstrated
microiontophoretically applied 5-HT to inhibit the neuronal firing of about one-half of the 
SCN and vLGN cells. It is tempting to speculate that the circadian variation in raphe 
neuronal firing and 5-HT release at the SCN, functions to modulate the neuronal firing 
activity of the SCN, but it is more probable that this input from the raphe nuclei is one of 
many which serves to enable the SCN to control and co-ordinate a variety of circadian 
rhythms.
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1.2 CIRCADIAN RHYTHMS IN PARAMETERS OF ONS 5-HT FUNCTION
Research into this aspect of 5-HT has generated a vast amount of data, and it is 
beyond the scope of this section to cover it in detail. The following sections give brief 
summaries of some of the results that have been obtained.
1.2.1 Anatomical distribution of 5-HT In the central nervous system
Significant quantities (0.1-0.36 pg/g of tissue) of the monoamine 5-HT were first
reported in mammalian brain by Twarog and Page (1953). It was found primarily in the 
mesencephalon (midbrain) and the diencephalon (hypothalamus and thalamus); the highest 
concentrations were found in the hypothalamus and the caudate nucleus, and the lowest in 
the cerebellum (Amin et al., 1954 ; Bertler and Rosengren, 1959).
The advent of fluorescence histochemistry enabled the mapping of 5-HT containing 
neurones in the brain (Falck et al., 1962). More recently, the development of other 
methods {e.g. autoradiography and immunohistochemistry) has contributed to a more 
detailed visualization of the fine structure and organization of 5-HT neurones in the CNS 
(Steinbusch and Nieuwenhuys, 1981).
The nine nuclei containing 5-HT cell bodies from which 5-HT neurones originate, are 
located in the medulla oblongata, pons and mesencephalon. These cell bodies are commonly 
referred to as raphe nuclei. They give rise to both ascending and descending neuronal 
pathways. The more caudal groups of nuclei project descending pathways to the medulla 
and spinal cord, whereas the more rostral 5-HT cell groups (dorsal, median and central 
raphe) project ascending pathways to innervate the amygdala, hypothalamus and thalamus, 
the hippocampus, olfactory bulb and tubercle, the SCN and the cerebral cortex.
1 . 2 . 2  Biosynthesis and catabolism of 5-HT
5-hydroxytryptamine is unable to cross the blood brain barrier and is synthesized 
in the brain from the amino acid L-tryptophan (obtained primarily from the diet).
L-tryptophan is transported from the plasma into neurones by an active uptake 
process. This process is also responsible for the uptake of a number of other neutral
amino acids (e.g. tyrosine, phenylalanine, leucine, isoleucine, valine, methionine and 
histidine) and, therefore, L-tryptophan uptake is a competitive process.
Once inside the neurone, L-tryptophan is hydroxylated at the 5-position of the 
indole ring to form 5-hydroxytryptophan (5-HTP). The hydroxylation is catalysed by the 
enzyme tryptophan hydroxylase, which requires molecular oxygen and a pterin cofactor as 
an electron donor. Once synthesized, 5-HTP is decarboxylated almost immediately to 5- 
HT, by the enzyme 5-hydroxytryptophan decarboxylase, and then stored in a bound form 
inside synaptic vesicles.
The enzyme responsible for the catabolism of 5-HT is monoamine oxidase (MAO), 
which oxidizes the amino group to form the aldehyde, 5-hydroxyindole acetaldehyde, and 
this can be oxidized further to 5-hydroxyindoleacetic acid (5-HIAA).
In the pineal gland, 5-HT is converted readily to melatonin, the reaction being 
catalysed by two enzymes. The first, N-acetyltransferase, acetylates 5-HT to form N- 
acetylserotonin, and the second, 5-hydroxyindole-o-methyl transferase, which requires 
S-adenosyl methionine as the methyl donor, methylates N-acetylserotonin to form 
melatonin.
The concentrations of both 5-HT and melatonin in the pineal gland display a 
circadian variation. These rhythms are considered to be under the control of the SCN (see 
Neural control of circadian rhythms). The SCN are thought to act via the sympathetic 
nervous system to regulate the activity of N-acetyltransferase.
1.2.3  Circadian variation In 5-HT concentrations
A circadian variation in the concentration of 5-HT was first reported for the mouse 
brain (Albrecht et al., 1956). Since then, a similar rhythm has been found to exist in the 
brains of a variety of species including rat (Quay, 1965), cat (Reis et al., 1969) and 
ferret (Yates and Herbert, 1979). The first studies measured whole brain 5-HT 
concentrations, whereas later studies have focused on measuring 5-HT concentrations in a 
number of brain regions including, frontal cortex, hypothalamus, dorsal and median raphe 
nuclei and the pineal gland (Quay, 1965,1968 ; Okada, 1971 ; Hery et al., 1972 ; Hiliier 
and Redfern 1976b ; Semba et al., 1984 ; Agren et al., 1986). Moreover, the rhythm in
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5-HT concentrations of the dorsal raphe persists under constant conditions suggesting that 
it is endogenously generated (Semba et al., 1984). In contrast, a recent study has 
demonstrated that the rhythm in hypothalamic 5-HT concentrations, in hamster brain is not 
circadian in nature and may be driven by the light : dark cycle (Ferraro and Steger, 1990).
The amplitude of the circadian variation in 5-HT concentrations varies from region 
to region (in the brain), and is at its highest in the frontal cortex, hypothalamus and the 
lower brainstem (Quay, 1968). A rhythm is also observed in the SCN (Martin and 
Marsden, 1985), where the concentrations of 5-HT during the light phase are double those 
seen during the dark phase. Although these studies demonstrate that 5-HT concentrations 
peak during the light phase, they are nevertheless, asynchronous (i.e. the phase of the
rhythms is not identical in all brain regions).
In order to understand the reasons for the marked changes in 5-HT concentrations 
observed during the light-dark cycle, much effort has been focused on the components of 
the 5-HT synthesis pathway, since it is thought that a circadian variation in one or more of 
these components may reflect the circadian variation of 5-HT concentrations. The 
following section discusses some of the results obtained from the analysis of the
components of the 5-HT synthesis pathway.
1 . 2 . 4  Tryptophan availability
The amino acid L-tryptophan is the precursor of 5-HT synthesis. It is converted 
by the enzyme tryptophan hydroxylase to 5-hydroxytryptophan. Experiments of
Fernstrom and Wurtman (1971) demonstrated that small changes in plasma and brain 
tryptophan, which occur during physiological conditions, could lead to a rapid elevation of 
brain 5-HT concentrations. Other authors have also reported a circadian variation in the 
availability of tryptophan in both plasma and brain (Rapoport et al., 1966 ; Martin and 
Redfern, 1982). Thus the availability of tryptophan may contribute in part to the changes 
in 5-HT concentrations seen over 24 hours. However, under normal physiological 
conditions, the concentrations of plasma and brain tryptophan are highest during the dark 
phase (Fernstrom and Wurtman, 1971), and are thus 180° out of phase with the rhythm of
5 -HT concentrations, which are highest during the light phase. Further evidence against 
tryptophan as the prime determinant is presented from the measurement of tryptophan 
concentrations in the cerebrospinal fluid (CSF) (by in vivo microdialysis); no significant 
change in tryptophan concentrations was seen over 24 hours (Hutson ef a/., 1984). It is 
likely, therefore, that tryptophan availability is not directly responsible for the circadian 
variation seen in 5-HT concentrations, although it can have an effect.
1-2 .5  lrypt?ph?n hydroxyl??? jpctiylty
This enzyme is the rate-limiting step in the intraneuronal conversion of tryptophan 
to 5-HT (Ashcroft ef a/., 1965), consequently variation in its activity may account for 
the circadian variation in 5-HT concentrations. However, the results obtained by a number 
of groups are inconclusive. For example, a significant circadian variation was first 
reported by Kan ef a/. (1977) in the rat, and by Natali ef a/. (1980) in the mouse. The 
presence of such a rhythm was confirmed for the rat by Cahill and Ehret (1981) and 
Redfem and Sinei (1985). The enzyme activity is highest during the dark phase, opposite 
to the peak in 5-HT concentrations.
Other groups, however, were unable to detect a variation in the activity of the 
enzyme, using similar techniques (Deguchi, 1977 ; McLennan and Lees, 1978). Two 
equally plausible explanations have been put forward to account for this discrepancy. 
Firstly, a circadian variation in enzyme activity has been reported by workers who have 
used specific brain regions, as opposed to whole brain preparations where no rhythms could 
be detected. Therefore, since the phase of the enzyme activity rhythm has been shown to 
vary from region to region (Natali ef a/., 1980), it is likely that the use of whole brain 
preparations would decrease the possibility of detecting such a rhythm. Secondly, the 
process of homogenization is considered to alter tryptophan hydroxylase activity, since 
enzyme activity in brain homogenates was considerably higher than that found in vivo 
(Kizer ef al.t 1976 ; Lin ef a/., 1969). It has been proposed that homogenization, by 
mimicking physiological depolarization, maximally activates tryptophan hydroxylase (Elks 
ef a/., 1979). In addition, the terminal 5-HT autoreceptor may be involved in the 
regulation of tryptophan hydroxylase activity (Hjorth and Magnusson, 1988).
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1 . 2 . 6  5-hvdroxvtrvptophan decarboxylase activity
Once synthesized, 5-HTP is decarboxylated almost immediately by the enzyme 5- 
hydroxytryptophan decarboxylase (5-HTP-decarboxylase) to 5-HT. This enzyme is highly 
active and is located inside monoamine neurones; it is also involved in the synthesis of both 
dopamine and noradrenaline (Anden et al., 1965). There is evidence to suggest that 
different enzymes are involved in the decarboxylation of 5-HTP and L- 
dihydroxyphenylaianine (DOPA). The intracisternal administration of 6 -hydroxydopamine 
preferentially reduces DOPA-decarboxylase activity but not 5-HTP-decarboxylase activity 
(Bloom et al., 1969 ; Breese and Traylor, 1970). In addition, Sims et al. (1973) found 
differences in kinetic properties, ease of denaturation, reliance of activity on the 
availability of co-factors, and the relative distribution in the brain of the two enzymes. It 
is therefore likely that the enzymes responsible for the decarboxylation of 5-HTP and
DOPA are functionally different, yet they both possess the capacity of non-selectively
decarboxylating 5-HTP or DOPA. Selectivity is probably achieved by the specific 
localization of 5-HTP-decarboxylase to 5-HT neurones and DOPA-decarboxylase to 
dopaminergic and noradrenergic neurones.
5-HTP-decarboxylase activity in crude brain homogenates varies over 24 hours, 
while that of the purified enzyme remains unchanged (Hillier and Redfern, 1976a). This 
variation in the activity of the enzyme, obtained from brain homogenates, was attributed to 
other factors, such as substrate competition or co-factor availability. The authors also 
showed that this enzyme is normally unsaturated, thus suggesting that it probably 
contributes little to the circadian variation in 5-HT concentrations.
1. 2 .7  5-HT release
Hery et al. (1972) first demonstrated that 5-HT release is greater during the dark
phase, they also found that newly synthesized 5-HT was released in preference to the old. 
Their results, however, were rather difficult to interpret because they had not 
differentiated between 5-HIAA derived from the intraneuronal metabolism of 5-HT or that 
from neuronally released 5-HT.
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Recent studies have used in vivo voltammetry to measure 5-HIAA concentrations 
over 24 hours, in the caudate nucleus, cerebral cortex, hippocampus, raphe nuclei 
(Cespuglio et al., 1983) and the SCN (Faradji et al., 1983 ; Martin and Marsden, 1985) 
of the rat, as 5-HIAA concentrations are a good indicator of 5-HT released (Faradji et al., 
1983 ; Sharp et a l, 1984). Martin and Marsden (1985) correlated their results of in 
vivo voltammetry with intracerebral microdialysis studies measuring extracellular 5-HT 
concentrations (release into the synaptic cleft) in the hypothalamus, while Faradji et al. 
(1983) correlated 5-HIAA concentrations with locomotor activity. The results from these 
studies suggest that extracellular 5-HIAA concentrations are higher during the dark phase, 
and also that the greatest change occurs during transition from light to dark (increase) and 
from dark to light (decrease). In support, microdialysis studies have confirmed that 5-HT 
release rates are higher during the dark phase in the hypothalamus (Martin and Marsden, 
1985) and the hippocampus (Kalen et al., 1989). Furthermore, the inability of Kalen et 
al. (1989) to observe corresponding changes in 5-HIAA concentrations may be a reflection 
of the use of a 5-HT re-uptake inhibitor in the perfusion fluid.
In general, these findings suggest that the functional activity of serotoninergic 
neurones is highest during the dark phase, i.e. when 5-HT concentrations are at their 
lowest, Implying that 5-HT concentrations do not function to regulate the release of 5-HT 
into the synaptic cleft.
1 . 2 . 8  5-HT uptake
The action of released 5-HT is terminated by its re-uptake into presynaptic nerve 
endings, where it is either degraded intraneuronally by MAO or reincorporated into 
synaptic vesicles. Meyer and Quay (1976) found that the in vitro uptake of 5-HT, by 
slices of the SCN, displays a circadian variation, with highest uptake taking place during the 
dark phase, and lowest during the light phase, while in the hypothalamus, they observed a 
rather complex rhythm which was characterized by three periods of high uptake mingled 
with three periods of low uptake. However, recent studies by Rovescalli et al. (1989) 
investigating the imipramine binding and the uptake of 5-HT by slices of the hypothalamus 
and cerebral cortex, during light and dark, reported a difference in both parameters only
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for the hypothalamus, with imipramine binding and 5-HT uptake being greater during the 
dark. Wirz-Justice et at. (1983) also found imipramine binding in the SCN to display a 
similar rhythm. The imipramine, or antidepressant binding site, and the 5-HT uptake site, 
resemble each other and it was recently proposed that the 5-HT uptake inhibitor, 
paroxetine, binds to a single non-heterogeneous site which resembles the antidepressant 
binding site (Marccusson et at., 1989). On this basis these authors proposed that the 
imipramine binding site and the 5-HT uptake site are part of the same complex, or even one 
and the same.
The rhythm in 5-HT uptake is in phase with that of 5-HT release, as would be
expected, since re-uptake is the primary means of terminating transmitter action, which
would need to be at its most active when 5-HT neurones themselves are most active.
1.2 .9  Functional significance of the clrcafllpn variation Ld SrHI
concentrations
Many of the factors involved in the biosynthesis process of 5-HT display a 
circadian variation, but their phases appear to be inconsistent with being directly 
responsible for the circadian variation seen in 5-HT concentrations. A few of these 
biosynthetic steps possess suitable characteristics which would enable them to act as 
regulators of neurotransmitter function. Dietary influences are shown to be important in 
determining CNS concentrations of tryptophan, whereas the rhythm in activity of the 
enzyme tryptophan hydroxylase in being 180° out of phase with 5-HT concentrations is 
considered unlikely to be able to adapt quickly to meet functional requirements. The 
enzyme 5-HTP-decarboxylase is susceptible to a variety of influences that may be part of 
a control mechanism for 5-HT function but the fact that this enzyme is normally 
unsaturated with substrate suggests that it is not of controlling importance. It may well 
be that 5-HT functions in the CNS as a general modulator, and that precise control of its 
activity is not desirable. All the factors mentioned are likely to contribute to the overall
activity of 5-HT. On the other hand, it seems unlikely that changes in the functional
activity of 5-HT neurones are a direct result of changes in 5-HT concentration. It is more
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plausible that the observed changes in presynaptic function are designed to replenish stores 
of transmitter that are used at various rates over 24 hours.
It is likely, therefore, that the changes in 5-HT release are partly responsible for 
the observed daily fluctuations in 5-HT concentrations. However, the situation is further 
complicated by the fact that 5-HT reuptake is also highest when release is highest. This 
seems to suggest that 5-HT release has little effect on 5-HT concentrations.
it has been demonstrated recently that there exist 5-HT receptors on presynaptic 
5-HT nerve terminals. These receptors are activated by the 5-HT released from their 
corresponding nerve terminals, and are therefore termed 5-HT autoreceptors. They 
function by feedback inhibition to regulate release and possibly synthesis of 5-HT. In this 
way they could be important regulators in controlling the circadian oscillation in 
presynaptic activity. It is the primary aim of this thesis to assess how 5-HT autoreceptor 
activity changes during the light : dark cycle.
1.3 RECEPTORS FQR_5-f-LT
Gaddum and Picarelli (1957) demonstrated the existence of two distinct 5-HT 
receptors, which they termed "D* and "M", based on the selective activity of the 
antagonists, dibenyline and morphine. Since this early classification, the identification of 
5-HT receptor subtypes has proliferated, largely helped by the development of more 
selective compounds and the increased sensitivity of biochemical techniques. The true 
classification and organization is still rather confusing, and made more so by the lack of a 
concerted standardized nomenclature.
1.3.1 Electrophvsloloalcal evidence for multiple 5-HT receptors
The technique of microiontophoresis has allowed the testing of agents, for example 
5-HT, that do not permeate the blood-brain barrier. From the results of this technique, 
Haigler and Aghajanian (1977) proposed the existence of three distinct 5-HT receptors 
based on the neuronal responses to 5-HT; Aghajanian (1981) designated these receptors 
S j, S2  and S^.
51
This receptor was identified from unit recordings of facial motor neurones (McCall and 
Aghajanian, 1979) and spinal motor neurones (White and Neuman, 1980). The activation of 
this postsynaptic receptor by 5-HT, and 5-HT agonists, facilitates the depolarizing action 
of the excitatory amino acid glutamate. The facilitatory actions of 5-HT are blocked by 
small doses of classical 5-HT antagonists, such as cyproheptadine, methysergide and 
metergoline (McCall and Aghajanian, 1979,1980).
52
This receptor is located on either the soma or dendrites of raphe neurones. Its activation 
results in reduction of the firing activity of 5-HT neurones. Whilst being extremely 
sensitive to the action of LSD, this receptor is completely insensitive to the classical 5-HT 
antagonists (Aghajanian, 1981). It is considered to be the somadendritic autoreceptor 
(Aghajanian, 1981), due to its location and its ability to regulate the activity of
serotoninergic neurones.
%
This receptor is located postsynaptically in the forebrain areas receiving a dense 5-HT 
input, for example, ventral lateral geniculate and the amygdala. Microiontophoretically 
applied 5-HT produces a depression in the firing rate. LSD is a weak agonist at this site, 
whereas the classical antagonists have little effect (Haigler and Aghajanian, 1974 ; 
Aghajanian, 1981).
1.3.2 Radlo-lloand binding evidence for multiple 5-HT binding sites
Peroutka and Snyder (1979) were the first authors to propose the existence of two 
major populations of central 5-HT binding sites. The sites labelled by nanomolar
q
concentrations of [°H]5-HT were designated "5-HT.j", whilst those labelled by nanomolar 
concentrations of [3H]spiperone (a neuroleptic used in dopamine binding studies) were 
designated "5-HT2". In contrast, lysergic acid diethylamide (LSD) displayed an equal 
affinity for both sites. These binding sites were observed to display a marked regional 
variation in binding densities, adding further support to the idea that they represent 
distinct molecular entities (Peroutka and Snyder, 1981).
Recently, a further 5-HT binding site has been identified in the CNS. This site was 
termed 5-HT3; it displays an intermediate affinity for 5-HT, in between that found for the 
5-HT1 and the 5-HT2 sites. Its discovery is largely attributed to the development of 
potent and selective agents (MDL 72222, GR 38032F "ondansetron" and ICS 205 930) 
whose properties differ from those of existing compounds for 5-HT.j and 5-HT2 sites 
(Kilpatrick et al., 1987 ; Watling, 1988).
1.3.2.1 S-IKIT^
In 1981, Pedigo et al. provided evidence to suggest that the 5-HT.j binding site 
was heterogeneous, based on the ability of spiperone to displace [3H]5-HT binding in a 
biphasic manner. Binding sites displaying a high and a low affinity for spiperone were 
termed 5 -H T ^  and 5-HT.j B respectively. Further support for this heterogeneity in 5- 
HT1 binding sites was provided by Schnellmann et al. (1984).
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A more comprehensive distinction between these sites came with the use of 8- 
hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (Arvidsson et al., 1981), a 
compound shown to be a 1000 fold more selective for the 5-HT.j A binding site (Middlemiss
q
and Fozard, 1983). Several binding studies have been performed using [°H]8-OH-DPAT 
(Gozlan et al., 1983 ; Hoyer et al., 1985 ; Palacios et al., 1987). Autoradiographic 
studies revealed a heterogeneous distribution of the 5-HT.j A binding sites in the brain 
(Marcinkiewicz et al., 1984 ; Pazos and Palacios, 1985), with the highest density of these 
binding sites being found in the hippocampus, septum, cortex, raphe and the striatum 
(Gozlan et al., 1983 ; Cortes et al., 1984 ; Hall et al., 1985 ; Verge et al., 1986).
The selective destruction of serotoninergic nerve terminals by the intracerebral 
administration of the neurotoxin 5,7-DHT was associated with an unaltered number of 5- 
HT1A binding sites in any region (Verge et al., 1986 ; Crino et al., 1990), whereas the 
destruction of intrinsic hippocampal neurones by the local injection of kianic acid, produced 
a marked reduction of the number of the hippocampal 5-HT^A sites (Hall et al., 1985), and 
the destruction of cortical neurones by ibotenic acid, reduced the number of cortical 5- 
HT1A sites (Crino et al., 1990), suggesting that these 5-HT1A binding sites are located 
postsynaptically.
When 5,7-DHT was used to lesion serotoninergic cell bodies of the dorsal raphe, 
their degeneration was associated with a marked reduction in [3H]5-HT and [3H]8-OH- 
DPAT binding sites, suggesting the presynaptic location of these binding sites on 
serotoninergic cell bodies and/or dendrites (Verge et al., 1986 ; Thor et al., 1990). In 
addition, a similar treatment was associated with a reduction in the number of [3H]8-OH- 
DPAT binding sites in the striatum (Gozlan et al., 1983 ; Hall et al., 1985). It was 
suggested therefore that this presynaptic site may be similar to that found on raphe cell 
bodies. However, this does not seem to be the case since the pharmacological properties 
of the raphe 5-HT1A sites are different. In particular, the raphe 5-HT1A sites exhibited a 
higher affinity for [3H]8-OH-DPAT, and this binding was sensitive to the presence of GTP 
analogues (Hall et al., 1985 ; Verge et al., 1986). Furthermore, [3H]8-OH-DPAT does 
not bind to the terminal 5-HT autoreceptor in the striatum (Middlemiss, 1985b). 
Moreover, under the assay conditions of Gozlan et al. (1983) it was considered to have 
bound to the 5-HT re-uptake site since binding was prone to displacement by a number of
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selective 5-HT uptake inhibitors (Schoemaker and Langer, 1986).
Indeed, [^H]8-OH-DPAT is considered to bind to a single binding site in the 
membranes of rat pig and human cortex and hippocampus. The affinity values and the rank 
order of potency of a variety of compounds in displacing [^H]8-OH-DPAT binding from this 
site were indistinguishable in these species. Also, the correlation between these species 
suggests that ^HjS-OH-DPAT binds to the same site in all three species. Moreover, its 
anatomical distribution in human brain resembles that found in rat and mouse brain 
(Palacios et al., 1987).
High numbers of the 5-HT.j q binding sites are found in the caudate nucleus, globus 
pallidus, subiculum and the substantia nigra (Cortes et al., 1984 ; Pazos and Palacios,
1985 ; Verge et al., 1986). These 5-HT.j q binding sites are located both, pre- and post­
synaptically on serotoninergic neurones, on the grounds that, transection of afferent axons 
or DRN ablation, or the local injection of ibotenic acid is associated with a reduction in their 
number (Crino et al., 1990). In addition, the local injection of 5,7-DHT is reported to 
produce, both a reduction in the number of non-5-HT^ sites (presumably 5-HT.j 0 ), in the 
substantia nigra (Verge et al., 1986), and an increase in the number of 5-HT^q binding 
sites in the caudate putamen (up-regulation of post-synaptic 5-HT^q) (Offord et al.,
1988). The 5-HT^q binding site has been identified only in rat and mouse brain, and is 
absent in guinea-pig, human, pig, pigeon and a number of other species (Heuring et al.,
1986 ; Hoyer et al., 1986a ; Martial et al., 1989 ; Waeber et al., 1989).
Autoradiographic studies of Cortes et al. (1984) first identified a binding site in 
rat choroid plexus that could be labelled by [3H]5-HT, [^HjLSD or [^Hjmesulergine. Its 
characteristics were distinct with respect to the rank order of potencies of agents with 
affinities for the 5 -H T ^ , 5-HT^q or the 5 -HT2 sites, and therefore it was designated the 
"5-HT^q site". A similar pharmacological binding site has been identified in pig cortex 
and choroid plexus (Pazos et al., 1984), human cortex, hippocampus and choroid plexus 
(Hoyer et al., 1986b), thus implying that this site may well be conserved within these 
species. This site displays certain characteristics which resemble the 5 -HT2  binding site, 
suggesting that the two may be related. The reader is referred to a recent review on this 
controversy (Hoyer, 1988).
A further 5-HT binding site was identified in bovine brain membranes, using [3H]5-
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HT in the presence of 100 nM 8 -OH-DPAT and 100 nM mesulergine, a condition designed to 
inhibit over 90% of specific binding to the 5 -H T ^  and the 5-HT.j q  site (Heuring and 
Peroutka, 1987). A considerable amcunt of [3 H]5-HT binding was still evident under these 
conditions. This binding site was distinct pharmacologically from those already identified 
and was designated the "S-HT-jp" binding site. Herrick-Davis and Titeler, (1988) and 
Waeber et al. (1988), using similar blocking conditions demonstrated this site to be 
present in pig, rat, calf and human brain. Although all five species possess this site, they 
do so in different proportions, the highest being found in bovine and human brain, where it 
is the most common 5-HT.j binding site, whereas it represents only a small proportion in 
rat brain.
In the presence of pharmacologically blocked 5 -H T ^  and 5 -H T jq  sites 
(remembering that there are no 5-HTjq sites in bovine brain), 5-carboxyamidotryptamine 
(5-CT) produced a biphasic displacement of [3 H]5-HT binding, suggestive of the 
heterogeneity of the 5-HTjq binding site (Titeler and Herrick-Davis, 1988). Under similar 
conditions, 5-CT, ergotamine or GR 43175 can selectively displace [3 H]5-HT binding from 
the high-affinity component, leaving the [3 H]5-HT still bound to the low-affinity site 
(Leonhardt et al., 1989 ; Sumner and Humphrey, 1989). This low-affinity ^HJS-HT 
binding site was designated ”5 -H T ^". It is also identified in human, pig and rat brain 
membranes, however, the numbers found in rat are much lower than those found in human 
brain (Titeler and Herrick-Davis, 1988 ; Leonhardt et al., 1989 ; Sumner and Humphrey, 
1989).
1.3.2.2.
The development of ketanserin has enabled the 5-HT2  binding sites to be correlated 
with the ”D" receptor, first described by Gaddum and Picarelli (1957). Spiperone was one 
of the first ligands to be used to bind these sites (Peroutka and Snyder, 1979), however, 
its lack of selectivity soon led to the development of [3 H]ketanserin, an antagonist 
exhibiting a high affinity and selectivity for the 5-HT2  sites (Leysen et al., 1981,1982). 
Using this radioligand, the 5-HT2  binding sites were demonstrated to be concentrated in the 
frontal cortex of the rat and guinea-pig brain (Leysen et al., 1982). A similar 5-HT2 
binding site was also identified in human and pig brain cortex (Hoyer et al., 1986b). In
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addition to binding the 5 -HT2  sites, [3H]ketanserin also exhibits an affinity for alpha j -  
adrenergic and H1 -histaminergic sites; its binding to these sites is considered to be 
minimal when used at low concentrations (Leysen et al., 1981). Furthermore, 
[3H]ketanserin binding to the 5-HT2 sites was displaced by a number of serotonin agonists 
and antagonists; antagonists generally revealed IC5q values in the nanomolar range, 
whereas agonists exhibit IC50 values of micromolar order (Leysen et al., 1982), adding 
further support to the initial subdivision of 5-HT binding sites as proposed by Peroutka and 
Snyder (1979).
Recently it was suggested that the rat cortex contains both a high and a low affinity 
state of the 5-HT2 binding site (Titeler et al., 1985,1987), with the agonist radioligand 
[3H]4-bromo-2,5-dimethoxyamphetamine ([3H]DOB) labelling the high affinity state, and 
the antagonist radioligand ^HJketanserin labelling both the high and the low affinity states. 
However, Pierce and Peroutka (1989) suggested that the 5-HT2 agonist ^HJDOB labels a 
distinct 5-HT2 binding "subtype” as opposed to a "state". Their evidence was derived 
from the six fold difference in affinity of 5-HT to displace ^HJketanserin binding from rat 
and human cortex as opposed to bovine cortex, the Hill coefficient for this displacement 
being significantly less than unity for rat and human cortex, while that for bovine cortex 
was essentially unity. On the basis of these results, Pierce and Peroutka (1989) proposed 
that the high affinity site labelled by [3H]DOB (found in rat and human cortex) be designated 
•5-HT2A\  while the low affinity site, labelled by [3H]ketanserin and found in all three 
species, be designated "5-HT2q". In contrast, Leonhardt and Titeler (1989) observed 
little difference in the Hill values from these three species, all being considerably less than 
unity.
The inability of both groups to demonstrate specific [3H]DOB binding in bovine 
cortex is considered to be due, partly, to the low density of the high affinity 5-HT2 binding 
sites in this species, to the ability of [3H]DOB to label only a small fraction of these sites, 
and to the low specific radioactivity of this ligand. In addition, Strange (1990) proposed 
that the apparent absence of ^HJDOB binding could result from a weakened interaction with 
a G protein. Furthermore, there was a significant difference in the IC50 value of 5-HT in 
displacing [3H]ketanserin binding from human and bovine cortex. However, the most 
important difference between the results from the two laboratories was considered to be
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3the positioning of the "datum" point for the displacing effect of 5-HT on [ H]ketanserin 
binding from bovine brain; while there was no statistical difference between the values 
obtained for the datum point from the two laboratories, it was considered to be a source of 
experimental variability. The controversy over whether the 5 -HT2 binding sites exists in 
different "states" or "subtypes" is considered to result from differences in the 
interpretation of data.
1.3.2.3 IdaU^_
The "M" receptor, first identified by Gaddum and Picarelli (1957) was designated 
"5 -HT3 " in the classification proposed by Bradley et al. (1986). The "M" receptor was 
first identified in the periphery on the basis of the inability of methiothepin or ketanserin to 
block the excitatory effects of 5-HT. Soon selective antagonists were developed, and 
their effects on animal behaviour suggested an action in the CNS (Costall et a l, 1987). 
Kilpatrick et al. (1987) and Watling (1988), using tritiated versions of these antagonists, 
demonstrated the existence of the 5 -HT3  binding sites in a number of regions of the 
mammalian brain. The highest number of binding sites were found in the cortex and the 
limbic areas, including the nucleus accumbens. Based on the location of these sites it was 
proposed that agents selective for the 5 -HT3  site may possess anxiolytic and/or 
antipsychotic activity; the results of such studies, however, are inconclusive. For 
example, GR 38032F is reported (Jones et a l, 1987) to display anxiolytic activity in the 
social interaction test of anxiety but is inactive in the Vogel test. In contrast, File and 
Johnston (1989), did not observe 5 -HT3  antagonist compounds to display anxiolytic 
activity in either the social interaction test or the elevated plus-maze test, but they 
attributed the anxiolytic effects of GR 38032F, observed by (Jones et al, 1987) to the 
low baseline scores of social interaction. Nevertheless, 5 -HT3 antagonists are potent 
anti-emetics (Andrews et a l, 1988), and GR 38032F (ondansetron) is currently being 
evaluated in man (Cubeddu et al, 1990).
1-3.3 D i s c r e p a n c i e s  between radio-llaand fringing s ta le s  and
electrophvsloloqlcallv characterized 5-HT receptors
The classical 5-HT antagonists which have high affinities for 5-HT.j and 5 -HT2
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receptors, fail to antagonize S3 -mediated responses. Methiothepin has a high affinity for 
5-HT.j and 5-HT2  binding sites (Leysen et al.f 1981) but it fails to block -mediated 
facial motorneurone responses (McCall and Aghajanian, 1980), suggesting that neither 
binding site corresponds to the -receptor.
A possible reason for such discrepancies lies in the fact that [^Hjspiperone (when 
used to characterize 5-HT binding sites), has a thousand times greater affinity than the 
neurotransmitter itself (Peroutka and Snyder, 1979), and such high concentrations of 5-HT 
may have non specific effects. In addition, Leysen (1984), questioned the idea that the 5- 
HT1 binding site corresponds to a 5-HT receptor on the grounds of its few functional 
correlates, and due to the limited number of chemical congeners. However, the 
development of more specific compounds, for example, 8 -OH-DPAT (Arvidsson et al., 
1981), TVX Q 7821 (ipsapirone) (Traber et al., 1984), and buspirone (Peroutka, 1985), 
refutes this possibility.
1.3.4 Biochemical evidence fo r m ultiple 5-HT receptors
1.3.4.1 5-HT-j A sites
5-HT stimulates adenylate cyclase in the rat (Markstein et al., 1986) and guinea- 
pig (Shenker et al., 1987) hippocampal membranes. The enhancement of adenylate 
cyclase in the rat was correlated with the affinity of several agonists for the 5-HT-j a 
binding site (Markstein et al., 1986), whereas in the guinea-pig the stimulation of 
adenylate cyclase was mediated by two distinct 5-HT receptors: a high affinity receptor 
which appears to be a functional correlate of the 5-HT.j A binding site, and a low affinity 
receptor which does not correspond to a known 5-HT binding site (Shenker et al., 1987).
De Vivo and Maayani (1985,1986) reported the presence of a 5-HT receptor which 
functions to inhibit forskolin-stimulated adenylate cyclase in the guinea-pig and rat 
hippocampal membranes. This inhibition was guanine triphosphate (GTP)-dependent in the 
guinea-pig and rat (De Vivo and Maayani, 1985), and pertussis toxin sensitive in the rat 
(Clarke et al., 1987). The 5-HT-j a agents (5-CT, 8 -OH-DPAT and buspirone) are potent 
agonists at this receptor, while methiothepin and spiperone are potent antagonists. 
Furthermore, the 5-HT2  and the 5-HT3  receptor antagonists, ketanserin and ICS 205 930 
respectively, exhibit little antagonist activity at this site (De Vivo and Maayani, 1986).
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1.3.4.2 5-HT.) B sites
Several studies report the presence of an adenylate cyclase system in serotonin 
nerve terminals. Forskolin is reported to enhance the stimulation-evoked release of 5-HT 
from rat brain cortex (Schoffelmeer et al., 1985 ; Schlicker et a i, 1987) and 
hypothalamic slices (Galzin et al., 1987) and cortical synaptosomes (Schlicker et al., 
1987), an effect that was mimicked by 8 -Br-cAMP, but not potentiated by 
phosphodiesterase inhibitors. However, it was noted that the effects of 5-HT and 
methiothepin on 5-HT release remain unaltered in the presence of forskolin and a 
phosphodiesterase inhibitor (Schlicker et al., 1987).
The inhibitory effect of 5-HT agonists on 5-HT release is abolished by the 
pretreatment of brain slices with pertussis toxin (Passarelli et al., 1988), thus 
suggesting that a G protein is necessary for autoreceptor function. In addition, the 
facilitatory effect of methiothepin on the stimulation-evoked release of 5-HT is unaltered 
by pertussis toxin pretreatment (Passarelli et al., 1988).
Bouhelal et al. (1988), using membranes of the substantia nigra (an area rich in 
the 5-HT.j Q binding sites), reported several 5-HT agonists to inhibit forskolin-stimulated 
adenylate cyclase, whilst being ineffective on unstimulated adenylate cyclase. The 5- 
H T ^  agonists, 8-OH-DPAT and ipsapirone, exhibited little agonist activity at this site. Of 
the antagonists, spiperone, ketanserin and mesulergine were inactive at reversing the 
inhibitory effect of 5-HT on forskolin-stimulated adenylate cyclase, whereas 
cyanopindolol, propranolol and metergoline fully reversed its effect. Such a 
pharmacological profile suggests that this 5-HT receptor, negatively coupled to adenylate 
cyclase in the substantia nigra, resembles the 5-HT.j 0  binding site.
Phorbol esters that stimulate protein kinase C, increase the rate of 5-HT synthesis 
in rat hippocampal and hypothalamic synaptosomes (Fillenz and Pei, 1987). In addition, 
they potentiate the stimulation-evoked release of 5-HT from rat hypothalamic (Ramdine et 
al., 1987) and cerebral cortex slices (Wang and Friedman, 1987), whereas, the protein 
kinase C inhibitor, exerts the opposite effect (Wang and Friedman, 1987). However, the 
inconsistency of the effect of compounds to interfere with agents acting as 5-HT 
autoreceptor agonists and antagonists, suggests that although protein kinase C can modulate 
the synthesis and release of 5-HT, it is not directly involved in the autoreceptor
transduction pathway (Wang and Friedman, 1987).
1.3.4.3 5-HT1D sites
Although the 5-HT^p binding site represents only a small proportion of total 5-HTj 
sites in the rat brain, its anatomical distribution in the bovine (Heuring and Peroutka, 
1987), guinea-pig and human (Waeber et al., 1989) brain resembles very closely that of 
the 5-HT-|b site in the rat brain (Pazos and Palacios, 1985 ; Waeber et al., 1989). 
Schoeffter et al. (1988) investigated the secondary messenger system coupled to this site 
in the calf substantia nigra. These investigators demonstrated 5-HT and a number of 5-HT 
related compounds to inhibit the forskolin-stimulated adenylate cyclase, the inhibition being 
GTP-dependent. The rank order of potency of 15 compounds acting as agonists on this 
receptor was almost the same as that of their affinity for the 5-HT.j q binding site. In 
addition, 8-OH-DPAT, buspirone and ipsapirone exhibited weak agonist activity in inhibiting 
forskolin-stimulated adenylate cyclase. The inhibitory effect of 5-HT was antagonized by 
methiothepin, mianserin and spiperone yielding displacement values close to their affinity 
values at the 5-HT.j p binding site, suggesting that this 5-HT receptor, negatively coupled 
to adenylate cyclase in calf substantia nigra, belongs to the 5-HT^q subtype. Moreover, 
Schoeffter and Hoyer (1989), based on the differences in the activity of agents, were able 
to distinguish between 5-HT.j p and 5-HT-jp receptors linked to adenylate cyclase in the rat 
and calf substantia nigra, respectively.
1.3.4.4 S ,-m 1 c  arnl 5-HTo sites
The rat choroid plexus contains a high density of the 5-HT.j q binding sites (Pazos 
and Palacios, 1985), whereas the frontal cerebral cortex of the rat and guinea-pig contain 
the greatest number of the 5 -HT2 binding sites (Leysen et al., 1982). These two binding 
sites are very similar, pharmacologically and possess several characteristics in common. 
For example, a number of agonists and antagonists display similar affinities for both these 
sites, their binding being G protein dependent (Hoyer,1988). In addition, Conn and 
Sanders-Bush (1987) demonstrated both these sites to be linked to the same second 
messenger system (i.e. phosphoinositide hydrolysis). Hartig (1989) described the cloning 
of the 5-HT.j^, 5-HT.jq and 5-HT2 receptor and the subsequent determination of their
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amino acid sequences. The 5-HT^q and the 5 -HT2 receptor share about 80% amino acid 
sequence homology, suggesting a common ancestry, which may account for the similarity in 
drug affinities. They were however quite different from the 5-HT-j^ receptor, with whom 
they share only 40% homology; based on this finding he proposed a molecular biological 
classification of 5-HT receptors into two superfamilies, namely the G protein receptor 
linked superfamily, and the ligand-gated ion channel superfamily.
1.3.4.5 5-HT q^  sites
Derkach et al. (1989) demonstrated the 5-HT3 binding site in the guinea-pig 
submucous plexus to be associated with an ion channel permeable to cations. Application of 
5-HT was associated with an inward current which was antagonized by 5-HT3 antagonists. 
Also, responses were unaffected by pretreatment with pertussis toxin, suggesting that G 
proteins are not necessary for functioning.
1.3.4.6 5 -H T ^s ite s
A novel 5-HT receptor identified in guinea-pig hippocampal membranes and in mouse 
colliculi neurones (Dumuis et al., 1988) was designated "5-HT4 " because it is 
pharmacologically dissimilar from the 5-HT receptors classified so far. This receptor is 
positively coupled to adenylate cyclase (Dumuis et al., 1988). Its radio-ligand binding 
identification is not possible due to a lack of putative high affinity compounds for this site.
1.3.5 Behavioural models linked to 5-HT receptor activation
Several behaviours described in the literature are considered to have a 5-HT 
component. These include locomotor activity, thermoregulation, aggression, sexual 
behaviour, feeding, head-twitch/wet-dog shake and the 5-HT behavioural syndrome. It is 
beyond the scope of this section to cover these in detail, but the reader is referred to a 
recent review for further information (Glennon and Lucki, 1988).
1.4 Autorecepfors for 5-HT in the central nervous system
Many factors are involved in the control of neurotransmitter release. Indeed, 
receptors located presynaptically on cell bodies and nerve terminals seem to play a 
prominent role in the modulation of synaptic transmission both in the central and in the 
peripheral nervous system. Those receptors located on nerve terminals and activated by 
the neurotransmitter released from the same nerve terminal are termed "presynaptic- or 
terminal-autoreceptors", while receptors located on cell bodies and or dendrites activated 
in a similar manner are termed "somadendritic autoreceptors". Both of these receptors 
are considered to play an important role in regulating the activity of serotoninergic 
neurones. Although autoreceptors have been identified for a great number of 
neurotransmitters, this section will concentrate only on the Information relating to the 
terminal and the somadendritic 5-HT autoreceptor, in the rat.
1.4.1 in vitro evidence for the existence of the terminal 5-HT autoreceptor
The terminal 5-HT autoreceptor has been identified in brain regions receiving either 
ascending or descending projections, originating from 5-HT cell bodies in the raphe. This 
5-HT autoreceptor has been most extensively studied in the rat brain but is also found in 
the brains of other species (see Table 1).
Farnebo and Hamberger (1971) first demonstrated that the 5-HT receptor agonist, 
LSD (lysergic acid diethylamide), inhibited the electrically-evoked release of [3 H]5-HT 
from slices of rat cerebral cortex, whereas methiothepin (a putative 5-HT autoreceptor 
antagonist) was shown to increase the rate of release of (3 H]5-HT (Farnebo and 
Hamberger, 1974). In 1979, extracellularly-applied 5-HT was shown to inhibit the 
depolarization-evoked release of ^HjS-HT from synaptosomes (Cerrito and Raiteri, 1979) 
and slices (Gothert and Weinheimer, 1979). The inhibitory effect of 5-HT was antagonized 
competitively by methiothepin, suggesting that the facilitatory effect of methiothepin was 
probably the result of its antagonism of the action of released 5-HT on its autoreceptor 
(Gothert, 1980).
Martin and Sanders-Bush (1982) were the first to suggest that the terminal 5-HT
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Tab le 1.
Terminal 5-HT autoreceptor Identification In the CNS of a number of species











Rabbit Cerebral cortex Slice
Hippocampus Slice
Hypothalamus Slice
G uinea-pig Cerebral cortex Slice
Pig Cerebral cortex Slice and
Synaptosome
Human Cerebral cortex Slice
Ftefensnfifi
Bonanno et al., 1986 
Gothert and Weinheimer, 1979 
Middelmiss, 1984a,b 
Gothert et al., 1987 
Langer and Moret, 1982 
Richards, 1985 
Cerrito and Raiteri, 1979 
Galzin et al., 1985 
Sawada and Nagatsu, 1986 
Middlemiss, 1987 
Monroe and Smith, 1985 
Murphy and Zemlan, 1988 
Middlemiss, 1984b
Figueroa et al., 1985
Limberger et al., 1986 
Feuerstein et al., 1987 
Schoups and De Potter, 1988
Middlemiss et al., 1988
Schlicker et al., 1989 
Fink et al., 1988
Schlicker et al., 1985b 
Galzin et al., 1988a
autoreceptor resembles more closely the 5-HT.j binding site. Further evidence in support 
of this hypothesis came from functional studies investigating the effects of a range of 
tryptaminergic agonists on the terminal 5-HT autoreceptor (Engel et at., 1983 ; Gothert 
and Schlicker, 1983). In addition, the 5 -HT2  receptor antagonists, ketanserin and 
spiperone were without effect at this receptor (Engel et at., 1983,1986). The 5-HT 
autoreceptor is unlikely to correspond to the 5-HT3 binding site, because 2-methyl-5-HT 
exhibits weak agonist activity (Engel et at., 1986), while the antagonist MDL 72222 is 
without effect (Middlemiss, personal communication).
A recent comprehensive study correlated the affinity of 17 5-HT agonists and 13 
antagonists for 5-HT binding sites with their functional activity at the terminal 5-HT 
autoreceptor in the rat cortex (Engel et at., 1986). A good correlation was obtained 
between their potencies or affinities for the 5-HT autoreceptor and their affinities at the 
5-HTfA and the 5-HT^q binding sites. However, the best correlation was obtained with 
5 -H T ib  binding site, suggesting that the terminal 5-HT autoreceptor in rat cortex 
corresponds to the 5-HT.j b binding site. The authors endeavour to point out that the 
distinction between the 5 -H T ^  and 5-HT.j b site would have been more prominent if the 
non-tryptamine derivatives, for example 8-OH-DPAT, ipsapirone and the 5-HT antagonists, 
spiperone and cyproheptadine, had been taken into account
8-OH-DPAT and buspirone exhibit considerable affinity for the 5-HT.j ^  binding site 
(Middlemiss and Fozard, 1983 ; Peroutka, 1985), but were demonstrated to be inactive as 
agonists or antagonists at the terminal 5-HT autoreceptor in the frontal cortex of the rat 
(Midddlemiss, 1984b, 1988), whereas Hamon et al. (1984) reported 8-OH-DPAT to 
attenuate the release of 5-HT from striatal slices, however at such a high concentration it 
may have acted at the 5-HT-j g receptor. In contrast, RU 24969 possesses a high affinity 
for the 5-HT.j £ binding site (Sills et at., 1984), and was a potent inhibitor of the release 
of 5-HT (Middlemiss, 1985a ; Gothert et at., 1987). These findings add further credence 
to the idea that the terminal 5-HT autoreceptor does not correspond to the 5 -H T ^  binding 
site, but instead bears similarity to the 5-HT.j b binding site.
To date, the terminal 5-HT autoreceptor has been identified in a variety of brain 
regions of a number of species (Table 1). Pharmacological analysis of this 5-HT
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autoreceptor in a number of regions of rat brain indicates no major differences with 
respect to the activity of agonists and antagonists, suggesting that these regionally 
distributed autoreceptors are similar and probably conserved within species.
Notably, the 5-HT.j g binding site has only been identified in rat and mouse brain, 
but is absent in guinea-pig, human, pig, pigeon and a number of other species. Although a 
5 -H T ib  binding site could not be identified in these species, they were instead 
demonstrated to possess a 5-HT1D binding site (Heuring et al., 1986 ; Hoyer et al., 
1986a ; Martial et al., 1989 ; Waeber et al., 1989). Autoradiographic studies have 
shown the distribution of the 5-HT^q site in guinea-pig and human brain (Waeber et al.,
1989) resembles the distribution of the 5-HT^q site in rat brain (Pazos and Palacios, 1985 
; Waeber et al., 1989).
Several research groups have identified a terminal 5-HT autoreceptor in guinea- 
pig, human, pig and rabbit brain (Feuerstein et al., 1987 ; Middlemiss et al., 1988 ; 
Galzin et al., 1988b ; Schlicker et al., 1989), which was different pharmacologically 
from the terminal 5-HT autoreceptor identified in the rat. This 5-HT autoreceptor in these 
species may bear similarity to the 5-HT.j q binding site (Hoyer et al., 1987 ; Hoyer and 
Middlemiss, 1989).
Although the terminal 5-HT autoreceptor found in the rat and mouse brain is 
pharmacologically different from that found in several other mammals, in particular man, 
this difference in classification should not detract from the fact that they are both involved 
in regulating the release of 5-HT from serotoninergic nerve terminals.
1.4.2 Characterization of the 5-HT binding site on 5-HT terminals
Early studies using radio-ligand binding and autoradiography had been unable to
demonstrate any changes in the number of 5-HT.j binding sites in the cortex, hippocampus
or the locus coeruleus after the destruction of serotoninergic nerve terminals with 5,7- 
DHT (Whitaker and Deakin, 1981 ; Verge et al., 1985 ; Weissmann-Nanopoulos et al.,
1985). More recent studies, however, using quantitative autoradiography, reported a 
reduction in the number of 5-HT.j binding sites in the dentate gyrus and the anterior
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hippocampus following the intracerebroventricular administration of 5,7-DHT (Fischette 
et al., 1987). Furthermore, destruction of the serotoninergic nerve bundle leaving the 
anterior raphe intact, using 5,7-DHT, was associated with a reduction in the number of 
n o n -5 -H T ^  binding sites (presumably 5-HTjq) in the substantia nigra (Verge et al.,
1986). These results suggest that at least some of the 5-HT1 sites in the dentate gyrus, 
anterior hippocampus and part of the non-5-HT.j^ in the substantia nigra, are probably 
located on serotoninergic nerve terminals and may correspond to the 5-HT^q autoreceptor. 
The inability of some studies to detect changes, following the degeneration of 
serotoninergic neurones is probably due to the small numbers of terminal 5-HT 
autoreceptors as well as the timing of the of the studies following degeneration.
1.4.3 Mechanism of regulation of release
The inhibitory effect of 5-HT on the release of [3 H]5-HT is reported to be related 
inversely to the stimulation frequency applied or the concentration of Ca2+ in the 
extracellular fluid, analogous to that observed for central and peripheral noradrenergic 
neurones (Langer, 1977). Gothert (1980) proposed that the action of 5-HT autoreceptor 
agonists and antagonists to control 5-HT release was the consequence of their ability to 
alter the affinity of the voltage-sensitive permeability channels of the cell membrane for
p .
C a ^  ions, thus modulating the amount available for stimulus release coupling.
The influx of Ca2+ ions is involved in the initiation, but several recently identified 
intraneuronal components have been implicated in mediating molecular events which bring 
about neurotransmitter release. Two of the more prominent candidates so far identified 
are synaptophysin and synapsin I (Trimble and Scheller, 1988). Synaptophysin, is located 
in the synaptic membrane, with its cytoplasmic domain possessing a Ca2+ binding site.
n ,
The binding of Ca*+ ions to this site of synaptophysin is considered to play a role in the 
exocytosis of neurotransmitter from synaptic vesicles. In contrast, synapsin I is found in 
the cytoplasm of all neurones, where it binds with high affinity to synaptic vesicles and to 
cytoskeletal components e.g. microtubules. This protein is rapidly phosphorylated during 
depolarization by cAMP- and Ca2 'f /calmodulin-dependent protein kinases, leading to its 
dissociation from synaptic vesicles, thus enabling release of vesicular contents.
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These two vesicle associated proteins represent only a small fraction of the 
components so far identified and implicated in regulating neurotransmitter release. Future 
research in this field is likely to lead to a better understanding of the molecular events as 
well as the mechanism/s by which presynaptic receptors function to modulate 
neurotransmitter release.
1.4.4 Compounds active at the terminal 5-HT autoreceptor
In the rat, [3 H]5-HT release is inhibited by 5-HT receptor agonists, all of which 
incorporate the indole nucleus. The most potent of these is 5-CT, plC5Q=7.65 (Engel et 
al., 1986) followed by RU 24969, plC5 0 =7.45 (Middlemiss, 1985a), the natural agonist 
5-HT, plC5 0 =7.34 (Middlemiss, 1984b) and LSD plCS0=5.50 (Engel et al., 1986).
Antagonists in terms of decreasing potency are: (-)cyanopindolol, pA2=8.30 
(Schlicker et al., 1985a); (isopropylester) of (±)-4[3-ter-butyl-am ino-2- 
hydroxypropoxy]indol-2 -carbonic acid £(±)-21 -009], pA2 =7.49 (Engel et al., 1986); (-) 
methiothepin, pA2=6.81 (Hibert and Middlemiss, 1986); (-)propranolol, pA2=6.72 
(Middlemiss, 1984a); (-)pindolol, pA2 =6.57 (Engel et al., 1986) and quipazine, pA2=5.29 
(Engel et al., 1983). Some of these compounds are competitive antagonists (Gothert, 
1980 ; Middlemiss, 1986), and some are also indole derivatives. Interestingly, with the 
exception of quipazine (which does not possess a chiral centre), the antagonist activity of 
the other compounds resides primarily in their laevo enantiomer (Nahorski and Willcocks, 
1983 ; Middlemiss, 1984a,1986 ; Schlicker et al., 1985a ; Hibert and Middlemiss, 1986). 
Methiothepin has been shown to increase the release of endogenous 5-HT from rat cortical 
and hypothalamic slices (Pettibone and Pflueger, 1984). In addition, some of these 
autoreceptor antagonists facilitate the stimulation-evoked release of 5-HT, when applied to 
brain slices. This is generally thought to be due to their antagonism of the endogenous tone 
created by the release of endogenous 5-HT on the presynaptic autoreceptor. However, 
some befa-adrenoceptor antagonists, at doses which exhibit antagonist activity at the 
autoreceptor, do not facilitate the stimulation-evoked release (Middlemiss, 1984a,1986). 
This is considered to be due to their partial agonist activity profile (Hjorth and Carlsson,
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1986 ; Maura et al., 1987), and separate from their membrane stabilizing activity 
(Barrett and Cullum, 1968).
Several of these autoreceptor antagonists are also potent befa-adrenoceptor 
antagonists, their antagonist activity at the 5-HT autoreceptor is unlikely to be mediated 
by a particular subtype of befa-receptor, because of the lack of effect of the befa- 
adrenoceptor agonists, isoprenaline (Schlicker et al., 1985a) and saibutamol (Baumann and 
Waldmeier, 1981) and the b e ta y  and be tag-selective antagonists, atenolol and ICI 
118551, respectively (Middlemiss, 1986).
As for the terminal 5-HT^p autoreceptor, the rank order of potency of agonists and 
antagonists is different to that found at the rat 5-HT^q autoreceptor. The rank order of 
potency of agonists and antagonists at the terminal 5-HT autoreceptor is given below for a 
number of species :
(1) Guinea-pig cerebral cortex slices (Middlemiss et al., 1988).
agonists : 5-CT (plC5 0 =8.1) > 5-HT (plC5 0 =7.4) > RU 24969 > GR 43175 ; 
antagonists : methiothepin (pA2 =8.2) > metergoline > methysergide = cyanopindolol 
(pA2= 6.5) *  yohimbine > mesulergine ;
(2) Pig cerebral cortex slices (Schlicker et al., 1989).
agonists : 5-HT > 5-methoxy-N,N-dimethyl-tryptamine *  5-CT > RU 24969 > 
yohimbine > cyanopindolol > 8 -OH-DPAT ; 
antagonists : methiothepin > metergoline > mianserin ;
(3) Rabbit hippocampal slices (Feuerstein et al., 1987).
agonists : 5-CT > 5-HT > 5-methoxy-N,N-dimethyl-tryptamine > 8 -OH-DPAT > 
methysergide > cyanopindolol ; 
antagonists : methiothepin > metergoline > cyanopindolol ;
(4) Human cerebral cortex slices (Galzin et al., 1988a,b).
agonists : 5-CT > RU 24969 ;
antagonists : methiothepin > metergoline = methysergide > propranolol.
It is worth noting that befa-adrenoceptor antagonists are only weakly active at 
the terminal 5-HT.j q autoreceptor in contrast to their marked potency at the 5-HT.j q 
autoreceptor. Furthermore, methiothepin is 24-40 times more potent at the guinea-pig 5-
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HT.J0  as compared to the rat 5-HT^g autoreceptor (Middlemiss et at., 1988).
1.4.5 Heteroreceptors regulating 5-HT release
In addition to possessing 5-HT autoreceptors, 5-HT nerve terminals are also 
endowed with a host of other receptors for other neurotransmitters. These receptors are 
known as presynaptic heteroreceptors, they are not activated by the 5-HT released form 
nerve terminals but can function to modulate its release. These heteroreceptors are 
generally studied using in vitro superfusion techniques. To date, a multitude of different 
heteroreceptors have been identified and their respective subtypes characterized. The 
most extensively studied of these is the a/pfta2-adrenoceptor in the cerebral cortex 
(Gothert and Huth, 1980) and the hippocampus (Frankhuijzen and Mulder, 1980 ; Maura et 
al., 1982). Neurotransmitter receptors located on 5-HT nerve terminals, which can also 
modulate 5-HT release include nicotinic and muscarinic (Marchi et al., 1986), GABAg 
(Schlicker et al., 1984), histamine H3  (Schlicker et al., 1988) and dopamine D2 
(Drescher and Hetey, 1988) receptors.
As these heteroreceptors are able to modulate 5-HT release, similarly, 5-HT 
heteroreceptors can also exercise control on the release of several other 
neurotransmitters in the brain. These 5-HT heteroreceptors are involved in regulating the 
release of acetylcholine (Maura et al., 1989), dopamine (Ennis et al., 1981) and 
noradrenaline (Molderings et al., 1989). The subtype of the 5-HT receptor involved in 
these effects has only been determined for acetylcholine release from slices of rat 
hippocampus, where it was reported to be of the 5-HT^q subtype (Maura et al., 1989). 
Furthermore, the 5-HT receptor located on sympathetic nerves of the rat vena cava is also 
of the 5-HT.j g subtype (Molderings et al., 1987).
1.4.6 interaction between the terminal 5-HT autoreceptor and the neuronal uptake site 
for 5-HT
In rat hypothalamic slices, the electrically-evoked release of [3 H]5-HT is inhibited 
in a dose-dependent manner by LSD. This inhibitory effect of LSD is attenuated by
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methiothepin and by the 5-HT uptake blocker, citalopram (Langer and Moret, 1982). This 
activity of citalopram was reproduced by a range of structurally diverse 5-HT uptake 
inhibitors, and wass unaffected by PCPA-depletion, suggesting that it was unrelated to the 
concentrations of 5-HT in the synaptic cleft (Galzin et at., 1985). On this basis, these 
authors proposed ithat 5-HT uptake inhibitors and 5-HT autoreceptor agonists interact by 
some functional link between the uptake mechanism and the autoreceptor, leading to a 
reduced autoreceptor function, similar to that proposed for noradrenergic neurones (Pelayo 
et at., 1980). Further extension of these studies demonstrated that this interaction 
occurred only under conditions of electrical stimulation (Galzin et at., 1986 ; Passarelli 
et at., 1987).
Bonanno and Raiteri (1987) also found citalopram attenuated the effect of 5-HT 
autoreceptor agonists on the stimulation-evoked release of [3 H]5-HT from rat cerebral 
cortex slices but not synaptosomes. Their findings suggested that the attenuating effect of 
citalopram was independent of the method of stimulation, occurring equally well under 
electrical as well as potassium-evoked release. They also questioned the existence of a 
functional link between the 5-HT autoreceptor and the 5-HT neuronal uptake site, instead 
attributing the effect of citalopram to the increased concentration of 5-HT expected in the 
synaptic cleft following 5-HT re-uptake block.
As regards to 5-HT neurones, if a functional link is present, then it may be of 
relevance in the treatment of depression because many antidepressant drugs are potent 
inhibitors of the neuronal uptake of 5-HT. Galzin et al. (1985) proposed that clinically 
prescribed antidepressant drugs, which block the neuronal uptake of 5-HT, may also lead to 
an attenuation of the activation of the 5-HT autoreceptor resulting in the enhanced release 
of 5-HT.
As yet, it is not clear whether a functional link exists between the 5-HT 
autoreceptor and the 5-HT neuronal uptake site or whether the uptake inhibitors influence 
the autoregulation by increasing synaptic concentrations of 5-HT.
1.4.7 ln_vitro identification of the somadendritic 5-HT autoreceptor
In vitro brain slices containing the dorsal raphe nucleus are monitored
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electrophysiologicaJly for their spontaneous firing activity. The spontaneous firing rate in 
slices, in vitro, is reported to be lower than that found in vivo, this is thought to result 
from the removal of an excitatory noradrenergic input (Vander Maelen and Agahajanian, 
1983). In contrast, Trulson and Crisp (1986) have reported the firing rate of 5-HT 
neurones to be higher in vitro. This discrepancy may be due to the membrane stabilizing 
action of chloral hydrate in the study of Vander Maelen and Agahajanian (1983).
In general, 5-HT, 5-HT-ja agonists and compounds that enhance 5-HT function, 
depressed the firing rate of these neurones, by an action on the 5-HT autoreceptor, while 
the depletion of 5-HT does not alter spontaneous firing rate (Trulson and Arasteh, 1986 ; 
Sprouse and Aghajanian, 1987 ; Trulson and Crisp, 1986). The 5-HT receptor 
antagonists, methiothepin, cyproheptadine and methysergide, did not alter the spontaneous 
firing rate, although methiothepin attenuated the inhibitory effect of 5-HT (Trulson and 
Crisp, 1986). In addition, the inhibitory effect of the putative 5-HTia receptor agonist, 
CM 57493, was antagonized by propranolol (Adrien et al., 1989). These in vitro studies 
should be interpreted with caution since rather high concentrations of agonists and 
antagonists were used.
1.4.8 In vivo evidence for the existence of the terminal 5-HT autoreceptor
Gallager and Aghajanian (1975) measured the in vivo release of newly-synthesized 
[^H]5-HT form [^Hjtryptophan in ventricular perfusates of the rat. They observed that 
systemically administered LSD (75 or 150 jig/kg) totally inhibited raphe cell firing and also 
produced a reduction in [^H]5-HT release. Although neuronal firing recovered to control 
rates 90 minutes after LSD administration, release was still depressed at this time. It 
was proposed that the inhibitory effect of LSD on neuronal firing was probably the result of 
its action on 5-HT cell bodies, yet it was unable to account completely for the reduction in 
[°H]5-HT release from terminals. In 1979, Hery et al., using a similar perfusion 
technique to Gallager and Aghajanian (1975), and measuring [^H]5-HT release from the 
caudate nucleus of enc£phale isol6 cats, demonstrated that locally applied LSD inhibited the 
release evoked by elevated potassium ions. These findings suggest that LSD also has an 
effect on 5-HT receptors located on presynaptic 5-HT terminals.
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Chaput et al. (1986a) measured the effect of electrical activation of the ascending 
5-HT pathway on the firing activity of postsynaptic hippocampal pyramidal neurones before 
and after the systemic administration of methiothepin. Methiothepin markedly increased 
the duration of the suppression of firing activity of these neurones without altering their 
responsiveness to microiontophoretically applied 5-HT. These in vivo findings suggest 
that methiothepin enhances synaptic transmission by blocking the activation of the terminal 
5-HT autoreceptor by endogenously released 5-HT.
The recent development of intracerebral dialysis and in vivo voltammetry which 
are used to measure extracellular concentrations of 5-HT and its primary metabolite 5- 
HIAA respectively, have allowed the determination of drug effects on central 5-HT 
function. Martin and Marsden (1985) reported similar results using both these techniques. 
Microdialysis has allowed the estimation of the extracellular concentration of 5-HT, which 
in the frontal cortex of freely moving rats was reported to be about 0.1 pM (Maidment et 
a!., 1986). However, following the recent development of an in vivo voltammetric 
electrode which selectively measures 5-HT concentrations in anesthetized rat frontal 
cortex and dorsal raphe nuclei were reported to be about 5 and 10 nM respectively (Crespi 
et al.f 1988). This disagreement is probably due to the underestimation of actual 
concentrations in anesthetized animals (Maidment et al., 1986), also, extracellular 
concentrations of 5-HT are not static but are constantly fluctuating, making their accurate 
estimation rather difficult. It is likely that the actual extracellular concentration in the 
frontal cortex is within the range used by Middlemiss (1984a,b) in in vitro studies to 
inhibit the evoked release of previously taken up [^H]5-HT. It has been suggested that the 
terminal 5-HT autoreceptor is under tonic inhibitory control. Evidence in support of this 
hypothesis has been provided by in vivo voltammetry, where the systemic administration 
of the putative terminal 5-HT autoreceptor antagonist, methiothepin was shown to increase 
5-HIAA concentrations in the hippocampus, hypothalamus, striatum (Baumann and 
Waldmeier, 1984) and SCN (Marsden and Martin, 1985a) of the rat. In contrast, the same 
dose of methiothepin reduced 5-HT release in the hippocampus as measured by 
microdialysis (Sharp et al., 1989b), this effect was considered to result from its partial
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agonist activity at the somadendritic 5-HT-j a  autoreceptor.
Following systemic administration, the putative 5-HT^q receptor agonist, RU 
24969, decreases extracellular concentrations of 5-HIAA in the rat frontal cortex (Brazell 
et al., 1985), SCN (Marsden and Martin, 1985a) and hippocampus (Sharp et al., 1989a). 
In addition, a similar effect was seen upon local application of RU 24969 to the SCN but not 
after its direct application to the dorsal raphe nucleus (Marsden and Martin, 1985a). 
Also, the local application of RU 24969 to the hippocampus via the perfusion fluid was 
associated with a decrease in 5-HT release (Sharp et al., 1989a, unpublished 
observations). Furthermore, the direct infusion of RU 24969 into the SCN prevents the 
dorsal raphe stimulated increase in 5-HIAA concentrations (Martin and Marsden, 1987). 
These results strongly suggest that the 5-HT-jq receptor regulating the release and 
metabolism of 5-HT is located in terminal containing regions and not on cell bodies or 
dendrites.
1.4.9 In vivo evidence for the existence of the somadendritic 5-HT autoreceptor
The systemic administration of 8 -OH-DPAT or ipsapirone produces a decrease in 
extracellular 5-HIAA concentrations in the SCN (implying a decrease in 5-HT release and 
metabolism), this effect is antagonized by ipsapirone and the a /p /^ -a d re n e rg ic  
antagonist, idazoxan (Marsden and Martin, 1986). A decrease in 5-HT release is also seen 
in the rat hippocampus, following the systemic administration of a number of 5-HT^a 
agonists, using brain microdialysis (Sharp et al., 1989a), whereas 5-HIAA concentrations 
were only slightly reduced or unchanged, suggesting that 5-HIAA may not be a good 
indicator of 5-HT released. In the same study, the common metabolite of buspirone, 
gepirone and ipsapirone, 1-(2 -pyrimidinyl)-piperazine, which also exhibits some affinity 
for a/p/ja2-adrenergic binding site, was without effect on 5-HT release, implying that the 
action of its parent compounds and 8 -OH-DPAT is likely to be mediated by the 5-HT^a and 
not a/p/}a2 -adrenoceptor. The poor correlation of 5-HIAA concentrations with 5-HT
released, reported in this study, is likely to be the result of the inclusion of an uptake 
blocker in the perfusion fluid, which would be expected to interfere with the reuptake and 
the subsequent metabolism of 5-HT, however, an uptake blocker is often necessary in order
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to achieve a stable and detectable concentration of 5-HT. In addition, changes in 5-HIAA 
concentrations are considered to be a reflection of the dose of 8 -OH-DPAT used, as a low 
dose (10  pg/kg) was shown recently to inhibit firing and release, while having little effect 
on 5-HIAA concentrations in the rat frontal cortex (Garratt et al., 1988 ; Crespi et al.,
1990). It therefore appears that the measurement of 5-HT metabolites may not provide an 
accurate reflection of alterations in the firing or the release of 5-HT.
The microiontophoretic application of 5-HT, 8 -OH-DPAT and other 5-HT1A agonists 
to the dorsal raphe nucleus produces a potent and consistent inhibition in raphe cell firing 
similar in magnitude to that seen following the systemic administration of these agents 
(Sprouse and Aghajanian, 1986,1987 ; Vander Maelen et al., 1986 ; Blier and deMontigny,
1987); this inhibitory effect on firing is likely to be responsible for the reduction in 5-HT 
synthesis as measured by 5-HTP accumulation in a number of forebrain regions (Hjorth and 
Magnusson, 1988) as well as the decrease in 5-HT release in the hippocampus in vivo 
(Sharp et al., 1989c). Furthermore, 8-OH-DPAT had no inhibitory effect on 5-HT release 
when applied to 5-HT terminal containing regions in vitro (Middlemiss, 1984b) or when 
added to the perfusion fluid during microdialysis, in vivo (unpublished observations 
reported by Sharp et al., 1989b).
The inhibitory effect of 5-HT and 5-HT1A agonists on raphe cell firing is considered 
to be the consequence of membrane hyperpolarization and decreased neuronal input 
resistance caused by an increase in membrane conductance to potassium ions (Sprouse and 
Aghajanian, 1987).
Several antagonists have been used to try to characterize the receptor/s involved 
in the regulation of 5-HT neuronal firing and release, following the administration of 5-HT 
agonists. Methiothepin, methysergide and metergoline display little antagonist activity to 
this response, (Haigler and Aghajanian, 1977 ; Steinberg et al., 1987 ; Sharp et al., 
1989b), whereas, in electrophysiological studies, propranolol when administered directly 
to the dorsal raphe nucleus, antagonized the effect of ipsapirone (Sprouse and Aghajanian,
1986), but was only weakly active when administered systemically (Adrien et al., 1989). 
This discrepancy may be due to the mode of administration, as Sharp et al. (1989b) also 
found propranolol to be inactive in attenuating the inhibitory effect of 8 -OH-DPAT on the
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release of 5-HT in the 'hippocampus when administered systemically. In contrast, pindolol 
partially attenuates the inhibitory effect of 8-OH-DPAT (Sharp et a l, 1989b), whereas, 
systemically administered spiperone attenuates the in vivo effects of 8-OH-DPAT and 
buspirone, on dorsal raphe firing (Lum and Piercey, 1988). Furthermore, the effect of 8- 
OH-DPAT is unlikely to be mediated by 5 -HT2 , 5-HTg, a/p/)a.|/2-adrenoceptors or 
dopamine2 receptors, as it proved resistant to antagonism by ritanserin, BRL 43694, 
phentolamine or sulpiride, respectively (Sharp et al., 1989b).
Systemic administration or the direct infusion of low doses of 8-OH-DPAT into the
raphe, produces hyperphagia in satiated rats. This hyperphagic response occurs 
independently of the behavioural syndrome, and is prone to antagonism by spiperone and 
pindolol, suggesting that it is likely to be mediated by the activation of the somadendritic 
5 -H T ^  receptor located in the raphe (Hutson et al, 1987).
Autoradiographic studies have identified a high density of the 5 -H T ^  binding site 
on 5-HT cell bodies and or dendrites in the dorsal and median raphe region of the rat brain 
(Verge et al, 1985 ; Weissmann-Nanopoulos, 1985 ; Thor et al, 1990). The selective 
destruction of 5-HT cell bodies, using 5,7-DHT, was associated with a more pronounced 
reduction in the number of 5-HT.j binding sites in the dorsal as compared to median raphe 
(Fischette et a l, 1987). In addition, a recent study has shown the dorsal raphe to be 
more responsive to 5 -H T ^  agonists as compared to the median raphe (Blier et al, 1990). 
Taken together, these results strongly suggest that 8-OH-DPAT, at low doses, 
preferentially activates the somadendritic 5 -H T ^  autoreceptor at the level of the dorsal 
raphe, regulating 5-HT neuronal firing as well as the synthesis and release of 5-HT (Hjorth 
and Magnusson, 1988).
1.4.10 Functional adaptations of the 5-HT autoreceptor
The putative 5-HT autoreceptor antagonists augment the release of 5-HT from 5-
HT neuroterminals both in vitro (Gothert, 1980 ; Schlicker et al, 1985a) and in vivo
(Baumann and Waldmeier, 1984 ; Chaput et a l, 1986a) are consistent with the presence 
of an endogenous tonic inhibitory 5-HT tone. This 5-HT autoreceptor lends itself to
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functional studies of adaptation of receptor sensitivity. For example, the terminal 5-HT 
autoreceptor is desensitized by the chronic long-term stimulation induced by a selective 5- 
HT uptake inhibitor, in conjunction with an MAOI (Maura and Raiteri, 1984) or following 
chronic tricyclic antidepressant administration (Schoups and De Potter, 1988). 
Conversely, chronic blockade with the 5-HT antagonist, methiothepin, is reported to have 
mixed effects, it produced hypersensitivity of cortical 5-HT autoreceptors (Maura and 
Raiteri, 1984) but was without effect on hypothalamic 5-HT autoreceptors (Hagan and 
Hughes, 1983).
Electrophysiological studies, in vivo, report chronic administration of the 5-HT 
uptake inhibitors, citalopram (Chaput et al., 1986b) or fluoxetine, but not the MAOI, 
clorgyline (Blier et al., 1988), to desensitize the terminal 5-HT autoreceptor. In 
contrast, Sleight et al. (1989) using in vivo brain microdialysis, did not observe any 
changes in the release of 5-HT as modulated by the 5-HT autoreceptor, following the 
chronic administration of either amitriptyline or MDL 72394 (an MAOI).
The somadendritic 5 -H T ^  autoreceptor is also desensitized following the chronic 
long-term administration of 5-HT uptake inhibitors (DeMontigny et al., 1984 ; Chaput et 
al., 1986b), an MAOI (Blier and deMontigny, 1985), 5 -H T j^  agonist (Blier and 
deMontigny, 1987), and also after the partial depletion of 5-HT in the raphe (Chaput et al.,
1987). In contrast, the repeated administration of 8 -OH-DPAT was recently demonstrated 
to be ineffective in altering the sensitivity of the somadendritic 5 -H T ^  autoreceptor 
(Larsson et al., 1990).
1.4.11 Therapeutic possibilities of compounds selective for the 5-HT autoreceptor
In the rat, the 5-HT.j q binding site has been correlated with the terminal 5-HT 
autoreceptor (Engel et al., 1986). However, this 5 -H T ^  binding site is only found in rat 
and mouse brain, and other species, namely, the human brain, do not possess a 5-HT^g 
binding site, but instead possess a 5 -HTlD  binding site (Heuring et al., 1986 ; Hoyer et 
al., 1986a). The terminal 5-HT autoreceptor in these species is considered to correspond 
to this 5-HT-jq binding site (Galzin et al., 1988a ; Waeber et al., 1989). Although these
two terminal 5 -HT autoreceptors can be differentiated pharmacologically, they are 
functionally very similar (Hoyer and Middlemiss, 1989 ; Schoeffter and Hoyer, 1989).
The somadendritic 5-HT autoreceptor in rat brain is of the 5 -H T ^  subtype (See 
section 1.4.9). Human brain contains a similar binding site in the raphe region, and this 
may correspond to the somadendritic 5-HT autoreceptor, which is conserved between 
species ( Hoyer era/., 1986a ; Palacios et al., 1987).
The selective activation by agonists of the somadendritic 5 -H T ^  autoreceptor 
located on 5-HT cell bodies is associated with an inhibition of neuronal firing and a decrease 
in 5-HT synthesis and release both locally and in terminal-containing regions (Hjorth and 
Magnusson, 1988). A similar effect on release and possibly synthesis of 5-HT in 
terminal-containing regions could be achieved by a selective terminal 5-HT autoreceptor 
agonist (Middlemiss, 1988). Thus, the selective activation of either autoreceptor would 
serve to decrease 5-HT function.
The development of a selective 5-HT autoreceptor agonist may have anxiolytic 
activity, since anxiolytic drugs, such as benzodiazepines (Stein era/., 1975) and 5-HT2 
antagonists (Ceulemans era/., 1985), are associated with a reduced 5-HT function. In 
support of this hypothesis the 5 -H T ^  receptor partial agonist, buspirone has recently 
been introduced clinically (Goa and Ward, 1986). For a more extensive account of the 
anxiolytic potential of 5-HT selective compounds, the reader is referred to a review by 
Marsden (1990).
An antihypertensive role is forecast, based on the ability of urapidil to reduce blood 
pressure by a selective action on the somadendritic 5 -H T ^  receptors located in the 
medulla (Mandal et al., 1989). In addition, presynaptic 5-HT heteroreceptors belonging to 
the 5-HTi g subtype have been identified on sympathetic nerves of rat vena cava (Gothert,
1988); their selective activation may also contribute to an antihypertensive effect.
Selective antagonists at the 5-HT autoreceptor would be expected to increase the 
release of 5-HT and thereby enhance 5-HT function. Currently available drugs that 
enhance 5-HT function are, the 5-HT uptake inhibitors (fluvoxamine and fluoxetine) used as 
antidepressants and the 5-HT releaser (fenfluramine) as an appetite suppressant. An 
enhanced 5-HT function may be involved in the the processing of noxious sensory stimuli in
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the spinal cord, which suggests for a analgesic role (Hammond, 1985).
1.4.12 Aims of this study
A circadian rhythm in the concentration of 5-HT in rodent brain is well established, 
although the phase of the rhythm is not the same in all brain regions, the peak 
concentrations generally occur during the light phase. The observed rhythm appears to the 
the result of several factors ; thus, whereas the concentrations are higher during the light 
phase, the rate of synthesis and release are greatest during the dark phase, when the 
animals are most active. Release of 5-HT is, in turn, affected by many factors, including 
the activity of the terminal 5-HT autoreceptor which, when stimulated by 5-HT, inhibit 
transmitter release.
Previous studies have demonstrated a marked circadian variation in behavioural 
responses to 5 -HT2  receptor stimulation, while those associated with 5-HT.j receptors are 
characterized by the apparent absence of any variation (Moser and Redfern, 1985).
Martin et al. (1987) proposed that the circadian variation rhythm in the release of 
5-HT from central serotoninergic neurones derives, at least in part, from the 
corresponding rhythm in sensitivity of the terminal 5-HT.j 0  autoreceptor.
The aims of this study were therefore :
1) to gauge the functional activity of the terminal 5-HT autoreceptor over 24- 
hours, in order to determine whether it is directly responsible for generating or controlling 
the circadian rhythm in the release of 5-HT;
2) to examine the binding of [3H]5-HT and relate this to the functional activity of 
the terminal 5-HT autoreceptor;
3) to determine the 24-hour activity of the a/pha2-adrenoceptors located on 
serotoninergic nerve terminals, as they can also modulate 5-HT release;
q
4) to monitor rH]ketanserin binding over 24-hours and relate this to the reported 
circadian variation in behaviour observed following 5-HT2 receptor stimulation;
5) to measure the in vivo functional activity of the somadendritic 5-HT.j A 
autoreceptor, over 24-hours, since this receptor is able to exercise control over the 
synthesis and release of 5-HT.
-45-
2 NEUROTRANSMITTER RELEASE FROM BRAIN SLICES
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2.1 HOUSING OF ANIMALS
2.1.1 1 M £
Special cabinets were constructed to house the animals. Domestic extractor fans 
(Phillips, type HR 3408) were fitted to supply a constant current of air through the 
cabinets. One fan served six cabinets. Lighting (650-850 Lux) was supplied in each 
cabinet by a small white fluorescent tube (Phillips, TL 8W), with the choke removed and 
refitted outside the cabinet to prevent overheating. Each tube light was connected to a 
time switch (Smiths, TS 100 C). The inside of the boxes was lined with polystyrene (2.4 
cm thick) to provide sound insulation. Plastic draught excluder foam strips (1.3 cm thick) 
were glued to the edge of the cabinet door to ensure light proofing. Similar cabinets have 
earlier been characterised and found to be adequate (Hillier, Davies and Redfern, 1973).
A single cage containing six rats was placed inside each cabinet. These animals 
were maintained on a 12 hour light : 12 hour dark cycle for at least 14 days prior to their 
use in experiments. Most of the experiments were performed during the normal working 
hours in the laboratory, however some were also performed outside normal working hours 
necessitating some animals to be phase shifted. These phase shifted animals were also 
allowed 14 days to entrain to the new light : dark cycle, prior to their,use (Davies, 
Navaratnam and Redfem, 1974). When the animals were killed or their cages cleaned in 
the dark phase, the holding room was illuminated only by a low intensity red lamp (GEC, 15 
W bulb, 4-6 Lux) since it has been shown not to have any significant effect on circadian 
rhythms (McGuire, Rand and Wurtman, 1973). The temperature of the room varied from 
18-22°C, while the temperature inside the boxes varied from 20-23°C.
The animals had free access to both food (CRM pellets, Labsure) and water so that 
the animals could be left undisturbed for several days. However, regular inspections were 
made to ensure that the timers were working properly and that the animals had not 
managed to escape from the cages. Cages were cleaned every two to three days, with the 
cleaning times being randomized in order to prevent them from being interpreted as a cue. 
These conditions ensured that the animals were isolated from undue enviromental 
influences.
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Male Wistar rats (University of Bath strain) weighing between 100-140g were 
housed in groups of six, with one group per cabinet (light on, 09.00 to 21.00 ; light off, 
21.00 to 09.00). Some animals were phase shifted to the opposite of this lighting 
schedule. After 14 days of acclimatization the animals weighed between 200-350g.
2.1.2
Guinea-pigs (Dunkin Hartley strain) of both sexes were used in these experiments. 
They were housed in groups of six, in stainless steel floor pens, each pen containing a 
reservoir of food (Labsure FD 1 pellets), and two water bottles. The animals also received 
a small supply of greens and hay. Two pens were placed in an air-conditioned room (temp. 
18-22°C). The room was lit by two fluorescent tube lights (each 6 foot long) located on 
the ceiling. The lighting was controlled by a 24-hour timer located in a different room 
(light on, 09.00 to 21.00 ; light off, 21 .00  to 09.00). The animals were kept on this 
lighting schedule for a minimum of two weeks prior to their use in experiments. When used 
they weighed between 450-550g. None of these animals were phase shifted.
2.2 SUPERFUSION STUDIES
2.2.1 The Suoerfuslon System for tissue slices
The superfusion apparatus consisted of jacketed glass general tissue baths (150 ml 
capacity, used as reservoirs), linked via tubing to a pump which in turn supplied the 
superfusion chambers (Fig. 1 and Fig. 2). There were seven tissue baths which functioned 
to maintain buffer at 37°C and ensure that it is was continuously gassed with 95% 0 2  and 
5% C02- The outlet at the base of these baths was connected via rubber tubing to a three 
way tap, which allowed for the switching of buffers and reduced the possibility of 
introducing air into the tubes. Air is known to produce irregular release rates and at 
worst tissue death (Middlemiss, personal communication). The taps were in turn 
connected via silicone manifold tubing (Watson and Marlow, model TE 6 ), to a twelve 
cassette peristaltic pump head (Watson and Marlow, model 501 AA) operated by a Watson 
and Marlow pump (model 502 S). Each cassette was linked to the base of an individual 
chamber via silicone manifold tubing, the tubing first having to pass through a water bath
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The Superfusion Apparatus
Figure 1. (top) and Figure 2 . (bottom) These figures display the relative positioning of 
the various components comprising the superfusion system. These figures show the tissue 
baths (buffer reservoirs), pump, water bath, water circulator, superfusion block, fraction 
collector and the collection vials. The temperature probe has been removed.
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maintained at 37°C (Grant water circulator, model SU 5). The ten superfusion chambers 
were housed in a perspex block which was lagged by a water jacket (Fig. 3). A 
temperature probe was fitted to the block to ensure that the temperature was maintained 
between 36-37°C (RS, model 612-849). The water circulator maintained the temperature 
of not only the superfusion block but also the tissue baths, containing buffer. Each chamber 
had its own stopper to keep its hollow glass cylinder in place and so prevent tissue loss. 
Tubing was connected to the top of each stopper to enable the effluent to be directed. The 
effluent of each chamber was collected via this outlet tubing being linked to a perspex arm 
of a modified fraction collector (Gilson micro fraction collector, model 203). This allowed 
for the effluent of all ten chambers to be collected simultaneously, at 4 minute intervals.
The superfusion system was cleaned at the end of each working day by flushing it 
through with distilled water for 30 minutes. Also, at the end of each working week the 
system was flushed with domestic detergent (Decon Laboratories), for 15 minutes followed 
by distilled water to wash away any detergent.
The flow rate for each of the chambers was calibrated at the beginning of each
working week. The silicone manifold tubings were regularly inspected and were replaced
when any inconsistency in flow rate or the growth of extraneous matter was discovered.
2.3 METHODS
2.3.1 Effect of uptake Inhibition on the accumulation of f3 H15-HT into
slices of rat cerebral cortex
The cerebral cortex from each of two male Wistar rats (200-350g) was rapidly 
dissected and chopped in two directions at 250 pm on a Mcllwain brain tissue chopper. 
Half of the slices were incubated for 15 minutes at 37°C (Grant water bath, model JB 2) in 
5ml Krebs buffer, p.H. 7.4 (composition (mM) : NaCI 135, KCI 5, NaHCOg 25, MgSO^ 1, 
KH2 PC>4 1.25, CaCI2  2 , Glucose 10; gassed with 95% 0 2  and 5% C02) containing 10 pM 
pargyline. The other half of the slices were incubated in an identical solution which 
contained the 5-HT uptake inhibitor, paroxetine (3.2 pM). Following this initial incubation,
q
[ H]5-HT containing ascorbic acid was added to both the tissue slice containing solutions so 
that the [3H]5-HT and ascorbic acid were present at a concentration of 0.1 pM and 200 pM
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respectively. Both the solutions were then incubated for a further 15 minutes, at 37°C. 
At the end of this second incubation period the slices from both solutions were washed 
three times'with 5ml Krebs buffer and 100 pi of slices were transferred to each of four 
chambers. Each chamber contained a hollow glass cylinder (10 mm high, 8  mm diameter, 
volume 500 pi) mounted on a piece of circular nylon mesh. After the slices were placed 
into the glass cylinder, another piece of circular nylon mesh was placed at the top, to 
prevent the escape of tissue slices. The stoppers were than located into place and the 
slices superfused against gravity with Krebs buffer (containing 3.2 pM paroxetine to 
prevent the re-uptake of [3 H]5-HT), at a rate of 0.4 ml/min. After a 30 minute period of 
superfusion the slices were removed from the chambers and weighed. After weighing they 
were transferred to a plastic scintillation vial and 10 ml of Optiphase "Safe” (LKB) added. 
They were then sonicated (Dawe, Ultrasonics Ltd.) for 15 minutes. After three hours of 
stabilization in the scintillation counter (LKB, 1215 Rackbeta) their radioactivity content 
was determined at an efficiency of 37.5%. Each sample was counted for 5 minr The 
radioactivity remaining in the tissue slices was expressed as disintegrations per minute, 
per milligram tissue (dpm/mg).
2.3.2 Effect of change In Incubation temperature on the accumulation of 
f3 HI 5-HT Into slices of rat cerebral cortex
The method of this study was essentially similar to that described in section 2.3.1, 
the only differences being that the initial incubation step with an uptake inhibitor was 
omitted, and the second incubation with [3 H]5-HT and ascorbic acid was performed at 0°C 
and 37°C.
2.3.3 Effect of varying concentrations of potassium ions on the fractional 
release rate
This work was carried out to determine a suitable concentration of potassium for 
evoking the release of tritium from brain slices. The method being essentially the same as 
that described in section 2.3.2, up to the point where the chambers were perfused with
Krebs buffer containing paroxetine 3.2 pM for 30 min. Thereafter, the chambers were 
exposed to Krebs buffer of varying potassium ion concentration (5, 15, 25, 35 and 50 
mM), containing paroxetine 3.2 pM. The varying concentrations of potassium ion in Krebs 
buffer were prepared by an appropriate reduction in the NaCI, thus maintaining osmolarity. 
Each concentration of potassium was exposed to two chambers. The chambers were 
superfused with these solutions for 16 min, thereafter the two successive 4 minute 
fractions were collected. Their fractional release rate was calculated following the 
determination of the radioactivity still retained by the tissue slices. This was done by 
removing the slices from the chambers and sonicating them with 10 ml of liquid scintillation 
fluid followed by counting in a liquid scintillation counter.
2.3.4 Effect of removal of calcium Ions on the potassium-evoked release 
of tritium from brain slices
The method used here was essentially similar to that described in section 2.3.3, up
to the point where the chambers were exposed to Krebs buffer containing elevated
potassium ions (25 mM for rat and 35 mM for guinea-pig) for 16 minutes. After this 
period, eleven successive 4-minute fractions were collected (ie t=46 min to t=90 min). In
q
order to prevent the re-uptake of [^H]5-HT into serotoninergic neurones, paroxetine (3.2 
pM) was present in the superfusion buffer from t=0 min.
From t=54 min, calcium ions were removed from the Krebs buffer (by iso-osmolar 
replacement of CaCI2  by MgCI2), supplying four of the chambers (of the remaining six 
chambers, four received elevated potassium containing calcium while two received 
unmodified Krebs). As before the radioactivity remaining in the slices and in each fraction 
was determined by liquid scintillation counting.
In one particular experiment, calcium ions were removed at t=54 min and then
subsequently reintroduced at t=78 min.
2.3.5 Effects of agonists and antagonists on the basal release of tritium
The agonists and antagonists that were to be used in the superfusion studies were 
tested individually at their highest concentration to assess their effects on the basal
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release of tritium. The agents (8 -OH-DPAT 1 pM, 5-HT 1 pM, noradrenaline 10 pM, 
methiothepin 1pM and phentolamine 100 nM) were tested on slices of the appropriate brain 
region, being added to the superfusing Krebs buffer at t=54 min and remained present until 
t=82 min. Three chambers received one drug, three another and the remaining four 
chambers served as control.
2.3.6 Rat cortical and hippocampal, terminal 5-HT autoreceptor activity 
over 24-hours
These studies were carried out using the cumulative dose-response technique of 
Frankhuijzen and Mulder (1982), in its modified version as described by Middlemiss (1984 
a,b).
Two rats (weighing 200-350g) were used per experiment, they were killed by 
cervical dislocation in the appropriate phase of the light : dark cycle. The cerebral cortex 
or hippocampus was then rapidly dissected, trimmed free of white matter and adhesive 
blood vessels and chopped in two directions at 250 pm on a Mcllwain brain tissue chopper. 
The resulting slices were incubated for 15 minutes at 37°C in 5 ml Krebs buffer, p.H. 7.4, 
containing 0.1 pM [3 H]5-HT, 200 pM ascorbic acid and 10 pM pargyline. After three 
washes with 5 ml Krebs buffer, (50 pi cortical or 25 pi hippocampal), aliquots of the slices 
(about 15-30 mg tissue of cerebral cortex), were transferred to the glass cylinder located 
in each chamber, of a ten chambered superfusion apparatus and superfused against gravity 
with Krebs buffer at a rate of 0.4 ml/min. In these experiments a piece of filter paper 
(Whatman, GF/F, 10 mm diameter), was placed at either end of the glass cylinder to 
prevent loss of tissue slices, this is different from the nylon mesh used in the uptake study. 
After a 30 minute period of superfusion, eight of the chambers containing the slices were 
exposed to Krebs buffer containing elevated potassium ions (25 mM, made by the iso- 
osmolar replacement of NaCI with KCI), for 16 minutes. After this period, fractions were 
collected every 4 minutes, 18 in all (ie t=46 min to t=118 min). In order to prevent the 
re-uptake of [3 H]5-HT or endogenous 5-HT into serotoninergic neurones, paroxetine (3.2 
pM) was present in the superfusion fluid from t=0 minutes.
At the end of each experiment the tissue slices were removed and placed in plastic 
scintillation vials. After the addition of 12 ml of liquid scintillation fluid (Optiphase 
"Safe”, LKB), to each vial, it was sonicated (Dawe Ultrasonics Ltd.) for 15 minutes. The 
ordinary fraction samples (i.e. those containing effluent only) were not sonicated but 
instead were vigorously shaken after the addition of scintillation fluid. All samples were 
allowed three hours of stabilization in the scintillation counter (LKB, 1215 Rackbeta), prior 
to counting. Each sample was counted for 3 min. The counter first subtracted a 
predetermined background value, and then corrected for the quenching of each sample by 
the use of the ratio procedure, against a stored quench curve. The final counts were 
therefore expressed as disintegrations per minute.
From t=54 min cumulative dose responses to 5-HT were constructed using four 
concentrations of agonist (30, 100, 300 and 1000 nM), with a 16 minute time interval 
between each successive increase in 5-HT concentration (preliminary experiments using 5- 
HT indicated that the maximum effect was present after 12 minutes). At its highest 
concentration, 5-HT (1000  nM) did not affect the baseline efflux of tritium, basal efflux 
was therefore taken as the release in the absence of added agonist. The fractional efflux 
rates were calculated as described by Frankhuijzen and Mulder (1982). The fractional 
efflux rate was calculated as the fraction of tritium content of slices at the onset of the 
respective 4-minute collection period. In each experiment involving an agonist, the 
fractional efflux rate (mean of 2-4 chambers per treatment), was determined for each 4- 
minute fraction for both basal and potassium-evoked efflux. The subtraction of basal from 
potassium-evoked efflux values was taken as control potassium-evoked tritium overflow. 
Drug effects were expressed as the percentage of the relevant control potassium-evoked 
tritium overflow, measured 16 min after their addition.
Experiments using the natural agonist, 5-HT were performed at four different, 
equally spaced time points in the 12 hour light : 12 hour dark cycle of the rat (i.e. mid­
light, mid-dark, end-light, end-dark).
Experiments using the 5-HT autoreceptor antagonist methiothepin were carried out 
by the addition of the drug at a concentration of 1 |iM to the superfusion fluid (elevated 
potassium), supplying four of the chambers, at t=30 min. Methiothepin was then present
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in the buffer, throughout the superfusion. All chambers received elevated potassium (four 
were used to assess the effect of the agonist in conjunction with the antagonist, three 
received only the agonist and the remaining three received no drug). These experiments 
were performed at the same time points as the agonist studies. Basal values from the 
agonist data were used in the calculation of the apparent pA2  values for methiothepin.
2.3.7 Rat hippocampal a/p/?a2-adrenoceptor activity over 24-hours
The ability of a/p/7a2 -adrenoceptors to regulate the release of tritium was 
examined over 24 hours. The experimental procedure employed was the same as that 
described above, with the exception that a cumulative dose-response curve was 
constructed using four concentrations of noradrenaline (0.01, 0.1, 1 and 10 pM), while 
phentolamine (100 nM) was used to antagonize the effect of noradrenaline.
2.3.8 Effect of 8 -OH-DPAT on tritium  efflux from cerebral cortex slices
This study was carried out in a similar manner to that described in section 2.3.6.
Cerebral cortex slices were prepared from rats during the mid-light point of their light : 
dark cycle. A cumulative dose-response curve was constructed to 8 -OH-DPAT (30, 100, 
300 and 1000 nM). All chambers received elevated potassium ions (25 mM), three of 
these received 5-HT in a cumulative manner and four received 8-OH-DPAT, the remaining 
three served as control. Basal release rate values from previous experiments were used 
to determine percentage inhibition.
2.3.9 Guinea-pia 5-HT terminal autoreceptor activity over 24-hours
These studies were carried out in exactly the same manner as the work
q
investigating the release of [°H]5-HT from rat cerebral cortex and hippocampal slices 
(section 2.3.6), with a few modifications. The potassium ion concentration used to evoke 
tritium efflux from slices was 35 mM, as opposed to the 25 mM used in rat. Also, 40 pi 
aliquots of cerebral cortex slices, were used in each chamber. Finally, in antagonist 
studies methiothepin was used at a concentration of 10 nM.
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2.3.10 Effect of chronic methiothepin on autoreceptor sensitivity
In order to assess whether changes in sensitivity of terminal 5-HT autoreceptors 
could be detected, work was carried out to investigate the sensitivity of presynaptic 5-HT 
autoreceptors in regulating tritium efflux from cortical slices from control and 
methiothepin injected rats. Control rats received daily injections of saline for 14 days, 
while another group of rats received methiothepin (10 mg/kg i.p.), daily for 14 days 
(Maura and Raiteri, 1984). All rats were injected at the same time of the day 
(corresponding to the mid-light point in their light : dark cycle), and were killed by cervical 
dislocation, exactly 3 days after the last injection. The cerebral cortex was then rapidly 
dissected and used in superfusion studies, as described earlier. Autoreceptor sensitivity 
was assessed using three concentrations of exogenous 5-HT (30, 100, 300 nM). Eight 
chambers received elevated potassium (four were exposed to the agonist 5-HT, in the 
concentrations described above, and four were received no drug). The remaining two 
chambers received unmodified Krebs and were used to determine basal release rates.
2.3.11 Criteria for the Inclusion/exclusion of chambers In the calculation 
of results
Criteria were set to ensure consistency of results. These were :
(1) Results from experiments would only be considered if more than two chambers of 
each treatment group had worked (/.e. shown no irregular, unexpected release rates);
(2) Chambers would be excluded if their initial starting release rate was ± 25% of the 
mean of the other chambers (this occurred rather frequently at the start of this work and 
became a rarity towards the end);
(3) The mean fractional release rate of the surrounding chambers would be taken if for 
some reason one sample exhibited an anomalous release rate {i.e. greater than 20% of 
previous sample);
(4) The entire data for a chamber would be excluded if it exhibited more than one 
anomalous release rate;
(5) The entire data for a chamber would be excluded if the release rate during sampling 
was consistently greater than that at the start of sampling.
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2.3.12 Calculations and Statistics
Student's t-test was used for comparing the effect of temperature and that of the
5-HT uptake inhibitor paroxetine on the uptake of [3 H]5-HT into slices of rat cerebral 
cortex.
The apparent IC5q (concentration of 5-HT required to inhibit the potassium-evoked 
release by 50%), was calculated for each experiment. This IC50  was converted to the 
PIC50  (-log10 of IC50) for each experiment. Apparent pA2  (-log1Q of the molar 
concentration of antagonist with which the ratio of equi-effective concentrations of agonist 
in the presence and absence of antagonist is two), values for methiothepin and phentolamine 
were calculated for each experiment as described by Schlicker and Gothert (1981).
The one-way analysis of variance test was used for comparison of the effect of 
effect of potassium ions and its enhancement by methiothepin as well as the apparent plC5 0  
agonist and the apparent pA2  antagonist values, at the four time points for each brain 
region. In experiments where autoreceptor sensitivity was determined at two 
diametrically opposite time points, the Student's t-test was used for comparison.
2.3.13 D rugs
[3 H]5-HT, 12-20 Ci/mM (Amersham lnt.,Amersham, England), 8-hydroxy-2-(di- 
n-propylamino)tetralin (Semat Technical Ltd., St. Albans, England), 5-hydroxytryptamine 
creatnine sulphate (Sigma, St. Louis, MO, USA), noradrenaline bitartrate (Sigma), 
pargyline hydrochloride (Sigma), paroxetine hydrochloride (gift from Beechams, 
Brentford, England), phentolamine mesylate ("Rogitine", Ciba, Horsham, England), 
methiothepin maleate (gift from Roche, Herts, England).
2.4 RESULTS
The selective accumulation of [3 H]5-HT into serotoninergic neurones was
q
performed using [°H]5-HT at a concentration of 0.1 jiM, a value corresponding to the Km of 
the high affinity uptake site (Shaskan and Snyder, 1970 ; Azmitia and Marovitz, 1980).
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2.4.1 Effect of uptake Inhibition or change In incubation temperature on 
the accumulation of f3 HI 5-HT Into slices of rat cerebral cortex
Incubations performed at 0°C were associated with a significant, 80%, reduction 
(37°C 3279±426 dpm/mg tissue, n=9 ; 0 °C 664±40, n=4 (mean±s.e.m.)) in the 
accumulation of [3 H]5-HT as compared to those performed at 37°C (Fig. 4).
Paroxetine is a 5-HT uptake inhibitor (Habert et al., 1985). Its inclusion at a 
concentration of 3.2 pM in the incubation medium produced a significant reduction in the 
accumulation of [3 H]5-HT by slices of rat cerebral cortex (Fig. 4). A reduction of about 
84% (control 3279±426 dpm/mg tissue, n=9 ; paroxetine 525±149, n=5 (meants.e.m.)) 
was observed, while the remaining 16% is likely to reflect either non-specific uptake or 
binding of [3 H]5-HT.
2.4.2 Effect of variation In potassium Ion concentration on the fractional 
release rate from brain slices
The fractional release rate of tritium was dependent on the potassium ion 
concentration of the Krebs buffer. When potassium ion concentration was plotted against 
fractional release rate a similar shaped curve was observed from slices of rat cerebral 
cortex (Fig. 5) and hippocampus (Fig. 6 ) and guinea-pig cerebral cortex (Fig. 7). 
Subsequent studies employed a sub-maximal 25 mM potassium ion concentration to evoke 
the release of tritium from slices of rat cerebral cortex and hippocampus. In contrast, 
guinea-pig cerebral cortex slices were less sensitive to the effect of potassium ions, 
consequently a 35 mM concentration was chosen to evoke release. This choice of 
potassium ion concentration represents a sub-maximal value, since the inhibition of release 
produced by 5-HT autoreceptor agonists is inversely related to the size of the stimulation 
(Gothert, 1980).
2.4.3 Effect of the removal of calcium Ions on the potassium-evoked 
release of tritium from brain slices
The iso-osmotic replacement of calcium ions in the Krebs buffer with magnesium 
ions caused the potassium-evoked release of tritium to fall towards basal levels from rat
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Figure 4. Effect of a change in incubation temperature or 












Slices of rat cerebral cortex were incubated with [3 H]5-HT for 15 min at 0°C, 
37°C and in the presence of the 5-HT uptake inhibitor, paroxetine. The slices were 
then washed using a superfusion apparatus for 30 min and their radioactivity 
content determined. The results are expressed as means ± s.e.m. of 4-5 separate 
experiments.
Control 37°C Incubation 0°C Paroxetine
3.2 pM, 37°C
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Figure 5. Effect of varying potassium ion concentration
on the release of f3H15-HT from slices of rat cerebral
cortex
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Tissue slices were exposed to a variety of concentrations of potassium ions at t=30 
min and the fractional release rate measured at t=46 min. The results are 
expressed as the mean of the fractional release rate, from two separate experiments.
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Figure 6. Effect of varying potassium ion concentration










0 1 0 20 30 40 50 60
Potassium ion concentration (mM)
Tissue slices were exposed to a variety of concentrations of potassium ions at t=30 
min and the fractional release rate measured at t=46 min. The results are 
expressed as the mean of the fractional release rate, from two separate experiments.
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Figure 7. Effect of varying potassium ion concentration
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Tissue slices were exposed to a variety of concentrations of potassium ions at t=30 
min and the fractional release rate measured at t=46 min. The results are 
expressed as the mean of the fractional release rate, from two separate experiments.
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cerebral cortical (Fig. 8 ) and hippocampal (Fig. 9) and guinea-pig cerebral cortical (Fig. 10) 
slices. Interestingly, the reintroduction of calcium ions was associated with an increased 
release of tritium from rat cerebral cortex slices (Fig. 11). These results suggest that 
the potassium-evoked release component is entirely calcium dependent, and are in good 
agreement with the findings of Gothert (1980).
2.4.4 Effect of agonists and antagonists on the basal efflux of tritium
The agonists and antagonists used in superfusion studies were tested individually at
their highest concentration for effects on basal tritium efflux. Basal tritium efflux is 
considered to represent mainly intracellular formed deaminated metabolites (Moret and 
Briley, 1988). Methiothepin (1 pM), 8 -OH-DPAT (1 pM) and 5-HT (1 pM) had no effect on 
the basal efflux of tritium from rat cerebral cortex slices. In addition, 5-HT (1 pM), 
noradrenaline (10 pM), methiothepin (1 pM) and phentolamine (100 nM) were without 
effect on basal tritium efflux from rat hippocampal slices. Furthermore, 5-HT (1 pM) and 
methiothepin (10 nM) were devoid of any significant effect on the basal efflux of tritium 
from guinea-pig cerebral cortex slices. The results are shown more concisely in Table 2.
2.4.5 Effect of agonist and antagonist on tritium efflux from rat cerebral 
cortex slices
The superfusion of [^H]5-HT preloaded rat cerebral cortex slices with continuously 
elevated (25 mM) potassium ions caused an increased efflux of tritium. This potassium- 
evoked efflux, measured at the start of the collection period (t=46 min), was virtually 
identical and not statistically different, at the four time points (Table 3). Baseline efflux 
at t=46 min was also similar at these time points. At the end of the superfusion period 
(t=118 min), basal and potassium-evoked efflux rates in the absence of exogenous 5-HT 
had dropped to about 80% and 40% respectively of their value at the start of the collection 
period (Table 3).
The addition of 5-HT (30 nM to 1 pM) in a cumulative manner to the superfusion 
buffer caused a dose related inhibition of the potassium-evoked tritium efflux (Fig. 12). 
The maximum effect, observed at 1 pM 5-HT, represented about 70% inhibition of the
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Figure 8. Ca lc ium  dependency of the potassium-evoked
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Tissue slices were exposed to Krebs buffer containing elevated potassium ions (25 
mM) at t=30 min, to evoke tritium efflux. At t=54 min, calcium ions were 
removed from the Krebs buffer (by iso-osmolar replacement with magnesium ions), 
supplying some of the chambers. The results are expressed as the mean ± s.e.m. of 
the fractional release rate, from two separate experiments.
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Figure 9. C a lc iu m  dependency of the potassium-evoked
release of r3H15-HT from slices of rat hippocampus
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Tissue slices were exposed to Krebs buffer containing elevated potassium ions (25 
mM) at t=30 min, to evoke tritium efflux. At t=54 min, calcium ions were 
removed from the Krebs buffer (by iso-osmolar replacement with magnesium ions), 
supplying some of the chambers. The results are expressed as the mean ± s.e.m. of 
the fractional release rate, from two separate experiments.
66
Figure 10. Calcium dependency of the potassium-evoked
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Tissue slices were exposed to Krebs buffer containing elevated potassium ions (35 
mM) at t=30 min, to evoke tritium efflux. At t=54 min, calcium ions were 
removed from the Krebs buffer (by iso-osmolar replacement with magnesium ions), 
supplying some of the chambers. The results are expressed as the mean ±  s.e.m. of 
the fractional release rate, from two separate experiments.
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Figure 11. Effect of calcium replacement (with Mg2* ) and 
its subsequent reintroduction on the potassium-evoked  
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Tissue slices were exposed to Krebs buffer containing elevated potassium ions (25 
mM) at t=30 min, to evoke tritium efflux. At t=54 min, calcium ions were 
removed from the Krebs buffer (by iso-osmolar replacement with magnesium ions), 
supplying some of the chambers and reintroduced at t=78 min. The results are 
expressed as the mean of the fractional release rate, from a single experiment.
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Table 2. Effect of 5-HT receptor agonists and antagonists on the 






Drug Release rate (% tissue stores/4 min)
Control 
5-HT (1 pM) 
Methiothepin (1 pM) 
Control
8-OH-DPAT (1 pM)
2 .947±0 .082  
2 .762±0 .072  
3 .089±0 .068  




5-HT (1 pM) 
Methiothepin (1 pM) 
Control















The results are expressed as the means ± s.e.m. of 2-4 separate experiments. The value 
for each experiment is itself the mean of 2-4 measurements. The drugs were added to the 
superfusion buffer at t=54 min and their effect on basal release determined at t=82 min. 
The superfusion buffer contained 3.2 pM paroxetine, throughout the experiment to prevent 
the re-uptake of 5-HT. The data was analysed using Student's t-test.
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Table 3, Release parameters for tritium from slices of rat cerebral 
cortex, measured at various tfme points of the light : dark cvcle
Hours after lights on = 0 (End-dark) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
3 .1 54±0.208  2 .7 7 9 ± 0 .1 92
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
9 .960±0 .559  4 .043±0 .286
maximum inhibition : 1p.M 5-HT = 72.00±4.15% (n=5)
potassium-evoked release above basal (t=46 min, n=5) = 11.516±0.179 
methiothepin enhancement (t=46 min, n=5) » 13.226±0.20r**
Hours after lights on > 6 (M id-light) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
3 .1 4 2 ± 0 .1 86 2 .8 0 5 ± 0 .1 88
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
10 .3 6 0 ± 0 .1 72 3 .588±0 .322
maximum inhibition : 1jiM 5-HT -  76.42±3.37% (n=5)
potassium-evoked release above basal (t=46 min, n=5) = 12.068±0.295 
methiothepin enhancement (t=46 min, n=5) = 13.873±0.340**
Hours after lights on = 12 (End-light) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
3 .2 7 8 ± 0 .1 78 2 .8 6 9 ± 0 .1 79
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
10 .395±0 .568  3.721 ±0.416
(continued on following page)
Table 3. cont.
maximum inhibition : 1pM 5-HT = 78.193±6.80% (n=5)
potassium-evoked release above basal (t=46 min, n=5) = 12.005±0.215 
methiothepin enhancement (t=46 min, n=5) = 13.799±0.125***
Hours after lights on = 18 (M id-dark) 
basal release (% tissue stores/4 min, n=5)
t-46  min t=118 min
3 .1 60±0.082  2 .5 3 5 ± 0 .1 03
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
10 .0 6 ± 0 .3 6 7  4 .1 9 7 ± 0 .1 07
maximum inhibition : 1pM 5-HT = 72.93±2.52% (n=5)
potassium-evoked release above basal (t=46 min, n=4) = 11.773±0.460 
methiothepin enhancement (t=46 min, n=4) = 13.953±0.300**
The results are expressed as means ± s.e.m. of the number of separate experiments in
parenthesis. The value for each experiment is itself the mean of 2-4 measurements. The
potassium (25mM) evoked release rate above basal was obtained by subtracting the basal
release rate from the potassium-evoked component, in the absence of exogenous 5-HT.
The percentage inhibition is calculated assuming a maximum effect at 1pM exogenous 5-HT.
Methiothepin (1pM) was added at t=30 min and its effect on the potassium (25mM) evoked
release was measured at t=46. Student's t-test was used for assessing the enhancing
**
effect of methiothepin on the potassium-evoked release of tritium, p < 0 . 0 1 ; 
+ * *
p<0 .001 . The one-way analysis of variance test was used to compare the effect of 
potassium ions and methiothepin, at the four time points.
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Figure 12. D o s e  response relationship of the inhibitory  
effect of 5-HT on f 3H 1 5-HT efflux from slices of rat 
cerebral cortex induced by continuous potassium (25 mM) 
s t im u la t io n
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The results are the means ±  s.e.m. of 5 separate experiments for each time point.
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potassium-evoked efflux at the four time points tested (Table 3). This maximum inhibition 
was used to calculate the apparent pICgQ value for each experiment, at the four time points 
of the light : dark cycle (Fig. 13). Statistical analysis did not reveal any significant 
differences. Interestingly, while the addition of exogenous 5-HT (100 nM) attenuated the 
potassium-evoked efflux of tritium, its removal produced complete recovery (Fig. 14).
Methiothepin (1 pM) when added to the superfusion buffer at t=30 min, caused a 
significant enhancement of the potassium-evoked efflux of tritium at t=46 min, at all four 
time points tested (Table 3). Statistical analysis, was unable to expose any significant 
differences in the level of enhancement produced by methiothepin at these time points. 
This concentration of methiothepin also attenuated the effect of 5-HT (30 nM to 1 pM) 
added in a cumulative manner at these time points. The apparent pA2  values calculated 
were virtually identical (Fig. 15) and not statistical different.
The apparent PIC5 0  value for 5-HT and the apparent pA2  value for methiothepin 
calculated in the present study, are identical to those reported by Middlemiss (1984a,b), 
when measuring the release of 5-HT from the rat frontal cortex.
2.4.6 Effect of 8-OH-DPAT on tritium efflux from cerebral cortex slices
The cumulative addition of 8 -OH-DPAT (30 nM to 1 pM) to the superfusion buffer 
containing paroxetine 3.2 pM, had little effect on the potassium (25 mM) evoked efflux of 
tritium (Fig. 16). In contrast, the cumulative addition of 5-HT produced dose related 
attenuation of the potassium-evoked efflux of tritium. The maximum inhibition observed at 
1 pM concentration of 5-HT and 8 -OH-DPAT was about 85% and 16% respectively.
A more extensive study of the effect of 8 -OH-DPAT on the terminal 5-HT 
autoreceptor was conducted by Middlemiss (1984b). In general, 8 -OH-DPAT was reported 
to be devoid of any agonist or antagonist activity when tested up to a concentration of 1 
pM.
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Figure 13. Apparent plC50 values for the inhibition of the
release of r3H15-HT from slices of rat cerebral cortex by
5 - HT
7.256±0.020 7.308±0.026 7.217±0.016 7.346±0.010
0 6 12 18 
Hours after lights on
The results are the means ±  s.e.m. of 5 separate experiments for each time point.
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Figure 14. Effect of 5-HT (100 nM) and its subsequent
removal on the potassium-evoked release of f3H15 -H T
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Slices of rat cerebral cortex were exposed to Krebs buffer containing 5-HT (100 
nM) at t=54 min and removed at t=74 min. The results are expressed as the mean 
fractional release rate from a single experiment.















Figure 15. A p p a re n t  d A :  values for m eth io thep in
antagonism of serotonin in slices of rat cerebral cortex
6.76310.056.78010.06 6.64810.11 6.72410.08
Hours after lights on
The results are expressed as means ±  s.e.m. of 4-5 separate experiments at each
time point.
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Figure 16. Dose response relationship of the inhibitory 
effect of serotonin or 8-OH-DPAT on the potassium -  
evoked release of r3H15-HT from slices of rat cerebral 
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The values represent the means of a single experiment.
2.4.7 Effect of agonist and antagonist on tritium efflux from rot
hippocampal slices
Continuously elevated (25 mM) potassium ion concentration in the superfusion 
buffer increased tritium efflux from rat hippocampal slices. The potassium-evoked efflux 
measured at t=46 min was much lower than that observed from rat cerebral cortex slices 
but was similar at all four time points (Table 4). Statistical analysis, showed that the 
potassium-evoked efflux was not significantly different at these time points. Baseline 
efflux at t=46 min was also very similar, except for the values obtained at mid-dark 
[2.420±0.194% tissue stores/4 min (mean ± s.e.m., n=5)] were much lower. At the end 
of the superfusion period (t=118 min), basal and the potassium-evoked efflux rates in the 
absence of exogenous 5-HT decreased to about 94% and 36% respectively of their value at 
the beginning of the collection period (Table 4).
When added in a cumulative manner to the superfusion buffer 5-HT (30 nM to 1 pM) 
caused a dose related inhibition in the potassium-evoked efflux of tritium (Fig. 17). The 
maximum effect, observed at 1 pM 5-HT was comparable to that observed for cerebral 
cortex slices. The inhibition produced at end-dark (78%) and at end-light (81%) was 
greater as compared to mid-dark (62%) or mid-light (67%), see Table 4. The apparent 
plC5o values calculated using these inhibitions were not statistically different at the four 
time jo in ts  (Fig. 18).
The addition of methiothepin (1 pM) to the superfusion buffer at t=30 min produced 
a significant enhancement of the potassium-evoked efflux of tritium at all four time points 
tested, measured at t=46 min (Table 4). The magnitude of this enhancement was not 
significantly different at the four time points. The presence of methiothepin in the 
superfusion buffer attenuated the effect of 5-HT (30 nM to 1 pM) added cumulatively at all 
four time points. The apparent pA2  values calculated for this antagonism were not 
statistically different at these time points (Fig. 19).
When added in a cumulative manner to the superfusion buffer, noradrenaline in the 
concentration range 10 nM to 10 pM caused a dose related inhibition of the potassium- 
evoked efflux of tritium, at all four time points tested (fig. 20). The maximum effect, 
observed at 10 pM noradrenaline was similar at these time points and was of the order
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Table 4. Release parameters for tritium from slices of rat 
hippocampus, measured at various time points of the light ; dark cycle
Hours after lights on = 0 (End-dark) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
3 .021±0 .137  2 .8 5 6 ± 0 .1 85
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
9 .865±0.392  3 .578±0 .333
maximum inhibition : 1jiM 5-HT = 78.12±6.15% (n=5)
10pM noradrenaline = 82.55±2.69% (n=5)
potassium-evoked release above basal (t=46 min, n=5) = 9.319±0.215 
methiothepin enhancement (t=46 min, n=5) = 11.206±0.270***
Hours after lights on = 6 (M id-light) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
2 .828±0 .076  2 .591±0 .140
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
9 .1 56±0.562 3 .3 9 3 ± 0 .1 98
maximum inhibition : 1pM 5-HT = 66.96±4.71% (n=5)
1OpM noradrenaline = 78.69±5.26% (n=5)
potassium-evoked release above basal (t=46 min, n=5) = 9.634±0.640 
methiothepin enhancement (t=46 min, n=5) = 11.987±0.468*
potassium-evoked release above basal (t=46 min, n=4) = 7.438±0.269 
phentolamine (t=46 min, n=4) = 8.009±0.162
Hours after lights on = 12 (End-light)
Basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
3 .0 0 4 ± 0 .1 72 2 .8 9 2 ± 0 .1 39
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t= 11 8
9 .078±0 .276  3.395±0.173 min
(continued on following page)
-79-
Table 4. cont.
maximum inhibition : 1pM 5-HT = 81.33±3.53% (n=5)
10pM noradrenaline = 78.15±3.31% (n=6)
potassium-evoked release above basal (t=46 min, n=5) = 9.129±0.151 
methiothepin enhancement (t=46 min, n=5) = 11.501 ±0.206***
Hours after lights on = 18 (M id-dark) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
2 .4 2 0 ± 0 .1 94 2 .332±0 .245
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
9.71710.123  3 .59710 .307
maximum inhibition : 1pM 5-HT = 62.3817.78% (n=5)
10pM noradrenaline = 70.0415.85% (n=5)
potassium-evoked release above basal (t=46 min, n=5) = 9.95310.242 
methiothepin enhancement (t=46 min, n=5) = 11.90810.216***
potassium-evoked release above basal (t=46 min, n=5) = 7.94710.100 
phentolamine (t=46 min, n=5) = 8.35610.092*
The results are expressed as means 1  s.e.m. of the number of separate experiments in
parenthesis. The value for each experiment is itself the mean of 2-4 measurements. The
potassium (25mM) evoked release rate above basal was obtained by subtracting the basal
release rate from the potassium-evoked component, in the absence of exogenous 5-HT.
The percentage inhibition is calculated assuming a maximum effect at either 1pM exogenous
5-HT or 10pM noradrenaline. Methiothepin (1pM) or phentolamine (100nM) was added at
t=30 min and its effect on the potassium-evoked release of tritium was measured at t=46.
Student's t-test was used for comparison of the potassium-evoked release with the
*  * * *
methiothepin or phentolamine added group, p<0.05; p<0 .0 0 1 . Furthermore, this
statistical test was also used for the analysis of the effect of phentolamine on the 
potassium-evoked release of tritium. In contrast, the one-way analysis of variance test 
was used to compare the effects of potassium ions and methiothepin, at the four time 
points.
Figure 17. Dose response relationship of the inhibitory 
effect of 5-HT on f3H15-HT efflux from slices of rat 
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Figure 18, Apparent piC50 values for the inhibition of the
release of r3H15-HT from slices of rat hippocampus bv
5 -H T
7.161 ±0.023 7.024±0.039 7.173±0.047
Hours after lights on 
The results are the means ±  s.e.m. of 5 separate experiments at each time point.
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Figure 19. A p p a re n t  d A:  va lues  to i  ip e th io t he p in 
antagonism of serotonin in slices of rat hippocampus
6.999±0.045 6.905±0.055 6.846±0.066 6.872±0.108
Hours after lights on
The results are expressed as means ± s.e.m. of 5 separate experiments for each time
point.
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Figure 20. Dose response relationship of the inhibitory  
effect of noradrenaline on r3H15-HT efflux from slices of
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The results are the means ± s.e.m. of 5-6 experiments at each time point.
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seen using 1 pM 5-HT (Table 4). The apparent plCgg values were also very similar at the 
four time points (Fig. 21). Statistical analysis was unable to reveal any significant 
differences in these values.
Phentolamine (100 nM) when added to the superfusion buffer caused a significant 
enhancement of the potassium-evoked efflux of tritium at mid-dark but not at mid-light 
(Table 4). its presence in the superfusion buffer caused the dose-response curve for 
noradrenaline to be shifted to the right, both, at mid-dark and at mid-light. The apparent 
pA2  values calculated at these time points were not statistically different (Fig. 22).
The apparent plC5g and apparent pA2  values agree well with those reported by 
Gothert et at. (1981) for the release of 5-HT from cerebral cortex slices.
2.4.8 Effect of agonist and antagonist on tritium efflux from guinea-pig 
cerebral cortex slices
Superfusion of guinea-pig cerebral cortex slices preloaded with (3 H]5-HT with 
continuously elevated (35 mM) potassium ions resulted in an increased efflux of tritium. 
This effect of potassium, measured at the start of the collection period (t=46 min) was 
lower than that measured in the rat cerebral cortex or hippocampus, but was essentially 
similar in magnitude at the four time points sampled (Table 5), and not statistically 
different. At the end of the superfusion period (t=118 min), basal and potassium-evoked 
efflux rates had declined to about 80% and 40% respectively of their value at the beginning 
of the collection period (Table 5).
The cumulative addition of 5-HT (30 nM to 1 pM) to the superfusion buffer caused a 
dose-related inhibition of the potassium-evoked efflux of tritium at all four time points 
(Fig. 23). The maximum inhibition occurred at about 1 pM 5-HT and represented a 
reduction of about 68% of the potassium-evoked efflux at each of the four time points 
(Table 5). The apparent plC^g values were calculated at each of these time points 
assuming a maximum effect at 1 pM 5-HT (Fig. 24). Statistical analysis did not reveal any 
significant differences.





















Figure 21. Apparent p lC; o values for the inhibition of the
release of f3H15-HT from slices of rat hippocampus bv 
no ra d re n a lin e
6.16310.024 6.10810.031 6.14810.030 6.14210.030
Hours after lights on 
The results are the means ± s.e.m. of 5-6 experiments at each time point.
- 8 6 -
Figure 22. A p p a re n t  p A 2 va lues for phento lam ine
a n t a g o n i s m  of  n o ra d re n a lin e  in s lices  of ra i




Hours after lights on
The results are expressed as means ± s.e.m. of 4-5 experiments for each time point.
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Table 5. Release parameters for tritium from slices of guinea-pig 
cerebral cortex, measured at various time points of the light : dark 
cycle
Hours after lights on = 0 (End-dark) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
1 .706±0 .042  1 .370±0 .024
potassium-evoked release above basai (% tissue stores/4 min, n=5) 
t=46 min t=118 min
6 .8 9 6 ± 0 .1 64 2 .9 1 9±0.058
maximum inhibition : 1jiM 5-HT = 68.41 ±2.06% (n=5)
Hours after lights on = 6 (M id-light) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
1 .759±0 .055  1 .423±0 .040
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
7 .2 4 3 ± 0 .1 68 2 .947±0 .09 8
maximum inhibition : 1p.M 5-HT -  68.64±1.49% (n=5)
potassium-evoked release above basal (t=46 min, n=4) -  6.668±0.082 
methiothepin enhancement (t=46 min, n=4) «= 7.612±0.049***
Hours after lights on « 12 (End-light) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
1 .640±0 .032  1 .3 1 8±0.045
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
6 .764±0 .149  2.651 ±0.111
maximum inhibition : 1p.M 5-HT = 67.07±1.24% (n=5)
(continued on following page)
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Table 5. cont.
Hours after lights on = 18 (M id-dark) 
basal release (% tissue stores/4 min, n=5)
t=46 min t=118 min
1.708±0.041 1 .379±0 .057
potassium-evoked release above basal (% tissue stores/4 min, n=5) 
t=46 min t=118 min
7 .088± 0 .17 8  2 .8 7 8 ± 0 .1 10
maximum inhibition : 1pM 5-HT -  67.59±0.80% (n=5)
The results are expressed as means ± s.e.m. of the number of separate experiments in 
parenthesis. Furthermore, the value of each experiment is composed of the mean of 2-4 
measurements. The potassium (35mM) evoked release rate above basal was obtained by 
subtracting the basal release rate from the potassium-evoked component, in the absence of 
exogenous 5-HT. The percentage inhibition is calculated assuming a maximum effect at 
1pM exogenous 5-HT. Methiothepin (10nM) was added at t=30 min and its effect on the 
potassium-evoked release was measured at t=46. The one-way analysis of variance test 
was used to compare the effect of potassium at the four time points. Student's t-test was 
used for comparison of the potassium-evoked release with the methiothepin added group, 
***p< 0 .0 0 1 .
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Figure 23. Dose response relationship of the inhibitory 
effect of 5-HT on r3H15-HT efflux from slices of guinea-
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The results are the means ±  s.e.m. of 5 separate experiments for each time point.

















Figure 24. A p p a r e n t  p IC; o values for inhibition of the
release of r3H15-HT from slices of guinea-pig cerebral
cortex bv 5-HT
7.369±0.018 7.365±0.030 7.33210.020 7.327±0.015
Hours after lights on
The results are the means ± s.e.m. of 5 separate experiments at each time point.
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significant enhancement of the potassium-evoked efflux of tritium (from slices prepared at 
mid-light), when measured at t=46 min (Table 5). This concentration of methiothepin 
attenuated the inhibitory effect of 5-HT (30 nM to 1 pM) when added in a cumulative 
manner, yielding an apparent pA2  value of 8.400±0.090 (mean ± s.e.m., n=4).
The apparent piCgg values for 5-HT and the apparent pA2  value for methiothepin 
are identical to those obtained by Middlemiss et ai, (1988), when measuring the release 
of 5-HT from the guinea-pig frontal cortex.
2.4.9 Effect of chronic methiothepin on autoreceptor sensitivity
Rats received daily injections for 14 days of either saline or methiothepin 
(1 0mg/kg i.p.) at a time point corresponding to mid-light of their light : dark cycle. 
Saline-injected rats gained weight and looked healthy. In contrast, rats injected with 
methiothepin were sedated shortly afterwards and lost weight during the first few days but 
later gained it although at a slower rate compared to saline-injected rats. Water 
consumption was also reduced in comparison to saline-injected rats. Immediately prior to 
being killed, 3 days after the last injection, methiothepin-injected rats were about 30% 
underweight in comparison to saline-injected rats (methiothepins169±9.118 ; 
control=243±6.984, mean ± s.e.m., n=6).
Exposure of [3 H]5-HT-preloaded cerebral cortex slices to elevated (25 mM) 
potassium ions produced an increased tritium efflux. This effect of potassium, measured 
at the start of the collection period (t=46 min) was significantly lower (Table 6 ) as 
compared to the mid-light point obtained from previous studies (Table 3). However, the 
stimulant effect of potassium from slices of methiothepin- and saline-injected rats was 
similar (Table 6 ), making it likely that methiothepin had been cleared by the rats. Baseline 
efflux at t=46 min was not significantly different (Table 6 ) from that obtained at the mid­
light point of previous studies (cf. Table 3), and was similar in the injected rats (Table 6 ). 
At the end of the superfusion period (t=118 min), basal and potassium-evoked efflux had 
declined to about 87% and 53% respectively of their value at the start of the collection 
period (Table 6).
The cumulative addition of 5-HT (30 nM to 300 nM) to the superfusion buffer
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Table 6. Release parameters for tritium from cerebral cortex slices 
of chronically injected rats
Saline injected daily for 14 days
basal release (% tissue stores/4 min, n=3)
t=46 min t=102 min
2 .5 6 3 ± 0 .0 8 7  2 .2 3 7 ± 0 .1 00
potassium-evoked release above basal (% tissue stores/4 min, n=3) 
t=46 min t=102 min
7 .4 8 5 ± 0 .0 4 2 **  3 .978±0 .064
maximum inhibition : 300 nM 5-HT = 72.42±3.47% (n=3)
M ethiothepin (10mg/kg i.p.) injected daily for 14 days 
basal release (% tissue stores/4 min, n=3)
t=46 min t=102 min
2 .5 4 3 ± 0 .1 03 2 .242±0 .073
potassium-evoked release, above basal (% tissue stores/4 min, n=3) 
t=46 min t=102 min
7 .5 2 6 ± 0 .0 5 3 **  3 .9 6 6 ± 0 .1 13
maximum inhibition : 300 nM 5-HT ■ 71.38±0.63% (n=3)
Rats were injected daily with either saline or methiothepin (10mg/kg i.p.) for 14 days and
killed 3 days after the last injection, at the time point corresponding to the mid-light
position of their light : dark cycle. The results are expressed as means ± s.e.m. of the
number of separate experiments in parenthesis. The value for each experiment is itself
the mean of 2-4 measurements. The potassium (25mM) evoked release rate, above basal
was obtained by subtracting the basal release rate from the potassium-evoked component,
in the absence of exogenous 5-HT. The percentage inhibition is calculated assuming a
maximum effect at 300 nM exogenous 5-HT. Student's t-test was used for comparing the
potassium-evoked release from saline- and methiothepin-injected rats with those of non-
**
injected rats, at mid-light, p<0 .0 1 .
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caused a dose-related inhibition of the potassium-evoked tritium efflux from slices of 
saline- and methiothepin-injected rats. The inhibition produced by each of the doses of 5- 
HT was very similar in the saline-injected rats to those previously observed at this time 
point in non-injected rats (cf. Figure 12). In contrast, a greater inhibition was observed 
in slices from methiothepin-injected rats (30 nM 5-HT : saline=29.92±2.21%, 
m ethiothepin=35.90±4.23%  ; 100 nM 5-HT : saline=57.87±3.98% ,
methiothepin=63.77±4.67%, mean ± s.e.m., n=3). However, the inhibition produced by 
300 nM 5-HT was very similar in saline- and methiothepin-injected rats. Although in this 
study a maximum inhibition was assumed to be produced by 300 nM 5-HT (Table 6), it was 
very similar to that previously observed with 1 jiM 5-HT in non-injected rats (cf. Table 
3). Statistical analysis (Student's t-test) of the apparent plC50  values calculated for the 
slices from saline- and methiothepin-injected rats shows a significant difference (Fig. 25). 
In addition, the apparent plC50  value for the saline-injected rats (Table 6) was not 
significantly different to that previously obtained from non-injected rats at this time point 
(cf. Table 3).
2.4.10 Timing of experiments
Little is known about the seasonal variation in the sensitivity of the terminal 5-HT 
autoreceptor. This area was not investigated, but the timing of the various experiments is 
provided so that it may be of use to experimenters wishing to investigate for seasonal 
variations in terminal 5-HT autoreceptor sensitivity.
The release studies from rat cerebral cortex slices using 5-HT and methiothepin 
were performed in march/april and april/may respectively. The release studies from rat 
hippocampal slices were performed in october/november (5-HT) and january 
(methiothepin). The release studies from rat hippocampal slices using noradrenaline were 
performed in january/february, while the antagonist studies using phentolamine were 
carried out in april/may.
The agonist (5-HT) and the antagonist (methiothepin) studies using guinea-pig 
cerebral cortex slices were carried out in july/august.
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Figure 25. Apparent p lC 50 values for inhibition of the
release of r3H15-HT from slices of rat cerebral cortex 
bv 5-HT. fo llo w in g  the chron ic  ad m in is tra t io n  of 
m e th io th e p in
7.306±0.014
s a lin e  m e th io th e p in
The rats in each group received daily injections of either saline or methiothepin (10 
mg/kg i.p.) for 14 days. Three days after the last injection the rats were killed and 
the sensitivity of the terminal 5-HT autoreceptor determined, by the ability of 
exogenous 5-HT to inhibit the release of previously taken up [3 H]5-HT. The 
results are the means ± s.e.m. of three separate experiments for each group.
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2.5 DISCUSSION
A circadian variation in the concentration of 5-HT in rodent brain is well 
established (Quay, 1968 ; Hiilier and Redfern, 1976b). Although the phase of the rhythms 
of 5-HT concentrations is not identical in all brain regions, the peak concentrations occur 
during the light phase (Hery eta!., 1972). This variation in neuronal 5-HT concentration 
is inversely related to the release of 5-HT, which is greatest during the dark phase (Martin 
and Marsden, 1985), when the firing of 5-HT neurones is highest and the animals are most 
active (Kaien et al., 1989). The release of 5-HT is, in turn, affected by many factors, 
including the activity of the terminal 5-HT autoreceptors which, when stimulated by 5-HT, 
inhibit transmitter release by a negative feedback mechanism (Moret, 1985). it was 
proposed recently that this 5-HT autoreceptor exhibits a circadian variation in sensitivity 
(Martin et a!., 1987) which may account for the circadian variation in 5-HT release and 
also for the variation in 5-HT concentrations. The aim of this study was to investigate the 
sensitivity of this 5-HT autoreceptor during the light : dark cycle.
The terminal 5-HT autoreceptor has been identified in a number of regions of the 
rat brain, where it has been correlated with the 5-HTjq binding site (Engel et al., 1986), 
while in the guinea-pig this 5-HT autoreceptor is shown to correspond to the 5-HT.j D 
binding site (Hoyer and Middlemiss, 1989)(see section 1.4).
Functional evidence for this classification in the rat has been provided by the weak 
and rather inconsistent effects of the 5-HT.j A receptor agonist, 8 -OH-DPAT, in inhibition 
of the potassium-evoked release of tritium from brain slices and synaptosomes 
(Middlemiss, 1984b ; Engel et al., 1986 ; Maura et al., 1986). These observations are 
consistent with those of the present study. In contrast, Hamon et al. (1984) observed an 
inhibition of the potassium-evoked release of tritium from cortical and striatal slices by 8 - 
OH-DPAT, an effect which was antagonized by metergoiine but not by yohimbine. This 
inconsistency may be due to the loss of selectivity of 8 -OH-DPAT when used at high 
concentrations. In addition, the lack of effect of another 5-HT1 ^-selective agent, 
buspirone (Middlemiss, 1988), further suggests that this 5-HT autoreceptor, modulating 
5-HT release, is unlikely to correspond to the 5-HT1A subtype. In contrast, RU 24969, 
which possesses a high affinity for the 5-HT.j q binding site (Sills et al., 1984), is a potent
inhibitor of the release of 5-HT (Gothert et al., 1987).
In the present study, the uptake of [3 H]5-HT by cerebral cortex slices of rat brain 
has been shown to be into serotoninergic neurones by a temperature-dependent mechanism.
q
Other studies have obtained similar results when monitoring the uptake of rH]5-HT by 
brain slices and synaptosomes (Shaskan and Snyder, 1970 ; Stauderman and Jones, 1985). 
Blackburn et al. (1967) found that the majority of the [3 H]5-HT taken up by brain slices 
could be recovered from subsequently-prepared synaptosomes, suggesting that the 
process/es responsible for this uptake is/are located on 5-HT nerve endings.
A circadian variation has been reported in the uptake of [3 H]5-HT by slices of rat 
SCN, with the highest uptake observed during the dark phase (Meyer and Quay, 1976). A 
variation In 5-HT uptake could lead to an altered release of tritium during stimulation. The 
circadian variability in the uptake of [3 H]5-HT by brain slices was not investigated in the 
present study, but the results obtained from the potassium-evoked release of tritium and 
its enhancement caused by methiothepin were very similar at the four time points (for rat 
cortical, rat hippocampal and guinea-pig cortical slices), suggesting that the uptake is 
unlikely to be drastically different.
The rat cerebral cortex and hippocampus were chosen for 5-HT autoreceptor 
sensitivity determination because these regions receive projections from the dorsal raphe 
and the dorsal and median raphe nuclei respectively (Blier et al., 1990). The superfusion 
of [3 H]5-HT preloaded brain slices with Krebs buffer, containing elevated potassium ions, 
caused an increase in the efflux of tritium (which was entirely calcium-dependent, 
suggesting that the release of tritium was from functionally-intact serotoninergic 
neurones), the magnitude of which was very similar at all four time points, for each region 
of both species. In contrast, Blier et al. (1989a) reported the electrically-evoked release 
of tritium from rat hypothalamic slices in vitro to be lower during the dark phase. These 
findings are in disagreement with in vivo intracerebral dialysis studies where the release 
of 5-HT from the rat hypothalamus (Martin and Marsden, 1985) and the hippocampus (Kalen 
et al., 1989) was greater during the dark phase, when the firing rate of 5-HT neurones is 
highest and the animals are most active (McGinty and Harper, 1976 ; Trulson and Jacobs, 
1979). Furthermore, the lower release rate of tritium observed during the dark phase 
(Blier et al., 1989a) is unrelated to the degree of activation of the 5 -HT autoreceptor or
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the increased uptake of 5-HT at this time, otherwise the methiothepin-evoked enhancement 
would have been different and the accumulation of [^H]5-HT would have been greater during 
incubation. Instead, the variation in the release of tritium is likely to be the result of a 
mechanism which is independent of the 5-HT autoreceptor (i.e. analogous to the increase in 
the release of tritium following the short-term administration of lithium, with an unaltered 
5-HT autoreceptor) (Blier et al., 1987). Moreover, the lack of a variation in tritium 
release observed in the present study is supported by the similar magnitude of enhancement 
of tritium release produced by methiothepin.
The virtually identical potassium-evoked release rates observed here throughout 
the light : dark cycle, suggest that there is also no inherent tendency of 5-HT nerve 
terminals to release greater amounts of 5-HT during the dark phase, and that the greater 
release rates seen during the dark phase in vivo are probably the consequence of other 
factors, such as the firing rate of 5-HT neurones.
The cumulative addition of 5-HT caused a dose-related inhibition of the potassium- 
evoked release of tritium, the dose response curves obtained at each of the four time points 
being essentially identical, suggesting that the sensitivity of the 5-HT autoreceptor was the 
same at these times. Similar results were obtained for the rat cortical, rat hippocampal 
and guinea-pig hippocampal slices. Recently, Blier et al. (1989a) have also reported the 
lack of variation in the sensitivity of the terminal 5-HT autoreceptor of the rat 
hypothalamus to 5-HT agonists, in slices prepared during the dark and the light phase.
The addition of the putative 5-HT autoreceptor antagonist, methiothepin, to the 
superfusion buffer produced a significant enhancement of the release of tritium, 
presumably by blocking the activation of the 5-HT autoreceptor by the released transmitter 
(Middlemiss, 1984a). The magnitude of this enhancement was similar at each of the four 
time points, in both the rat cortical and hippocampal slices. Methiothepin also produced an 
enhancement of the potassium-evoked release of tritium from guinea pig cortical slices, 
which is in contrast to the findings of Middlemiss et al. (1988). This enhancement is 
likely to be the consequence of the greater endogenous tone created by the use of a higher 
potassium ion concentration in the present study. The presence of methiothepin in the 
superfusion buffer resulted in a rightward shift in the dose response curve of 5 -HT. The 
apparent pA2  values calculated for this shift were not significantly different at the four
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time points for the rat cortical and hippocampal slices.
In order to check whether this superfusion technique was capable of detecting 
sensitivity changes in terminal 5-HT autoreceptors, methiothepin was administered to rats 
daily for 14 days. This treatment produced a leftward shift of the dose response curve to 
5-HT, when compared to control rats. This shift is suggestive of an up-regulation, or 
increased sensitivity, of the terminal 5-HT autoreceptor to exogenous 5-HT, suggesting 
that these 5-HT autoreceptors are under a tonic inhibitory influence in the brain. Maura 
and Raiteri (1984) have reported similar results for sub- and super-sensitive 5-HT 
autoreceptors in superfused brain synaptosomes following long-term stimulation or 
blockade respectively, a finding supported by the electrophysiological studies of Chaput et 
al. (1986b) and Blier et al. (1988). In contrast, Hagan and Hughes (1983) were unable 
to detect any changes in 5-HT autoreceptor sensitivity, following chronic methiothepin. 
This reason for this discrepancy is not clear but it may reflect regional differences.
The changes produced in the sensitivity of the terminal 5-HT autoreceptors by 
long-term drug administration are likely to be marked changes which may bear little 
similarity to those expected of an endogenous circadian variation. However, the ability of 
the terminal 5-HT autoreceptors to exhibit sensitivity changes suggests that they are 
capable of adapting to their environment and makes it likely that they are in a state of flux, 
although their inability to change quickly (Hagan and Hughes, 1983 ; Maura and Raiteri,
1984) implies that these changes take some time to become established, thus making it 
unlikely that they would be produced by the circadian variation in the release of 5-HT. The 
superfusion technique applied in the present study is capable of detecting the changes in 
autoreceptor sensitivity induced by the long-term administration of methiothepin, however 
its ability to detect changes expected of a circadian rhythm will depend on the amplitude of 
that rhythm, and on the sampling times corresponding to the zenith and nadir of the rhythm.
The release of 5-HT from the serotoninergic terminals of rat brain is also 
modulated by inhibitory presynaptic a/p/ia2-adrenoceptors (Gothert and Huth, 1980 ; 
Gothert et al., 1981). Activation of these heteroreceptors by exogenous noradrenaline 
decreases the stimulation evoked release of 5-HT (Gothert and Huth, 1980 ; Maura et al.,
1985). If these alpha-adrenoceptors are also activated by endogenous noradrenaline, 
then any alteration in their affinity or functional activity would be reflected as a change in
-99-
the release of 5-HT. In support of this concept is the reported circadian variation in the 
number of a/p/^-adrenoceptor binding sites in a number of regions of rat brain during the 
light : dark cycle (Kafka et al., 1986).
The results presented here clearly demonstrate that the sensitivity of the alpha2 ' 
adrenoceptors regulating 5-HT release in the rat hippocampus, to both agonist and 
antagonist, is unchanged during the light : dark cycle. In addition, the alpha2 " 
adrenoceptor antagonist, phentolamine, failed to enhance the potassium-evoked release of 
5-HT at mid-light but did so at mid-dark, thus suggesting that the concentration of 
endogenously released, noradrenaline that activates this receptor, may be higher at mid­
dark. This hypothesis is supported by in vivo microdialysis studies of the hippocampus, 
in which endogenous concentrations of noradrenaline were 43% higher during the dark 
phase (Kalen et al., 1989). Gothert and Huth (1980) also reported phentolamine to 
enhance the potassium-evoked release of 5-HT from rat cerebral cortex slices in the 
absence of a noradrenaline uptake inhibitor. In contrast, phentolamine failed to enhance the 
stimulation evoked release of 5-HT from rat hypothalamic slices, in the absence or even in 
the presence of a noradrenaline uptake inhibitor (Galzin et ai, 1984). This discrepancy 
may be due to regional or time-dependent differences in noradrenaline concentrations and 
implies that the a/p/^-adrenoceptors present on serotoninergic nerve terminals may play 
a physiological role in regulating the activity of serotoninergic neurones.
The 5-HT receptor antagonist, methiothepin, exhibits considerable affinity for the 
a/p/ia2 -adrenergic and dopaminergic binding sites (Leysen et al., 1981). Its lack of 
selectivity for the terminal 5-HT autoreceptor suggests that its enhancement of the 
potassium-evoked release of tritium may be the result of its action on these sites {i.e. 
heteroreceptors regulating 5-HT release). The neurotransmitters that act on these 
heteroreceptors, themselves display a circadian variation in release. The possibility 
exists therefore that the circadian variation in 5-HT release may derive from a variation 
in the activity of one or more heteroreceptors. However, the results presented in this 
thesis demonstrate that the a/p/7a2 ~adrenoceptor regulating 5-HT release in the rat 
hippocampus is devoid of a circadian variation in its sensitivity. An investigation into the 
circadian fluctuation in the sensitivity of the other heteroreceptors and their 
neurotransmitters needs to be performed. It is likely that factors such as these would
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complicate the detection of a circadian variation in 5-HT autoreceptor sensitivity.
The continuous stimulation superfusion technique applied in the present study was 
analogous to that of Middlemiss (1984a,b) and the results are in excellent agreement with 
those reported for the rat and the guinea-pig by Middlemiss (1984a,b), Middlemiss et al. 
(1988). This technique has not gained general acceptance. Its unpopularity is attributed 
to the use of long periods of stimulation of brain slices with elevated potassium ions, an 
unphysiological condition, although the release during this entire period is calcium- 
dependent. Comparison with the more conventional S2 /S1 technique suggests that the two 
techniques yield similar results (Richards, 1985). Indeed, the continuous stimulation 
technique possesses the advantage of "enabling cumulative dose-response curves to 5-HT 
autoreceptor agonists to be constructed within one experiment, thereby reducing 
variability and increasing productivity” (Middlemiss, 1988). Although the S2 /S .1 
technique does allow each slice or synaptosomal preparation to act as its own control, 
thereby reducing variability, this advantage is offset by the need to carry out at least 6-8  
experiments at each drug concentration to ensure adequate reproducibility.
Superfusion studies of brain slices are generally performed in the presence of a 
selective 5-HT uptake inhibitor, to prevent the reuptake of transmitter and the 
displacement of [3 H]5-HT from its storage sites. An uptake inhibitor is also necessary to 
achieve detectable and stable release rates (Gothert, 1980). The inclusion of uptake 
inhibitors has also been shown to attenuate the inhibitory effect of agonists at the 5-HT 
autoreceptor and the a Ipha2 -adrenoceptor by means of the proposed functional link 
(Gothert et al., 1983 ; Galzin et al., 1985). In addition, uptake inhibitors can change the 
biophase concentration of the liberated transmitter by raising its extracellular 
concentrations. The extent to which this phenomena contributed to the results obtained in 
this thesis is not known, but they could account for the discrepancies between functional 
potencies (plC50) or apparent pA2  values, and the pK^ values from binding experiments 
which are performed in the absence of an uptake inhibitor.
A low frequency stimulation technique has been described recently which 
circumvents this problem. It involves the superfusion of brain slices in the absence of a 
5-HT uptake inhibitor, and yields apparent plC50  values which are closer to the pKp values 
of binding studies (Blier et al., 1989b). Stimulation is performed using a frequency which
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corresponds to the firing rate of 5-HT neurones (1-3 Hz), producing low concentrations of 
endogenous 5-HT in the synaptic cleft and thus minimizing feedback inhibition. The 
apparent plC^g value for the inhibitory effect of the putative 5-HT autoreceptor agonist, 
5-methoxytryptamine is sixteen times lower at 1 Hz than at 3 Hz, suggesting a lesser 
degree of activation of the 5-HT autoreceptor. Also, the putative 5-HT autoreceptor 
antagonist, methiothepin, produces a greater enhancement of the release of tritium at 3 Hz 
than at 1 Hz. This technique may prove useful in the detection of rhythms of small 
amplitude (i.e. smaller changes in autoreceptor sensitivity). It would interesting to use 
this technique to determine the sensitivity of the hypothalamic terminal 5-HT autoreceptor, 
during the light : dark cycle, since this region contains the primary endogenous pacemaker 
which is responsible for the regulation of circadian rhythms of several functions.
As yet there are no suitable behavioural models for assessing the activity of the 
terminal 5-HT autoreceptor, although the hyperlocomotion observed following the 
administration of RU 24969 was attributed to the activation of the 5-HT^q receptors 
(Green et al., 1984), since RU 24969 exhibits considerable affinity and selectivity for the 
5-HTfB binding site (Sills et al., 1984). Examination of the effect of RU 24969 during 
the light : dark cycle did not reveal any evidence of a significant 24 hour variation (Moser,
1986). In contrast, Martin et al. (1987) reported a variation in the ability of metergoline 
to antagonize the RU 24969-induced hyperlocomotion, metergoline being three to five times 
more effective during the light phase in comparison to the dark phase. These authors 
suggested that this difference, in effect, was the result of a circadian variation in the 
sensitivity of the terminal 5-HT autoreceptor. However, the link between the RU 24969- 
induced hyperlocomotion and the involvement of a 5-HT receptor has been questioned on the 
grounds of the ineffectiveness of a number of 5-HT antagonists (Green et al., 1984 ; 
Tricklebank et al., 1986). Also, this behavioural effect of RU 24969 cannot be attributed 
to the activation of a presynaptic 5-HT receptor because it was not affected by PCPA 
depletion (Green et al., 1984) or by the intracerebroventricular injection of 5,7-DHT 
(Tricklebank et al., 1986). In addition, the RU 24969-induced hyperlocomotion can be 
blocked by haloperidol or prazosin, suggesting a catecholamine involvement in this 
behavioural effect (Tricklebank et al., 1986). The changes in autoreceptor sensitivity 
proposed by Martin et al. (1987) may be secondary to a variation in pharmacokinetic
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handling and/or the dopamine antagonist activity of metergoline.
On the basis of the greater selectivity of RU 24969 for the 5-HT^q binding site, it 
was proposed recently that this receptor may mediate hypophagia (Kennett et al., 1987). 
This hypophagic effect of RU 24969 is considered to be mediated by a postsynaptic 5-HT1 
receptor (Kennett et al., 1987 ; Hutson et al., 1988 ; Kennett and Curzon, 1988). In 
addition, the hypophagic effect is not secondary to the hyperlocomotion, since haloperidol 
blocks the hyperlocomotion but not the hypophagia, whereas metergoline blocks the 
hypophagia (Kennett et al., 1987). Furthermore, the direct infusion of RU 24969 into the 
paraventricular nucleus of the hypothalamus produced hypophagia with no change in 
locomotor activity, whereas 8 -OH-DPAT was devoid of any activity, suggesting that the 
effect of RU 24969 is likely to be mediated by a non-S-HT-j^ receptor, possibly 5-HT.j g 
(Hutson et al., 1988). A circadian variation in this hypophagic response of RU 24969 has 
not been investigated.
It was reported recently by Clark et al. (1988), that considerably lower doses of 
RU 24969 than those used in the behavioural studies described above produced 
hypolocomotion, which was secondary to a sedative effect, and mediated by the 
presynaptic 5-HT1B autoreceptor. However, studies performed in our laboratory (not 
reported here) to repeat this work and to investigate the existence of a circadian variation 
in this behavioural effect were unsuccessful.
The question that needs to be addressed is, what is the exact functional role of the 
terminal 5-HT autoreceptors ? Their location on 5-HT nerve terminals is ideal for 
enabling them to modulate neurotransmitter release. The neurotransmitter released into 
the synaptic cleft activates not only the post-synaptic 5-HT receptors but also the 
presynaptic 5-HT autoreceptors which act via negative feedback to inhibit further release 
of the transmitter. At the same time, the majority of the released transmitter is taken 
back up from the synaptic cleft into 5-HT nerve terminals by the 5-HT uptake mechanism. 
The combined effect serves to reduce the concentrations of transmitter in the synaptic 
cleft, thereby preparing the system for the arrival of the next action potential. In this 
way, each presynaptic depolarization would be expected to produce a corresponding clear- 
cut activation of the postsynaptic 5-HT receptor. On this basis, the presynaptic 5 -HT 
autoreceptor functions to make neurotransmission not only more efficient but also more
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precise.
The results of the present in vitro study demonstrate that the sensitivity of rat 
cortical and hippocampal terminal 5-HT.jb autoreceptors, to both agonist and antagonist, is 
unchanged during the light : dark cycle. Similarly, the sensitivity of the guinea-pig 
cortical, terminal 5-HT^p autoreceptor to the agonist is the same during the light : dark 
cycle. The inability to detect changes in terminal 5-HT autoreceptor sensitivity, in either 
the rat or the guinea-pig, suggests that these receptors intrinsically lack circadian 
activity. It is therefore unlikely that they would be directly responsible for the observed 
circadian variation in the synthesis, release or the metabolism of 5-HT, although their 
activity would be susceptible to modulation by the changes in 5-HT concentration in the 
synaptic cleft In addition, the low affinity of noradrenaline for the a/pf^-adrenoceptors 
located on 5-HT nerve terminals, and their unchanged sensitivity over 24 hours also makes 
their direct responsibility for the circadian rhythm in 5-HT concentrations unlikely. 
Furthermore, the circadian rhythm of noradrenaline release, which is greater during the 
dark period, would serve to dampen the rhythm in 5-HT release.
In conclusion, the continuous stimulation technique is capable of detecting drug- 
induced changes in terminal 5-HT autoreceptor sensitivity, but these receptors were 
devoid of an innate variation in their sensitivity to agonist or antagonist, during the light : 
dark cycle. The failure to observe a circadian variation in their sensitivity may be due to 
its absence, as suggested by the results presented here or the inability of this technique to 
detect them. It is also possible that this same class of terminal 5-HT autoreceptors could 
display a circadian variation in their sensitivity, when examined in other brain regions. It 
is likely therefore that factors other than any circadian rhythm, in terminal 5-HT 
autoreceptor or a/p/ia2 -adrenoceptor function, must be assumed to control the observed 
circadian rhythm in 5-HT release.
* The detection of a circadian rhythm in 5-HT autoreceptor sensitivity may be hampered 
by the experimental protocol employed, since this superfusion technique measures 
autoreceptor sensitivity during the course of the experiment (i.e. over 118 min.), it may 
not allow for the detection of acute changes which could take place during the course of the 
experiment.
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3 RADIO-LIGAND BINDING STUDIES
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3.1 METHODS FOR fSHIg-ftUT blnrillinfli
3.1.1 Preparation of membranes
The procedure of membrane preparation described by Herrick-Davis and Titeler 
(1988), was used with minor modifications. Six male Wistar rats (University of Bath 
strain, 200-350g), were killed by cervical dislocation in either the dark or the light phase 
as appropriate. The animals killed in the dark phase had their eyes enucleated prior to 
them being brought out into the light for dissection. The brains were then rapidly removed 
and placed on an ice-cooled petri-dish. The cerebral cortex was then dissected. The 
tissue pooled (approx. 2.5 g wet weight) and homogenized (Ultra Turrax, 1/3 maximum 
speed for 30 seconds) in ice-cold buffer (composition : 50 mM Tris-HCI, 0.5 mM EDTA and 
10 mM MgSC>4 , p.H. 7.4 (1:10 wt/vol). The homogenate was further homogenized using a 
teflon mortar and pestle (Tri-R Stir-R, model K 41), four slow up and down strokes at 1/3 
speed. The homogenate was then centrifuged (Beckman Ultracentrifuge, model L8 -M) at 
30,000 x g for 15 minutes. The resulting pellet was resuspended and homogenized (Ultra 
Turrax for 30 sec.) in ice-cold distilled water, to disrupt nerve endings containing 
endogenous 5-HT (1:30 wt/vol, p.H. 7.4), and recentrifuged for 10 minutes. The 
subsequent pellet was this time resuspended and homogenized (Ultra Turrax for 30 sec.) in 
Tris-HCI buffer (1:30 wt/vol ), incubated at 37°C (Grant, model JB 2) for 15 minutes and
centrifuged a further four times, 10 minutes each, with a resuspension between
centrifugations. The pellet was suspended once more in distilled water preceding the 
fourth centrifugation. The final pellet was resuspended in buffer containing 50 mM Tris- 
HCI, 0.5 mM EDTA, 10 mM MgSO^, 0.1% ascorbic acid and 10 pM pargyline. Some 
membranes were frozen overnight in liquid nitrogen (-195°C).
The method described above was also used to prepare membranes from male 
hamster and guinea-pig cerebral cortex. Due to the smaller size of the hamster brain, six 
animals were killed for each experiment and their cerebral cortices pooled. In contrast, 
the tissue obtained from a single guinea-pig was sufficient for each experiment.
3.1.2 Purity of f3 H15 -H T
It is essential to ensure that the [^H]5-HT used in the binding studies is not only
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pure but does not degrade during the course of the experiment, as this would cause an 
underestimation of the equilibrium dissociation constant. In addition, any product formed 
as a result of the degradation of the ligand possesses the potential to interfere with the 
binding assay. The results of such studies can be misleading, as the breakdown product 
may well contribute to the binding of the ligand.
It is essential therefore to identify any potential hazards which are likely to 
interfere with the assay, and if possible eliminate them. [3 H]5-HT is prone to oxidation, 
therefore the inclusion of an antioxidant (ascorbic acid 0 .1%), is commonly employed to 
reduce this potential. 5-HT is metabolized to 5-hydroxyindole acetic acid (5-HIAA) by the 
action of monoamine oxidase (MAO). The inclusion of pargyline (10 pM), which is an ir­
reversible MAO-inhibitor, reduces the likelihood of this happening to [3 H]5-HT.
The [3 H]5-HT when used was 97.7% pure, and all the necessary binding 
experiments were performed within one month of its receipt. In addition, some of the 
preliminary work was carried out using an older batch of [3 H]5-HT which was only 48% 
pure, as assayed by HPLC linked to a electrochemical detector.
3.1.3 Investigation of the serial dilution o fr3 H15-HT concentrations
Serial dilutions of ^HJS-HT were carried out in 20 ml plastic scintillation vials.
Six standard concentrations of ^H ^-H T were prepared in Tris-HCI buffer and used in the 
radioligand binding studies described. The standards being prepared immediately prior to 
each experiment.
3.1.4 Assessment of the degree of f3 H15-HT binding to filter paper
The extent of [3 H]5-HT binding to Whatman GF/B filter paper was investigated. 
This type of binding is an example of non-specific binding which can sometimes obscure the 
specific component. It is therefore imperative that all forms of non-specific binding be 
kept to a minimum.
The filters underwent a variety of treatments :
( a ) soaked in Tris-HCI ;
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( b ) soaked in a 10 pM solution of 5-HT ;
( c ) soaked in a 0 .1% solution of polyethyleneimine ;
( d ) kept dry.
A concentration of [3 H]5-HT approximating to its dissociation constant (Kq) value 
(2 nM) was chosen to pass through the filters. A volume of 1 ml was passed through each 
filter, followed by two 5 ml washes with ice-cold Tris-HCI buffer. The filters were then 
placed into plastic scintillation vials and 12 ml of liquid scintillation fluid added. Following 
sonication for 15 minutes they were allowed to equilibrate in the scintillation counter for 
three hours, prior to counting for 5 or 10 min each. The results were expressed as 
disintegrations per minute.
3.1.5 Protein assay
A 1:10 dilution of the final membrane suspension was made and this was used for 
the estimation according to the method of Lowry et al. (1951). Standard concentrations 
of bovine serum albumin were prepared ranging from 10-60 pg.
Stock solutions of 2% (w/v) Na2 C 0 3  in 0.1 M NaOH, 1% (w/v) CuS04  and 2% 
(w/v) Sodium tartrate were made and stored at 4°C. They were mixed in a ratio of 
100 :1:1 immediately prior to the assay. A 100 pi sample diluted to 200 pi with buffer or 
in the case of standards the appropriate volume being made up to 200 pi with buffer. One 
ml of the above prepared mixture was added to all the tubes. They were whirlimixed and 
left at room temperature for 10 min. After this period, 100 pi of 50% Folin's reagent 
was added to all the tubes. The tubes were again whirlimixed and left at room temperature 
for 40 min, for the blue colour to develop. The absorbance at 750 nM was measured using 
a Pye Unicam PU 8610 UV spectrophotometer. All standards were run in duplicates, while 
the samples were run in triplicate. The protein concentration was determined graphically 
from the linear range of the standard curve.
3.1.6 Investigation of Washing
The binding of a radioligand to a single set of sites, displaying the law of mass 
action kinetics, is completely described by the two parameters Kq and Bmax.
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The dissociation constant calculated experimentally should theoretically be 
independent of the membrane concentration, so long as the bound and free ligand have been 
carefully quantified. However, the protein concentration can influence the Kq value 
(Leysen and Gommeren, 1981). Furthermore, non-specific binding and the dissociation 
constant have been reported to double when the protein concentration is increased four fold 
(Lazareno and Nahorski, 1982). This problem was attributed to the inefficient washing of 
the membranes and can be minimized if a lower protein concentration is used, in conjunction 
with adequate washing.
Washing of the membranes was therefore investigated experimentally. 
Unfortunately, the washing process is a compromise between removing as much unbound or 
non-specifically bound ligand as possible, whilst causing little dissociation of the 
specifically bound ligand. Practically, it is best to use a copious amount of buffer in as 
shorter time as possible.
The following protocol was employed. A 1 ml suspension of membranes (containing 
0.5 mg protein) was incubated at 37°C together with [3 H]5-HT at a concentration of 2 nM, 
for 30 min. After this period of incubation the membranes were filtered through Whatman 
GF/B filters followed by either two or three 5 ml washes with ice-cold Tris-HCI buffer.
3.1.7 Investigation of the specific binding of f3 H15-HT at varying protein 
concentrations
As reported in the section 3.1.6, the concentration of protein used can have a 
marked influence on the parameters being determined. It is therefore important to use a 
concentration of protein which is in the range at which the degree of binding shows a good 
linear relationship with the amount of membrane protein. This has the effect of minimizing 
problems which could occur as a result of receptor or ligand degradation during the 
incubation or uneven washing of the free radioligand as the protein concentration varies.
An investigation was carried out into the effect of varying concentrations of 
protein on specific binding, and the ability of the filter paper to cope with this amount of 
protein without getting blocked. Protein concentrations between 0.2 and 1.0 mg per
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q
incubation were used and binding was assessed using approximately 2 nM of [°H]5-HT. 
Non-specific binding was that measured in the presence of 10 pM 5-HT.
3.1.8 Investigation of protein loss through filters
It is important to establish that the process of membrane washing does not result in 
the loss of protein through filters, as this is likely to lead to an underestimation of the
q
amount of [°H]5-HT bound per mg protein.
To establish whether protein was being lost through the filter, incubations were 
carried out as previously described. They were filtered through Whatman GF/B filters 
followed by one or two 5 ml washes with ice-cold Tris-HCI buffer. The filtrate was 
collected in test-tubes and the protein was estimated by the method of Lowry et al. 
(1951).
3.1.9 Specificity of f3H15-HT binding to membranes
Some binding studies have been plagued with the binding of the ligand to rather 
obscure and unsuspected sites. Bielkiewicz and Cook (1985), reported the specific, high 
affinity binding of the histamine receptor ligand, mepyramine, to glass fibre filters. 
Peroutka and Demopulos (1986), reported similarly the specificity of the binding of 8 -OH- 
DPAT to glass fibre filter papers. The binding of radiolabelled insulin to talc is another 
classic example (Cuatrecasas and Hollenberg., 1975). It is therefore imperative that 
necessary steps are taken to ensure that the ligand binding to these non-specific sites is 
kept to a minimum, or it may obscure the view of the physiologically relevant sites.
In order to establish that the ligand does in fact bind to the membranes being used, 
the membranes (0.25 mg protein) were heated to boiling in order to denature the receptor 
proteins. The binding procedure was then carried out in the usual way. The amount of 
binding detectable was very low (total=208±19 ; non-specific=217±10 (mean±s.e.m., 
n=2)) and was of the order usually seen in the presence of a large excess of 5-HT (i.e. 
non-specific binding). This implies that denaturation of the receptor protein leads to a 
significant reduction in ligand binding, approximating to non-specific levels.
In addition, the number of counts produced when no ligand was used in the incubation
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{i.e. when membranes were filtered on their own and the samples counted) was also 
determined. The number of counts produced was very low and in line with those observed 
during background estimates. Also, when 2 nM [3 H]5-HT, 100nM 8 -OH-DPAT and 1 pM 
(-)propranolol were incubated without membranes, to determine the extent of filter 
binding, no specific binding was detected. These findings suggest that the ligand binds to 
membranes and not to the filter.
A further experiment was performed in which membranes (0.5 mg protein in 0.8 
ml), ligand (2 nM [3 H]5-HT), 5-HT (10 pM) and buffer were used in a number of 
combinations to further establish the specificity of binding :
( a ) 0.8  ml membranes + 0.1 ml Tris-HCI + 0.1 ml ligand ;
( b ) 0.8  ml membranes + 0.1 ml 5-HT + 0.1 ml ligand ;
( c ) 0.8 ml Tris-HCI + 0.1 ml Tris-HCI + 0.1 ml ligand ;
( d ) 0.8  ml Tris-HCI + 0.1 ml 5-HT + 0.1 ml ligand.
3.1.10 f3 H15-HT binding to rat cerebral cortex membranes over 24-hours
The procedure for the binding assay of [3 H]5-HT was adapted from Herrick-Davis 
and Titeler (1988). Saturation experiments were performed using polystyrene tubes in 
duplicate with a final volume of 1.0 ml [0.8 ml membrane homogenate (containing 0.5 mg 
protein), 0.1 ml radioactive ligand and 0.1 ml of the appropriate concentration of drug or 
buffer]. Six concentrations of [3 H]5-HT (0.5-16 nM) were used to determine total 
binding. Non-specific binding was defined as that measured in the presence of 10 pM 5-HT. 
Competition experiments were performed in triplicate using 2 nM [3 H]5-HT as the ligand 
concentration. The competing drugs used were 8 -OH-DPAT (100 nM) and (-)propranolol (1 
pM). All assay tubes were incubated at 37°C in a water bath (Grant, model JB 2), for 30 
minutes, incubations were then rapidly terminated by vacuum filtration through Whatman 
GF/B filters (presoaked in a 0 .1% solution of polyethyleneimine for approx. 18 hours), 
followed by two 5 ml washes with cold buffer, using a Millipore sampling manifold (model 
No. 1225). The complete washing procedure took approximately 12 seconds per filter. 
Filters were placed in plastic scintillation vials containing 10 ml of liquid scintillation fluid
(Optiphase "Safe"). The vials were then sonicated (Dawe ultrasonics) for 15 minutes and 
following vigorous shaking they were left in an LKB liquid scintillation counter for 3 hours 
to equilibrate. After this period, they were counted at an efficiency of 37.5% efficiency, 
for 5 minutes. The scintillation counter corrected for the background counts as well as the 
low efficiency of counting and expressed the results as disintegrations per minute, these 
were converted to fmol/mg protein.
3.1.11 f3 HI 5-HT binding to cerebral cortex membranes of hamster and 
fl»lnea=plfl
Saturation and competition studies were performed in the same way as that 
described above for the binding of pH]5-HT to rat cerebral cortex membranes.
3.1.12 Effect of chronic methiothepin on f3H15-HT _blndlng
Methiothepin was administered to rats on a chronic basis, as described in section 
2.3.10. Rats were killed by cervical dislocation 3 days after the last injection. The
cerebral cortex from five male rats which had previously received either methiothepin or
saline injections was dissected and pooled separately. Membranes were prepared as 
described in section 3.1.1. Competition experiments were performed in triplicate using 2 
nM ^H^-HT as described in section 3.1.10.
3.1.13 Calculations and Statistics
The binding data of saturation studies with both ligands was assumed to fit a one- 
site model. It was analysed using the program of Tallarida and Murray operated on a 
Superbrain II computer. This Scatchard analysis program enabled the estimation of the 
correlation coefficient of binding (r), the equilibrium dissociation constant ( K q ) and the 
number of binding sites (Bmax).
The one-way analysis of variance test was used for comparison of K q  and Bmax 
values for the 5-HT-j binding site as well as the reduction in the binding caused by the 
presence of 8-OH-DPAT or (-)propranolol.
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3.1.14 Drugs
[3 H]5-HT, 12.5-13.5 Ci/mmol (Amersham Int., Amersham, England), 5- 
hydroxytryptamine creatnin© sulphate (Sigma, St. Louis, MO, USA ), 8-hydroxy-2-(di-n- 
propylamino) tetralin (Semat Technical Ltd., St. Albans, England), methiothepin maleate 
(gift from Roche, Herts, England), pargyline hydrochloride (Sigma), polyethyleneimine 
(Sigma) and (-) laevopropranolol hydrochloride (gift from ICI, Cheshire, England).
3.2 R ESU LTS OF r^Mlfi-HT blndHing sM iiaa
3.2.1 Investigation of the serial dilution of f3 H15-HT ggncgntrotlong
Six different concentrations (5, 10, 20, 40, 80 and 160 nM) of [3 H]5-HT were
prepared by serial dilution in plastic scintillation vials using Tris-HCI buffer of the
composition used to suspend the final pellet. These concentrations were ten fold higher 
than those used in binding studies because a further 1:10 dilution would occur when 100 p.l 
of these solutions was added to 900 p.l of membranes/drug. A 100 y.l solution of each of 
these concentrations was counted in triplicate. A good correlation was seen when D.P.M. 
counts were plotted against [3 H]5-HT concentration (Fig. 26), suggesting that pipetting was 
satisfactory and that [3 H]5-HT dissolution was uniform.
3.2.2 Extent of f3 H15-HT binding to filter paper
Soaking of filter papers (in Tris-HCI, 5-HT or polyethyleneimine) was associated
with a reduction in the binding of ^HJS-HT as compared to dry filters. The greatest
reduction in this form of non-specific binding was produced in filters previously soaked in 
either 10 pM 5-HT or 0.1% polyethyleneimine (Table 7). As a result, filters were soaking 
routinely in a solution of 0 .1% polyethyleneimine for at least 12 hours prior to use.
3.2.3 Investigation of washing
Rat cerebral cortex membranes (0.5 mg protein) were incubated at 37°C with 
[3 H]5-HT (2 nM) for 30 minutes. The membranes were then filtered on GF/B filters and 
washed either twice or three times with 5 ml ice-cold Tris-HCI buffer. Washing with less 
than a total volume of 10 ml was not tested on the grounds that it may not be enough to
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The serial dilutions were performed in plastic scintillation vials using Tris-HCI 
buffer of the composition described in the methods. The results are the meansts.e.m  
of two separate experiments each performed in triplicate.
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wash away unbound ligand. There was little difference between the counts remaining after 
washing either twice or three times with 5 ml buffer (Table 8 ). From this study, a 
washing procedure involving two 5 mi washes with ice-cold buffer was chosen for 
subsequent studies.
3.2.4 Specific binding of f3 H15-HT at varying protein concentrations 
Increasing protein concentration in the incubation was associated with a linear
increase in the total and the specific binding components, up to about 0.6  mg protein (Fig. 
27). In contrast, non-specific binding increased linearly with protein concentration. The 
filter was blocked when 1.0 mg protein was filtered. From this study, a membrane protein 
concentration of 0.5 mg was chosen for future work on the grounds that it falls on the 
linear range of the specific binding line and also because higher protein concentrations yield 
higher binding counts.
3.2.5 Investigation o f protein loss through filters
No protein was detected in the eluate when the filters were washed twice with 5 ml 
Tris-HCI buffer. As a further check, the membranes were washed with just 2 ml of ice- 
cold Tris-HCI buffer. It was found that approximately 4.14% ± 0.72% (n=4) of the protein 
used (0.5 mg per incubation), was recovered in the filtrate. This small amount of protein 
was undetectable when the membranes were washed with either 5 or 10 ml of buffer, 
perhaps because of the dilution effect. This filtered protein is likely to consist of small 
membrane fragments and/or small intracellular synaptic components. While this loss is 
undesirable, it is acceptable.
3.2.6 Specificity o f f3 H15-HT binding to membranes
The absence of membranes in the incubation (replaced with 0.8  ml Tris-HCI buffer) 
was associated with a marked reduction in the total and non-specific binding of [3 H]5-HT 
(Table 9), suggesting that the ligand was binding to membranes. In addition, the 
denaturation of membrane proteins resulted in a lowering of the binding of [3 H]5 -HT.
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Table 7. Effects of various treatments on the binding of
f3H15-HT to filter paper
Treatment D.P.M. counts 
(meants.e.m.)
soaked in Tris-HCI 
soaked in 10 pM 5-HT 






The filter papers were soaked in the appropriate solution for at least least 4 hours, after
q
which 1 ml of 2 nM [°H]5-HT was filtered, followed by two 5 ml washes with ice-cold 
Tris-HCI buffer. The counts represent the means ± s.e.m. of [3 H]5-HT bound to the filters.












208 3± 53 .57
2043±55 .39
Rat cortical membranes (0.5 mg protein) were incubated at 37°C with [3 H]5-HT at a 
concentration of 2 nM, for 30 min. The membranes were then filtered and washed with 
either two or three 5 ml of ice-cold Tris-HCI buffer. The counts are the means ± s.e.m. of 
determinations performed in triplicate, from a single experiment.
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Figure 27. Effect of varying protein concentrations on
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The results are presented as mean D.P.M. counts of a single experiment performed in 
duplicate. Total binding was measured using approximately 2 nM [3 H]5-HT and 
non-specific binding was that present after the addition of 10 pM unlabelled 5-HT. 
Specific binding was calculated by subtracting non-specific binding from the total 
binding.
- 117 -
Table 9. Specificity of f3H15-HT binding to membranes of 
rat cerebral cortex
0.8 ml membranes 0.8 ml Tris-HCI
0.1 ml f3 H15-HT_ 0,1 .ml .[3 H]5_-HI
0.1 ml 5-HT : 3 0 4  141
0.1 mi Tris-HCI : 1056  133
Results are the mean D.P.M. counts of a single experiment performed in triplicate. 
Incubations were performed in a number of combinations using membranes (0.5 mg protein 
in 0.8 ml), 0.1 ml [3 H]5-HT (2 nM final conc.), 0.1 ml Tris-HCI (50 mM) and 5-HT (10  pM 
final conc.), for 30 minutes and then filtered on GF/B filters. The results are expressed 
as the counts remaining following two washes with 5 ml ice-cold Tris-HCI buffer.
These results add further support to the idea that [3 H]5-HT was binding to a protein 
component of membranes.
3.2.7 f3 H15-HT binding to cerebral cortex membranes over-24 hours
Saturation studies were performed at each time point (mid-dark, mid-light, end-
q
dark and end-light) using six different concentration of [°H]5-HT (0.5 to 16 nM). Non­
specific binding was defined as that measured in the presence of 10 pM 5-HT. A plot of
q  q
non-specific [°H]5-HT binding against pH]5-HT concentration produced a straight line with 
a correlation value of 0.991, as analysed by linear regression (Fig. 28). The good 
correlation confirms that the washing procedure removed all the washable non-specific 
binding at all concentrations of [3 H]5-HT. A similar linear relationship of non-specific 
binding was also seen at the other three time points.
The specific binding of [3 H]5-HT, obtained by subtracting non-specific from the 
total binding, displayed a monophasic saturation curve (Fig. 29), suggesting that it binds to 
a single site. Similar curves were obtained at all four time points. A Scatchard plot of 
this data produces a straight line (Fig. 30), further confirming that [3 H]5-HT binds to a 
single site. Similar plots of experiments performed using tissue obtained at the other time 
points yielded similar results: high reproducibility between independent experiments and 
straight Scatchard plots. K q  and Bmax values were calculated from Scatchard plots for 
each experiment by regression analysis. In general the specific binding represented about 
82% of total binding, Kq and Bmax values were very similar and not statistically different 
at the four time points. A summary of the results is shown in Table 10.
A concentration of 2 nM [3 H]5-HT (corresponding to the Kq value) was used in 
competition studies, with specific binding accounting for over 80% of the total binding. 8- 
OH-DPAT (100 nM) was used to specifically block the 5 -H T ^ binding sites (Middlemiss and 
Fozard, 1983), while (-)propranolol (1 pM) is capable of blocking both the 5 -H T ^  and the 
5-HT1B binding sites (Nahorski and Willcocks, 1983 ; Hoyer et ai, 1985). The results of 
this study are shown in Table 11.
This 2 nM concentration of [3 H]5-HT specifically bound to about 120 fmol/mg 
protein, at each of the four time points. This total probably represents the binding of
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Figure 28. Effect of varying concentrations of r3H15 - H T
on the non-specific binding component
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Increasing concentrations of [3 H]5-HT (0.5-16 nM) were incubated with 
membranes (rat cerebral cortex at end-light) in the presence of 10 pM 5-HT, 
expressed as fmol/mg protein. Each point represents the mean of a duplicate 
determination, derived from three separate experiments.
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Figure 29. The amount of specific  r3H 1 5-HT b in d in g  
against varying concentrations of r3H15 - H T
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Increasing concentrations of [3 H]5-HT (0.5-16 nM) were incubated with 
membranes (rat cerebral cortex at end-light) in the absence or presence of 10  pM 
5-HT. Specific binding was calculated by subtracting the non-specific binding from 
the total binding, expressed as fmol/mg protein. Each point represents the mean ± 
s.e.m. of three separate experiments each performed in duplicate.
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Figure 30. Scatchard plot of the specific binding of
r3H15-HT to membranes of rat cerebral cortex
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Scatchard plot of the saturation data of specific [3 H]5-HT binding. Specific binding 
was calculated by subtracting the non-specific binding from the total binding, 
expressed as fmol/mg protein. This data is from a single assay (rat cerebral cortex 
at end-light) and is representative of three separate experiments. Each point 
represents the mean of a duplicate determination.
- 122 -
Table 10. Estimation of the affinity constant and the
number of 5-HT-| binding sites in cerebrai cortex 
membranes of the rat, over 24-hours
mid-dark mid-light end-dark end-liaht
KD (nM) 2 .450±0 .24 2  2 .992± 0 .82 3  2 .401±0.161 2 .903± 0 .18 9
Bmax 3 0 3 ± 1 6.29  3 2 1 ± 2 0 .9 4  313 ±5 6 .6 5  32 4 ±1 1 .6 9
(fmol/mg protein)
Specific 5-HT^ binding was obtained by calculating the difference between total [3 H]5-HT 
binding and binding in the presence of 10 pM 5-HT. Scatchard plots of this data were 
analysed by linear regression. The affinity constant (K q ) and the number of [3 H]5-HT 
binding sites (Bmax) were determined for each experiment, at the four time points. Each 
value represents the mean ± s.e.m. of three separate experiments, each performed in 
duplicate.
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Table 11. Effect of 8-OH-DPAT and propranolol on the 
binding of r3H15-HT to rat cortical membranes
Siifi m id -dark % displacement m ld - lla h t % displacement
(fmol/mg protein) (fmol/mg protein)
Total 5-HT1 116.18±19.49 119.89±7.82
8 -OH-DPAT 66.31 ±7.47 43±6.4 64.72±2.66 46±2.2
propranolol 31.77±2.10 73±1.8 33.48±2.65 72±2.2
Sllfi end-dark % displacement e n d -lig h t % displacement
(fmol/mg protein) (fmol/mg protein)
Total 5-HT1 119.74±21.67 127.70±4.61
8 -OH-DPAT 68.29±7.20 43±6.0 72.48±4.36 43±3.4
propranolol 33.81 ±3.93 72±3.3 35.03±1.44 73±1.1
Competition studies were performed using a 2  nM concentration of [^H]5-HT in the absence 
or presence of blocking drugs [8 -OH-DPAT (100 nM) or (-)Propranolol (1 pM)]. The 
results are expressed in fmol/mg protein of the ^HJS-HT binding taking place. Each value 
is the mean ± s.e.m. of three separate experiments at each time point, performed in 
triplicate.
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[3 H]5-HT to a range of 5-HT<j subsites. The presence of 8 -OH-DPAT (100 nM) in the 
incubation medium produced a marked reduction (about 43%) in the number of specific 
l3 H]5-HT binding sites, at each of the four time points. This component probably 
represents the hindrance caused by 8 -OH-DPAT in the binding of [3 H]5-HT to the 5 -H T ^  
site (Table 11).
(-)Propranolol (1 |iM) consistently produced a greater reduction in the binding of
q
[ H]5-HT (representing about 72% displacement of the total), as compared to 8 -OH-DPAT. 
It is likely that this concentration of propranolol interferes partially with the binding of 
[3 H]5-HT to the 5 -H T ia , 5-HT-jb ancI the 5-H T jq  binding sites (Hoyer et al., 
1985,1987). As a consequence the results of the use of propranolol are difficult to 
interpret.
Statistical analysis (one-way analysis of variance) did not identify any significant 
differences in the affinity of binding, the number of binding sites or the reduction in the 
binding produced by the presence of drugs.
3.2.8 [3 H ] 5-HT binding to cerebral cortex membranes of hamster and
oulnea-pig
Saturation studies were performed as described for the rat. Specific binding 
represented about 84% of total binding in both species. The affinity of [3 H]5-HT for these 
membranes was very similar to that previously observed for the rat. In addition, the 
Bmax va*ues were a,so °f similar magnitude (Table 12).
Competition studies performed using 2 nM [3 H]5-HT identified a total of 147±11.12 
and 132±6.08 fmol/mg protein (meanls.e.m., n=3) binding sites in hamster and guinea-pig 
respectively. Of this total, the 5 -H T ^  binding site accounted for about 45% in hamster 
and 49% in guinea-pig (Table 12). (-)Propranolol produced a greater reduction of the
Q
binding of [°H]5-HT binding as compared to 8 -OH-DPAT from hamster cortex membranes, 
similar to that previously observed in the rat. In contrast, (-)propranolol caused a 
consistently smaller reduction in the binding of [3 H]5-HT binding as compared to 8 -OH- 
DPAT from guinea-pig membranes (Table 12). The inability of propranolol to hinder
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Table 12. Extent of f3 HI 5-HT binding to the 5-HT-| 
binding site in hamster and guinea-pig cortical 
membranes
displacing ham ster % displacement
drug (fmol/mg protein)
Total 5-HT1 147 .02±11 .12
8-OH-DPAT 80 .67±6 .79  45±4 .6
propranolol 59 .27±6 .36  60±4 .3
Kd (nM) 2 .588±0 .022
Bmax (fmol/mg protein) 344 ±2 6 .0 2
displacing gu lnea -p la  % displacement
drug (fmol/mg protein)
Total 5-HT-j 131 .67±6 .08
8-OH-DPAT 66 .86±5 .36  49±4.1
propranolol 88 .54±5 .59  33±4 .2
Kd (nM) 2 .264±0 .084
Bmax (fmol/mg protein) 292 ±1 3 .4 8
Membranes were prepared from these species at the mid-light time point of their light : 
dark cycle. Scatchard plots of the saturation data were analysed by linear regression. 
The affinity constant ( K q ) and the number of [3 H]5-HT binding sites (Bmax) were 
determined for each experiment. Each value represents the mean ± s.e.m. of three 
separate experiments, each performed in duplicate. Competition studies were performed 
in the absence or the presence of displacing drugs [8 -OH-DPAT (100 nM) or (-)Propranolol 
(1 |iM)], and analysed as described for studies of rat cerebral cortex membranes. The 
results of competition studies are expressed as the amount of [^HJS-HT binding in the 
presence or absence of drug, and each value represents the mean l  s.e.m of three separate 
experiments, each performed in triplicate.
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[3 H]5-HT binding to a greater extent than that produced by 8 -OH-DPAT, suggests that at 
this concentration it is either incapable or only partially able to prevent [3 H]5-HT binding 
to the 5 -H T ^  site. In addition, propranolol exhibits considerable affinity for the 5-HT.j B 
binding site in rat brain, however, its inability to yield similar results from guinea-pig 
cortex membranes suggests that this [3 H]5-HT binding site may display an altered affinity 
for propranolol or that it may be absent.
3.2.9 Effect of chronic methlothepin on f3H15-HT binding
The results of competition studies from saline-injected animals were very similar 
to those previously obtained from non-injected rats at this time point. The daily injection 
of methiothepin (10 mg/kg i.p.) for 14 days produced very little change in the total number 
of specific [3 H]5-HT binding sites {sa line^ 23.52±6.83 ; methiothepin=127.06±3.75 
fmol/mg protein (meanis.e.m., n=3)}. There was no significant difference with respect to 
control in either the total number of binding sites or the components reduced by 8 -OH-DPAT 
or propranolol (Table 13).
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Table 13. Effect of daily methiothepin or saline 
injections on the number of 5-HT-| binding sites in the 
cerebrai cortex of the rat
SilS sa line % displacement
(fmol/mg protein)
Total 5 -M \ 123.52±6.83I
8 -OH-DPAT 68.22±3.81 45±3.1









A group of five rats received daily injections of methiothepin (10 mg/kg i.p.) or saline for 
14 days, at the mid-light point of their light : dark cycle. The rats were killed at mid­
light, 3 days after the last injection, and the cerebral cortex dissected. Binding studies 
were performed, following the preparation of membranes, using a 2 nM concentration of
q
[°H]5-HT in either the absence or the presence of blocking drugs [8 -OH-DPAT (100 nM) or 
(-)Propranolol (1 pM)]. The results are expressed as fmol/mg protein of the [3 H]5-HT 
binding taking place. Each value is the mean 1  s.e.m. of three separate experiments, each 
performed in triplicate.
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3.3 METHODS FOR ff3 mCS©ttgitn)g©rllini b ind ing
3.3.1 f3 H1Ketanserln binding protocol
The procedure for this study was adapted from similar work carried out by Pazos 
and collaborators (Pazos et ai., 1985). Membranes were prepared by pooling the frontal 
cortex of six male Wistar rats (approx. 1.15 g wet weight). The tissue was then 
immediately placed in ice-cold 0.32 M sucrose solution (1:10 wt/vol), and homogenized 
(Ultra Turrax, 1/3 maximum speed for 30 seconds). The homogenate was further 
homogenized using a teflon mortar and pestle (Tri-R Stir-R, model K 41), four slow up and 
down strokes at 1/3 maximum speed. The homogenate was then centrifuged (Beckman 
Ultracentrifuge, model L8 -M) at 900 x g for 10 minutes. The supernatant fluid (lacking 
cell debris) was then centrifuged at 70,000 x g for 15 minutes. The resulting pellet was 
suspended in ice-cold Tris-HCI buffer (50 mM, p.H. 7.5) at a concentration of 1:10 wt/vol. 
It was homogenized (Ultra Turrax for 30 sec.) and the suspension incubated at 37°C (Grant, 
model JB 2) for 15 minutes. The suspension was then centrifuged again at 70,000 x g for 
15 minutes. The final pellet was resuspended in buffer (p.H. 7.7), containing 50 mM Tris- 
HCI, 4 mM CaCI2  and 0.1% ascorbic acid (with 1 pM pargyline being added prior to the 
binding experiment). When prepared, the membranes were stored in liquid nitrogen until 
used. They were not kept for more than 4 days. The membrane protein was determined 
using the assay described by Bradford, 1976.
The preliminary studies performed with [3 H]ketanserin were similar to those 
already described for (3 H]5-HT binding, with minor differences. Saturation studies were 
also performed in exactly the same manner as those described for the binding of [^HJS-HT 
to membranes of the cerebral cortex (see section 3.1.10). However, binding experiments
q
with [^H]ketanserin were only performed at two time points, corresponding to mid-light 
and mid-dark of the light : dark cycle. Mianserin hydrochloride (1 jiM) was used to define 
non-specific binding.
3.3.2 Calculations and S ta tis tics
The results of saturation studies were analysed as described in section 3.1.13.
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Student's t-test was used for the statistical comparison of the results obtained at mid-light 
and mid-dark, of the light : dark cycle.
3.3.3 D ru g s
[3 H]ketanserin 64.9 Ci/mmol (NEN research products, was a gift from Beecham 
pharmaceuticals, Harlow, Essex, England), mianserin hydrochloride (Beecham 
pharmaceuticals, Epsom, Surrey, England), pargyline hydrochloride (Sigma) and 
polyethyleneimine (Sigma).
3.4 RESULTS OF ffs mK®figiin)S®irllin) b ind ing  r tu d ta *
The [^HJketanserin used in this study was 97.8% pure; all experiments were 
completed within three months of this analysis.
3.4.1 Investigation of the serial dilution of f3 H1Ketanserln concentra tions 
[3 H]ketanserin was obtained from NEN (Du Pont), dissolved in an ethanolic solution. 
This solution posed a considerable problem in the preparation of standard ligand 
concentrations for use in saturation experiments. When serial dilutions were prepared 
using Tris-HCI buffer, the counts produced by some of the concentrations were suggestive 
of up to a 30% loss of ligand. The problem was thought to be attributable to either the 
binding of the ligand to pipette tips and tubes used in the preparation of serial dilutions or 
the inability of the ligand to dissolve in buffer. Several different makes and compositions 
of tubes were tried, however the problem was still evident. In addition, aging of the tubes 
had little effect on the loss. Also, when serial dilutions were prepared in a closed system 
(no-loss) manner, a considerable amount of ligand was still being lost, suggesting that it 
was binding to pipette tips, since this was the only variable. Serial dilutions prepared in 
distilled water were still associated with a loss of ligand. However, when dilutions were 
prepared using 95% ethanol, no loss in counts was observed. Overall, the problem was 
probably a mixture of the ligand binding to pipette tips and tubes as well as its inability to 
dissolve freely in buffer.
This problem was finally overcome when buffer containing ethanol was used in the
-130-
preparation of serial dilutions. A 10% ethanol concentration in Tris-HCI buffer still 
resulted in more than 5% loss of ligand. However, when a solution of buffer containing 
20% ethanol was used, the counts from the respective concentrations were indicative of a 
less than 2% loss, this value was considered acceptable. It is rather surprising that other 
authors of binding studies have not encountered similar problems with the ethanolic solution 
of this ligand. Leysen et al. (1982), are the only authors to report that such a problem 
actually exists and take appropriate action to counter it.
Six different concentrations (0.3125, 0.625, 1.25, 2.5, 5 and 10 nM) of
q
[aH]ket an serin were prepared by serial dilution in polystyrene tubes using ice-cold Tris- 
HCI (containing 20% ethanol) of the composition used to suspend the final pellet. These 
concentrations were ten fold higher for reasons described in the serial dilution of [3 H]5-HT 
(see section 3.2.1). A 100 pi solution of each of these concentrations was counted in 
duplicate. A good correlation was seen when D.P.M. counts were plotted against
q
[°H]ketanserin concentration (Fig. 31), suggesting that pipetting was satisfactory and that
q
pHketanserin dissolution was uniform.
The standard concentrations of ligand were prepared in Tris-HCI buffer containing 
20% ethanol, a ten fold dilution occurred during membrane binding studies, which meant 
that the ethanol was present only at a concentration of 2%. This concentration is 
considered unlikely to interfere with the binding (Lunt, personal communication).
3.4.2 Extent of f3 H1Ketanserln binding to filte r paper
Filter papers were either kept dry or soaked for 90 minutes or Tris-HCI buffer or 
0.1% polyethyleneimine. Following this soaking period, 1 ml of [3 H]ketanserin (about 3 
nM) containing no membranes was filtered, and the filters washed twice with 5 ml Tris-HCI 
buffer. The amount of radioactivity binding was lowest in filters that had previously been 
soaked in 0.1% polyethyleneimine (Table 14). As a result, filters were routinely soaked in 
a solution of 0 .1% polyethyleneimine prior to use.
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The serial dilutions were performed in polystyrene tubes using Tris-HCI containing 
20% ethanol. The results are the meansts.e.m of two separate experiments each 
performed in duplicate.
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3.4.3 Investigation of washing
Rat frontal cortex membranes (0.3 mg protein) were incubated at 37°C with 
[^Hjketanserin (0.2 nM) for 30 minutes, in the presence or the absence of 1 pM mianserin 
to determine non-specific and total binding respectively. The membranes were then 
filtered on GF/B filters and washed either two, three or four times with 5 ml ice-cold 
Tris-HCI buffer. There was little difference between the counts remaining after washing 
either two, three or four times with 5 ml buffer (Table 15). As a result, a washing 
procedure involving two 5 ml washes with ice-cold buffer was chosen for subsequent 
studies.
3.4.4 Specific binding of f 3 H 1 Ketanserin al VSly ing  PTdtgin
concentrations
Increasing protein concentration in the incubation was associated with a linear 
increase in the total and the specific binding components, up to about 0.4 mg protein (Fig. 
32). In contrast, non-specific binding increased linearly with protein concentration. From 
this study, a membrane protein concentration of 0.3 mg was chosen for future work on the 
grounds that it falls within the linear range of the specific binding line.
3.4.5 investigation of protein loss through filters
No protein was detected when the filters were washed twice with 5 ml Tris-HCI 
buffer. As a further check, the membranes were washed with just 2 ml of ice-cold Tris- 
HCI buffer. It was found that approximately 18.7% (n=2) of the protein used (0.3 mg per 
incubation), was recovered in the filtrate. This loss is more likely to reflect the filtering 
of cellular components rather than membranes, resulting from the less stringent washing 
procedure employed in the preparation of membranes. It is nevertheless a source of error.
3.4.6 Specificity of f3 H1Ketanserln binding to membranes
The replacement of membranes with Tris-HCI buffer was associated with a marked 
reduction in the total and non-specific binding of [3H]ketanserin (Table 16), suggesting that 
the ligand is binding to membranes. In addition, denaturation of membrane proteins by
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Table 14. Effects of various treatments on the binding of
r3H1Ketanserin to filter paper
Treatment D.P.M. counts (mean±s.e.m.)
soaked in Tris-HCI 2613±318
soaked in 0.1% polyethyleneimine 1557±104
kept dry 2177±207
The filter papers were soaked in the appropriate solution for at least least 90 minutes, 
after which 1 ml of about 3 nM [^HJketanserin was filtered, followed by two 5 ml washes 
with ice-cold Tris-HCI buffer. The counts represent the means ± s.e.m. (n=4) of 
[3H]ketanserin bound to the filters.

















Membranes (0.3 mg protein) of rat frontal cortex were incubated at 37°C with
Q
[ H]ketanserin at a concentration of 0.2 nM, for 30 min. The membranes were then 
filtered and washed either two, three or four times with 5 ml of ice-cold Tris-HCI buffer. 
Specific binding was calculated by subtracting non-specific binding (using 1 jiM mianserin) 
from total binding. The counts are the means from a single experiment performed in 
duplicate.
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Figure 32. Effect of varying protein concentrations on
















0.2 0.3 0.4 0.50.0 0.1 0.6
Protein concentration (mg)
The results are presented as mean C.P.M. counts of a single experiment performed in 
duplicate. Total binding was measured using 0.2 nM [3 H]ketanserin and non­
specific binding was that present after the addition of 1 pM mianserin. Specific 
binding was calculated by subtracting non-specific binding from the total binding.
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boiling resulted in the complete loss of specific ^HJketanserin binding. These results add 
further support to the idea that [3H]ketanserin specifically binds to a protein component of 
membranes.
3.4.7 f3 H1Ketansertn binding to membranes of the rat frontal cortex at 
mid-dark and at mid-Haht
Saturation studies were performed on membranes (0.3 mg protein per incubation) 
prepared at mid-dark and at mid-light using six different concentrations of [3H]ketanserin 
(from 0.02 to about 1 nM). The actual concentration of ligand present in the incubation 
was estimated from the counts produced by a 100 pi sample of the standard, counted in 
duplicate. Non-specific binding was defined as that measured in the presence of 1 pM 
mianserin. Non-specific l3 H]ketanserin binding increased linearly with increasing 
[3H]ketanserin concentration (Fig. 33), confirming that the washing procedure removed all 
the washable non-specifically bound ligand. A similar linear relationship of non-specific 
binding was seen in experiments performed at mid-dark.
The specific binding of [3H]ketanserin obtained by subtracting non-specific from the 
total binding represented over 80% of total binding. It increased gradually and was 
starting to plateau at the highest concentration of ligand used (Fig. 33). Similar curves 
were produced by experiments performed at the mid-dark time point A Scatchard plot of 
this data produces a straight line (Fig. 34), suggesting that ^HJketanserin was binding to a 
single site. The Kq and the Bmax values were calculated from Scatchard plots for each 
experiments by regression analysis. No significant difference in the kinetic properties of 
[3H]ketanserin binding was found in Kq and Bmax values obtained at mid-dark were 
compared to those obtained at mid-light (Table 17). These results suggest that neither the 
affinity nor the density of the 5 -HT2  binding sites as labelled by this ligand is altered, at 
these time points.
In the incubation medium, ethanol was present at a concentration of 2%. This 
may have contributed to the slightly higher K q  values and also the inability to fully reach 
saturation. In addition, the K q  and Bmax values can be reduced by the use of electrolytes, 
ascorbic acid and pargyline (Leysen eta!., 1982).
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Table 16. Specificity of f3H 1 Ketanserin binding to
membranes of rat frontai cortex
0.8 ml membranes 0.8 ml Tris-HCI
0.1 ml [3 H]ketanserin QJ.jnL[3 H]Ketansefin
0.1 ml mianserin : 7 2 9  370
0.1 ml Tris-HCI : 600 8  5 2 7
Results are the mean D.P.M. counts of a single experiment performed in triplicate. 
Incubations were performed in a number of combinations using membranes (0.3 mg protein 
in 0.8 ml), 0.1 ml [3H]ketanserin (0.23 nM final conc.), 0.1 ml Tris-HCI and mianserin (1 
pM final conc.)), for 30 minutes and then filtered on GF/B filters. The results are 
expressed as the counts remaining following two washes with 5 ml ice-cold Tris-HCI 
buffer.
Table 17. Estimation of the affinity constant and the 
number of r3H1Ketanserin binding sites in membranes of 
rat frontal cortex
mid-dark m id-light
KD (nM) : 1.1916±0.078 1.1975±0.120
Bmax (fmol/mg protein) : 61.14±6.48 63.69±7.62
Specific 5 -HT2  binding was obtained by calculating the difference between total 
FHJketanserin binding and that measured in the presence of 1 i^M mianserin. Scatchard 
plots of this data were analysed by linear regression. The affinity constant (K q ) and the 
number of [3H]ketanserin binding sites (Bmax) were determined for each experiment, at 
mid-dark and at mid-light. Each value represents the mean ± s.e.m. of four separate 
experiments, each performed in duplicate.
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Increasing concentrations of [3 H]ketanserin (0.025 - 0.937 nM) were incubated 
with membranes (rat frontal cortex at mid-light) in the absence and in the presence 
of 1 pM mianserin (non-specific binding). Specific binding was calculated by 
subtracting the non-specific binding from the total binding, expressed as fmol/mg 
protein. Each point represents the mean of a single experiment performed in 
duplicate.
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Figure 34. Scatchard plot of the specific binding of
r3H !Ketanserin to membranes of rat frontal cortex
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correlation coeff= 0.989 
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Scatchard plot of the saturation data of specific [3 H]ketanserin binding. Specific 
binding was calculated by subtracting the non-specific binding from the total 
binding, expressed as fmol/mg protein. This data is from a single assay (rat frontal 
cortex at mid-light) and is representative of four separate experiments performed 
at this time point. Each point represents the mean of a duplicate determination.
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3.5 DISCUSSION
Circadian rhythms have been reported in a number of neurotransmitter receptor 
binding sites, in several regions of the rat brain (Kafka et al., 1986). In addition, beta- 
adrenoceptor binding sites in the rat pineal gland display a marked circadian variation, 
which parallels the accumulation of cAMP (Romero et al., 1975). Harden (1983) 
proposed that this change was the result of befa-adrenoceptors moving in and out of the 
surface membrane by the formation of small vesicles by invagination of the cell membrane; 
the possible mechanism/s responsible for these rapid changes in receptor number and 
function are discussed by Campbell et al. (1985).
The aim of the present study was to determine whether 5-HT receptors are capable 
of exhibiting similar changes in either the affinity or the number of binding sites. The 
results presented here demonstrate the existence of a saturable, high affinity, specific 
binding site for [3 H]5-HT, in membranes prepared from the rat cerebral cortex. The 
affinity of binding and the maximum number of ^HJS-HT binding sites agree with those of 
Herrick-Davis and Titeler (1988), who also reported the existence of a high affinity 
[3 H]5-HT binding site in this region, with a Kp of 2.1 nM and a Bmax of 245 fmol/mg 
protein. This [3 H]5-HT binding site has been identified in a number of regions of rat brain 
(Pazos and Palacios, 1985 ; Herrick-Davis and Titeler, 1988), as well as in the brains of a 
number of other species (Schnellmann et al., 1984 ; Heuring and Peroutka, 1987).
The pharmacological characterization of this [3 H]5-HT binding site was not 
considered necessary because the results of kinetic, saturation and competition 
experiments suggest that low nanomolar concentrations of this ligand bind to a single class 
of 5-HT binding sites, designated 5-HT.j (Peroutka and Snyder, 1979 ; Nelson, 1988).
The affinity of ^HJS-HT binding to the 5-HT^ binding site in the membranes of rat 
cerebral cortex, and the maximum number of binding sites, were not significantly different 
in membranes prepared at the four different time points of the light : dark cycle. 
Wesemann et al. (1983) also reported that the affinity of [3 H]5-HT binding during the light 
: dark cycle was unaltered, but they observed a circadian variation of small amplitude in 
the number of binding sites when using 5 nM [3 H]5-HT and one of greater amplitude when
using 20 nM (3 H]5-HT. This rhythm in the binding, at 20 nM ^HJS-HT varied inversely 
with the concentration of endogenous 5-HT (Wesemann eta/., 1986). Their use of such a 
high concentration of [3 H]5-HT (20 nM) suggests that binding took place to a site which is 
different from the high affinity 5-HT.j binding site. High and low affinity binding sites for 
[3 H]5-HT have been observed by a number of authors (for an extensive list the reader is 
referred to Nelson, 1988); however, it is at present a matter of controversy whether 
these binding sites represent physically distinct molecular entities or whether they 
represent different states of the same binding site (Nelson, 1988). Furthermore, the use 
of crude brain homogenates by Wesemann et al. (1986) is likely to have yielded results 
which reflect the summation of rhythms from a number of brain regions. In addition, the 
observed circadian rhythm in 5-HT concentrations would, if membranes were not washed 
properly, produce an inverse rhythm in [3 H]5-HT binding. These particular obstacles 
were overcome in the present study by incubating membranes for 15 minutes at 37°C, in 
order to enable the endogenous 5-HT to be metabolized by MAO. Also, the tissue was 
osmotically shocked, twice (to burst nerve endings and disrupt vesicles containing 
endogenous neurotransmitter), and the thorough membrane washing procedure ensured that 
the circadian variation in 5-HT concentrations (Quay, 1968) would not interfere with the 
binding of [3 H]5-HT.
As the 5-HTj binding site is heterogeneous (Pedigo et at., 1981 ; Herrick-Davis 
and Titeler, 1988), it is possible that the individual rhythms of its component subsites 
could summate and cancel out. For this reason, competition studies are useful for the 
subclassification and quantification of a single heterogeneous binding site into its individual 
components. To date, the 5-HT.j binding site is reported to be composed of five separate 
binding subtypes (See section 1.3.2.1). The potent 5 -H T ^  receptor agonist, 8 -OH-DPAT, 
when present at a concentration of 100 nM, prevents the binding of (3 H]5-HT to the 5- 
HT-ja subtype (Heuring and Peroutka, 1987), and also selectively displaces [3 H]5-HT from 
the 5 -H T ^  subtype (Middlemiss and Fozard, 1983). These 5 -H T ^  binding sites in the 
cortex probably correspond to the post-synaptic 5-HT.j ^  receptor (Verge et al., 1986 ; 
Crino et al., 1990). In contrast, the 5-HTjq binding sites in the cortex are located 
located pre- and post-synaptically (Crino et al., 1990).
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Pindolol, at a concentration of 1 pM, selectively displaces (or prevents) the binding 
of ^HJS-HT to the 5 -H T ^  and the 5-HT.j g binding sites (Herrick-Davis and Titeler, 
1988). Propranolol, like pindolol, is also a befa-adrenoceptor antagonist, with efficacy 
for preventing or displacing [3 H]5-HT binding from the 5-HT1 binding site (Nahorski and
g
Willcocks, 1983). It is, however, not as selective as pindolol, and displaces [°H]5-HT 
binding from the 5 -H T^, 5-HT.j g, and the 5-HT.j q binding subtypes, and only weakly from 
the 5-HT.j p subtype (Hoyer et al., 1987). The ability of propranolol to displace the 
binding of [3 H]5-HT from the 5-HT.j g binding site has not been investigated.
In the present study, 8 -OH-DPAT (100 nM), produced a reduction in the binding of 
[3 H]5-HT to rat cortical membranes, the size of which was not significantly different at
g
the four time points. This 5 -H T ^  component accounted for about 50% of the total [ H]5- 
HT binding taking place, a value which correlates well with that reported by Middlemiss and 
Fozard (1983) and Herrick-Davis and Titeler (1988). Furthermore, the amount of [3 H]5- 
HT binding still evident in the presence of 8 -OH-DPAT (i.e. non-5-H T^) was not 
significantly different at the four time points.
The presence of propranolol (1 pM) in the incubation medium consistently produced 
a greater reduction (about 72%) in the binding of [3H]5-HT, when compared to 8-OH-DPAT 
in membranes of rat cerebral cortex. The magnitude of this reduction was very similar at 
the four time points, however, these results are difficult to interpret because of the lack of 
selectivity of propranolol at this concentration. It is likely that propranolol partially 
prevented the binding of [3H]5-HT to the 5 -H T ^, 5-HT.j g and the 5-HT.j q subtypes. With 
hindsight, the choice of this agent for use in competition studies was not an appropriate one. 
As a consequence, the results obtained with the use of propranolol could only be interpreted 
qualitatively. Moreover, if a drug had been used successfully to prevent [3H]5-HT binding 
to the 5-HT.j g binding site, the results would still have been difficult to interpret because 
these sites are located both pre- and post-synaptically (Crino et al., 1990). As a 
consequence, it is not possible to correlate the results of binding studies with those 
measuring the functional activity of the terminal 5-HT autoreceptor.
The results of competition studies performed on membranes of the hamster
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cerebral cortex were similar to those found for the rat, suggesting that these two species 
contain a similar complement of 5>HT binding sites. However, in cortical membranes, 
prepared from the guinea-pig brain, propranolol (1 pM) produced a smaller reduction (about 
33%) in the binding of [^H]5-HT, in comparison to the 50% produced by 8 -OH-DPAT. This 
difference is likely to result from the partial ability of propranolol to prevent the binding of 
[3 H]5-HT to the 5-HT.j ^  subtype (Hoyer et al., 1987), and may also be related to the 
absence of the 5-HT.j q binding site in the guinea-pig (Heuring et al., 1986). In place of 
the 5-HT.j 0  binding site, the guinea-pig is reported to possess the 5-HT.j p binding site, for 
which propranolol has a lower affinity (Hoyer and Middlemiss, 1989).
The daily administration of methiothepin (10 mg/kg i.p.) to rats produced little 
change in the total number of 5-HT.j binding sites or its displaceable components in the 
cerebral cortex, suggesting that 5-HTj binding sites are resistant to change following 
blockade. A similar finding has also been reported by Peroutka and Snyder (1980) and 
Blackshear et al. (1983). In contrast, the same treatment was associated with an up- 
regulation or an increased sensitivity of the terminal 5-HT autoreceptor, as reported in the 
superfusion studies section. The inability to detect changes in receptor number is 
attributed to the lack of specificity of propranolol, and also to the low numbers of 
presynaptic 5-HT1B binding sites. In addition, a change may have been produced in the 
affinity of [^H]5-HT binding, but this was not measured.
In the cerebral cortex of the rat, 5-HT concentrations display a circadian 
variation, values being generally higher during the light phase in comparison to the dark 
phase (Quay, 1968). In contrast, the in vivo release of 5-HT, is greater during the dark 
phase (Cespuglio et al., 1983), when the firing rate of 5-HT neurones is highest and the 
animals are awake (McGinty and Harper, 1976). Although the release of 5-HT is greater 
during the dark phase, the unaltered affinity and number of 5-HT.j binding sites 
corresponding to receptors in this region, over 24 hours, suggests that these receptors 
would undergo greater activation during the dark phase. These 5-HT receptors would 
therefore be expected to pass on any changes applied to them. Changes at the level of the 
cortex, although easily studied, have little bearing on any of the 5-HT receptor-mediated 
behaviours so far identified. Clearly, [3 H]5-HT or [3 H]8 -OH-DPAT binding and 5-HT
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release need to be investigated at the level of the brainstem or the spinal cord to enable any 
correlation with the apparent absence of a circadian variation in the 5-HT behavioural 
syndrome.
The radioligand binding studies using [3H]ketanserin have demonstrated the 
existence of a saturable, high-affinity, specific binding site in membranes prepared from
q
the rat frontal cortex. The Kp and the Bmax values for the binding of [°H]ketanserin to 
this site are similar to those reported by Leysen et al. (1982) and Pazos et a!. (1985). 
The Kp values observed in the present study were slightly lower than those previously 
reported (Leysen et al., 1982 ; Pazos et al., 1985), and are considered to result from the 
presence of CaCl2 , ascorbic acid and pargyline in the incubation medium (Leysen et al., 
1982). In contrast, the presence of these agents is reported to be associated with an 
underestimation of the Bmax value (Leysen et al., 1982). Furthermore, an 
underestimation of the Bmax value would also be expected because of the protein loss 
experienced during filtering. As a consequence, the actual "real” Bmax is likely to be 
higher than that observed in the present study. It is not known to what extent this binding 
of [3H]ketanserin reflects the presence of the different states or subtypes of the 5-HT2 
site (see section 1.3.2.2). In addition, a small proportion of [3H]ketanserin binding at high 
concentrations may reflect its binding to either alpha  1 -adrenergic and/or H<|- 
histaminergic sites (Leysen et al., 1981 ; Fischette et al., 1987).
q
Binding studies using [^HJketanserin were performed on membranes prepared at 
mid-light and mid-dark, of the light : dark cycle, and did not reveal any significant 
differences in either the affinity or the total number of binding sites. There is conflicting 
evidence in the literature for the presence of a circadian variation in the binding to the 5- 
HT2 site; for example, Lauro et al. (1986) were unable to observe a circadian variation in 
the binding of [3 H]spiperone to the 5 -HT2 binding sites in the cerebral cortex, 
hypothalamus or the brain stem, similarly Koshikawa et al. (1988) were unable to detect a 
rhythm in the number of cortical 5-HT2 binding sites, using ^HJketanserin. In contrast, a 
marked circadian variation in the binding of [3H]spiperone was reported for the rat 
forebrain (Bruinink et al., 1983). The reason for this discrepancy is not known.
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The failure to observe a significant difference in the binding of [°H]5-HT or 
[3H]ketanserin to the 5-HT1 and the 5-HT2 binding sites respectively, may be a reflection 
of the timing of the sampling, or the method of membrane preparation, or the use of the 
whole cortex rather than specific cortical regions. In addition, it may be that the regions 
were arrhythmic at the time of the year that the binding was performed, or that rhythms 
were cancelled by the "pooling” of the brain regions from several animals. Also, rhythms 
may not be prevalent in different strains of the some species (Quay, 1968). Rhythms can 
also be obscured if their amplitude of cyclic oscillation is too low. The amplitude of binding 
rhythms is also influenced by the age of the animal under investigation (Jenni-Eiermann et 
al., 1985). Furthermore, radio-ligand binding only detects the total number of binding 
sites and does not distinguish between functional and non-functional receptors, hence the 
findings of this technique may be useful only as a general indicator of receptor change. The 
majority of radio-ligand binding studies have investigated the changes in receptor number 
because changes in this parameter are more likely to result from the exposure or covering 
of available binding sites, and also because receptor synthesis is a slow process. Affinity 
changes have not been investigated thoroughly and it is possible that a change in affinity 
could go undetected and a wrong conclusion be drawn.
Several behaviours attributed to 5-HT receptor stimulation have also been 
investigated for a circadian component. The head-twitch response (5-HT2 receptor-
mediated) is reported to display a marked circadian variation with higher scores at mid­
light, whilst the 5-HT behavioural syndrome (5-HT^ receptor-mediated), or its individual 
components, were devoid of a circadian component (Moser and Redfern, 1985). In 
addition, other behavioural effects of 5-HT.j receptor stimulation, such as the 8-OH-DPAT- 
induced hypothermia and the RU 24969-induced hyperlocomotion, are free of any circadian 
variation (Moser, 1986).
The circadian variation observed in the head-twitch response is unlikely to be 
secondary to a pharmacokinetic variation. This variation may be the consequence of a 
change in the number of 5-HT2 receptors or their sensitivity. The circadian variation in 
the behavioural response to 5-HT2 receptor stimulation parallels the daily variation in 
neuronal 5-HT concentrations. However, the observed variation in neuronal 5-HT
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concentrations is related inversely to the release of 5-HT, which is greater during the dark 
phase. Therefore, when 5-HT release, and 5-HT neuronal firing, are highest, the 5 -HT2 
receptors mediating the head-twitch response are less sensitive to stimulation and vice 
versa. This arrangement would mean that these post-synaptically located 5-HT 
receptors although less sensitive, are capable of detecting changes in presynaptic neuronal 
activity. If however, these post-synaptic receptors were most sensitive at the same time 
as 5-HT release was greatest, then these receptors would be maximally stimulated during 
the dark phase and unresponsive during the light phase. In this condition, any changes in 
presynaptic activity are likely to go undetected.
Moser (1986) proposed that presynaptic neuronal activity drives the changes seen 
in 5 -HT2  receptor activity, causing the activity of these receptors to "up-regulate" and 
"down-regulate" when presynaptic activity is lowest and highest respectively. Support 
for this theory comes from ontogenetical studies, where the rhythm in 5-HT concentrations 
only develops fully 35 days after birth (Okada, 1971), whereas the rhythm in 5-HT2 
binding sites is established not at 30 days but at 90 days (Bruinink et al., 1983). The 
time course of development of a rhythm in the release of 5-HT has not been investigated, 
but its findings would be of great interest.
In a recent study, the administration of phenelzine followed by either citalopram or 
paroxetine was associated with an unaltered Kp but a reduction in the number of 5 -HT2 
binding sites in the cerebral cortex, and also a reduction in the number of wet-dog shakes, 
three hours after drug administration (Koshikawa et al., 1985). These drugs probably 
caused an increase in the synaptic concentration of 5-HT, leading to the increased 
activation of the 5 -HT2  receptor, and its consequent down-regulation. However, these 
authors failed to mention whether this study was performed during the light or the dark 
phase. Rapid changes in either the functional activity or the number of 5-HT.j binding sites 
have not been investigated.
The head-twitch response is considered to be mediated via the activation of 5-HT2 
receptors located in the brainstem (Bedard and Pycock, 1977). A correlation of the 
number and affinity of the 5-HT2 binding sites in this region, over 24 hours, would be of 
fundamental importance; however, the majority of binding studies have looked for changes
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in the cerebral cortex, where the greatest density of 5 -HT2  binding sites are found (Leysen 
et al., 1982). Lauro et al. (1986) are the only authors to have investigated the 
circadian variation in the binding to 5 -HT2  sites in the brainstem. They reported the 
number of 5 -HT2  binding sites to be unchanged over 24 hours, but these authors made no 
attempt to determine the affinity of binding over 24 hours.
An alternative hypothesis is that the circadian rhythm in the head-twitch response 
is not due to changes at the level of the 5 -HT2  receptor, but the consequence of a change(s) 
further down-stream of this receptor (i.e. a variation in the secondary messenger system 
or in the neuronal pathway/s linking this receptor to the initiation of the head-twitch 
response).
With reference to the 5-HT behavioural syndrome, neither the total syndrome or 
its individual components display a circadian variation, indeed, the behaviours attributed 
to 5-HTi receptor stimulation would be more likely to display a variation in response 
because of the greater affinity of 5-HT for the 5-HT.j binding site, and also because of the 
circadian variation in the release of 5-HT. However, the circadian rhythm in the release 
of 5-HT in the brainstem has not been investigated. The lack of a rhythm in 5-HTj 
receptor mediated behaviours is probably the result of a damping effect caused by 
compensatory changes.
Clearly, more fundamental research needs to be performed in order to determine 
the cause and the consequence of the circadian variation in the head-twitch response and 
also the apparent lack of variation of the behaviours attributed to 5-HT.j receptor 
stimulation.
4 SOMADENDRITIC 5-HT AUTORECEPTOR SENSITIVITY
ESTIMATION
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4.1 H IG -H  P E R F O R M A N C E  L IQ U ID  C H R O M A T O G R A P H Y  W IT H
ELECTROCHEMICAL DETECTION
The indole ring of L-tryptophan and its metabolic derivatives, is readily prone to 
oxidation with the subsequent release of electrons. The electrons released can be 
measured as an electric current, the size of which is proportional to the amount of 
compound oxidized. The basis of electrochemical detection is that oxidation is made to take 
place at the surface of a carbon (graphite) electrode which acts as the oxidizing agent.
The presence of certain oxidizable groups (e.g. -OH or -NH) determine the 
potential at which oxidation takes place. 5-HTP, 5-HT and 5-HIAA, all of which are 
hydroxylated on the indole ring, oxidize at lower potentials (about + 0.50 V), while a higher 
potential (about + 0.90 V) is required to release the electron from the nitrogen in the indole 
ring of L-tryptophan.
The majority of HPLC columns used with electrochemical detectors are of the 
reverse phase type. Reverse phase systems consist of a non-polar stationary phase and a 
polar mobile phase. The stationary phase is usually composed of fine silica particles (5-10 
pM diameter), on to which are bonded hydrocarbon alkyl chains, commonly octadecylsilyl 
(ODS, C- 18 columns). The mobile phase is usually a mixture of buffer and methanol. 
Under such a system, polar compounds are poorly retained on the column and are 
consequently eluted first. An ion-pairing agent is sometimes added to the mobile phase. 
This is usually a bulky group which ion pairs with a compound of the opposite charge and 
increases its hydrophobic character, thus retarding its rate of passage down the column 
and aiding separation. The ion-pairing agent used in this study was sodium octane 
sulphonic acid.
4.2 METHQPS
4.2.1 The HPLC system
The column (length 15cm and diameter 6 mm) was packed with Hypersil ODS (5 pm 
particle size, Shandon) in the department. It was connected to the rest of the 
chromatographic system which consisted of the following : LKB (bromma) 2150 HPLC pump 
; amperometric electrochemical detector with working glassy carbon and reference
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Ag/AgCI electrodes (Bioanalytical Systems Inc., model LC-4A) ; Rheodyne Injection valve 
(model 7125) fitted with a 100pl injection loop (Fig. 35). Samples were injected into the 
loop using a 100jil Hamilton HPLC syringe (model 710) and peaks were recorded on a JJ 
instruments chart recorder (model CR 650 S). The column and the injection loop were 
immersed in a water bath maintained at a temperature of 29-31 °C by a water circulator 
pump (Grant, model SU 5) and monitored using a temperature probe (RS, 612-849).
Fresh mobile phase was made up each day using doubly "polished", deionized water 
prepared using Milli Q water systems (Millipore Corporation). The mobile phase contained 
: 0.07 M sodium dihydrogen phosphate (NaH2  PO4 . 2H20), 0.3 mM sodium octane sulphonic 
acid, 0.1 mM EDTA and 8% methanol. The p.H. was adjusted to 2.75 with 6  M perchloric 
acid. It was vacuum-filtered through 0.2 pm membrane filters (Whatman) and degassed by 
bubbling helium gas through for 20 min. It was then sonicated for 5 min to remove any 
bubbles of helium. Mobile phase was pumped at a flow rate of 1 ml/min, and a pressure of 
130-150 bar. The sensitivity of the detector was set at 5 nA for full scale deflection. 
Fresh mobile phase was pumped through the detector each morning for 30 min and then it 
was left pumping at a reduced flow rate during the day. This procedure resulted in a stable 
baseline being obtained in the evening. Because of electrical interference a stable baseline 
was unattainable during the daytime, even after considerable damping had been employed. 
As a result all samples were injected at night when the baseline was markedly better.
The electrode potential, methanol concentration and p.H. were adjusted to ensure 
that the 5-HTP peak was sharp and eluted well clear of any interfering peaks. This is 
described in the method that follows.
4.2.2 The routine maintenance of the HPLC
Every month after disconnecting the column, the HPLC pump was cleaned by 
pumping warm 30% decomatic detergent (Decon Laboratories) at 5 ml/min for 30 min, 
followed by several combinations of water/methanol. At the end of each working week, 
the top of the column was inspected for the presence of a dark deposit. This deposit was 
scraped off and replaced with a freshly prepared slurry of hypersil ODS in methanol. The
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Figure 35. The High Performance Liquid Chrom atography System
The HPLC system consisted of: (1) LKB (bromma) HPLC pump; (2) a reverse phase HPLC 
column located in a insulated water bath; (3) water circulator; (4) temperature probe; (5) 
rheodyne injection valve fitted with a 100^1  injection loop; (6 ) electrochemical detector 
with working glassy carbon and reference Ag/AgCI electrodes; (7) JJ chart recorder.
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pre-column filter was also replaced at this time. Occasionally, the surface of the glassy 
carbon electrode was cleaned using alumina polish on a polishing pad. The potential of the 
reference electrode was checked prior to the experiment. Any air bubbles trapped in its 
housing were also dislodged.
This routine maintenance of the HPLC system ensured its smooth and relative 
trouble-free running.
4.2.3 Effect of varying electrode potential on the peak height of 5-HTP
As the electrode potential is increased, then potentially more compounds will be 
detected, therefore the lowest potential at which the compound of interest is detectable is 
usually preferred. Since 5-HTP is a hydroxylated indoleamine, it would be expected to 
oxidize at a potential of + 0.50 V. In order to find the optimum potential for its detection, 
the peak produced by a standard concentration of 500 pg/100 pi loop, was investigated 
against varying electrode potentials (Table 18).
Table 18.
Effect of varying oxidation potential on the peak height of the 5-HTP peak 
potential (V) 5-HTP peak Height (mm) baseline noise (mm)
+ 0.50 13 3
+ 0.60 49 1
+ 0.70 50 2
+ 0.80 46 4
On increasing the potential from + 0.50 V to + 0.60 V there was a large increase in 
the peak height. However, any further increases in the electrode potential did not result in 
an accompanying increase in the peak height In general, as the electrode potential is 
raised, baseline noise is also seen to grow.
It is evident that an electrode potential of + 0.60 V offers not only optimum peak 
height but also a low background noise. Consequently this electrode potential was used 
throughout the rest of this study.
4.2.4 Effect of methanol concentration. p.H. and column temperature on 
the_retentlon time of the 5-HTP peak
Methanol is a commonly used solvent in HPLC systems because it does not interfere 
with the common methods of detection nor does it react chemically with the type of 
compounds under investigation. The inclusion of methanol in the mobile phase has the 
effect of reducing the retention times of all compounds irrespective of their molecular 
state. It is able to achieve this because of its non-polar nature. As a result it exhibits a 
very high affinity for the stationary phase, while that of polar compounds is reduced 
causing them to elute earlier.
Adjustment of the p.H. has the effect of determining the extent to which the 
compound of interest is ionized/unionized. The ionized/unionized nature of the compound of 
interest primarily determines whether ion-pairing takes place and this in turn determines 
its affinity for the stationary phase. However, all columns have a safe working p.H. range 
depending on their composition and harm may be caused to the column if this range is 
exceeded.
Manipulation of the column temperature is often used to decrease the retention time 
of compounds as well as the operating pressure of the pump. Using a fixed column 
temperature has the advantage of cutting down on laboratory temperature fluctuations 
(e.g. day/night), which would otherwise cause the retention time to be changed. It can 
also act as an aid to resolution. The results are shown in Tables 19 and 20.
Unfortunately, the initial compositions of mobile phase were investigated with little 
control over column temperature. However, when it was realized that samples would have 
to be run at night as a result of excessive electrical interference during the day, column 
temperature was taken into consideration (Table 20). The general findings of this 
preliminary work are unlikely to be affected.
Increasing methanol concentration, p.H. and column temperature all had the 
predicted effect of reducing the retention time. Since these three factors can alter the 
retention time, their manipulation to different extent allows for the peak of interest to be 
eluted well clear of any interfering peaks.
Various concentrations of mobile phase were tried with preliminary brain samples.
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Table 19.
Effect of varying methanol concentration and p.H. on the retention
time for the 5-HTP peak
methanol conc. (%) p.H. retention time of 5-HTP
of buffer (min/sec)










In these experiments the column was maintained at room temperature.
Table 20.
Effect of varying methanol concentration. p.H. and column temperature 
on the retention time for the 5-HTP peak 
methanol Conc. (%) pH. Temp (°C) retention time of 5-HTP
of buffer (min / sec)
10 3.0 37 8.00
1 0 2.5 30 19.20
1 0 2.5 37 13.20
1 0 2.75 25 19.00
1 0 2.75 30 14.40
1 0 2.75 37 10.40
8 2.75 30 19.15
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A mobile phase containing 8% methanol at a p.H. of 2.75 was finally chosen, with the 
column being maintained at 30°C by means of a water bath. This combination ensured that 
the 5-HTP peak was sharp and eluted well clear of any interfering peaks.
4.2.5 Estimation o f the linearity o f peak height to 5-HTP and 5-HIAA 
concen tra tions
The relationship of peak height to a variety of standard concentrations of 5-HTP 
and 5-HIAA was investigated Fig. 36 and 37. A range of standard concentrations was 
chosen which would cover that expected from treated brain samples.
4.2.6 Effect o f 8 -OH-DPAT on 5-HTP synthesis In the cerebral cortex 
examined at mtd-Haht and at mid-dark
Male Wistar rats (University of Bath strain), were housed in specially constructed 
wooden cabinets, under controlled conditions for at least 2  weeks prior to use (see section 
2.1.1). Some animals were phase shifted to enable all experimental procedures to be 
carried out during normal working hours. When used in experiments the animals weighed 
between 190-320g.
8-hydroxy-2-(di-n-propylamino)tetralin (8 -OH-DPAT) was dissolved in 0.9% 
saline, but required gentle warming and stirring to achieve dissolution. m- 
hydroxybenzylhydrazine dihydrochloride (NSD 1015), was dissolved in saline, the p.H. 
being adjusted to 7 with NaOH.
Rats were injected with 8 -OH-DPAT (0.01-0.30 mg/kg) or saline subcutaneously 
and after 30 min again with NSD 1015 (100 mg/kg i.p.). After another 30 min the rats 
were killed by cervical dislocation. See experimental protocol diagram below :
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Figure 36.
Effect of increasing concentrations of 5-HTP concentrations









750 1000 12500 250 500
5-HTP concentration pg/100 pi loop
A range of standard concentrations of 5-HTP were prepared. A 100 pi volume of 
these solutions was injected into the column (5-HTP tp=19.15 min/sec), and the 
peak height measured. The graphs represent the means of two separate experiments.
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F ig ure  37.
Effect of increasing concentrations of 5-HIAA concentrations
pn the pegk height
200 -






125 250 375 500 625 750 875 10000
5-H IAA concentration pg/100 pi loop
A range of standard concentrations of 5-HIAA were prepared. A 100 pi volume of 
these solutions was injected into the column (5-HIAA tp=23.20 min/sec), and the 
peak height measured. The graphs represent the means of two separate experiments.
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Figure 38.
Procedure for somadendrltic 5-HT autoreceptor activity measurement
8 -OH-DPAT NSD 1015 Animal
or saline killed
30 min 30 min
Following decapitation, the brains were rapidly taken out and the cerebral cortex 
dissected on an ice-cooled petri dish and assayed for their content of 5-HTP.
In addition, a group of rats which received no pharmacological treatment was used 
to establish basal concentrations of 5-HTP, at mid-light and at mid-dark.
4.2.7 Preparation of samples
All animals were first killed by cervical dislocation in either the light or the dark 
phase as appropriate and were then subsequently decapitated. Their brains were then 
rapidly removed and placed on an ice-cooled petri dish. The cerebral cortex was then 
dissected and weighed. It was homogenized using a teflon mortar and pestle (Tri-R 
instruments), at a concentration of 10% w/v using 0.1 M perchloric acid (p.H. 1.47, at 
4°C). This 0.1 M solution of perchloric acid was prepared using Milli Q water. The 
homogenate was then transferred to centrifuge tubes (Ultra-clear, Beckmann), shaken for 
1 min using a whirlimixer (Fisons) and centrifuged at 4°C and 15,000 x g for 15 min using 
a Beckmann ultracentrifuge (model L 8 -M and a Ti 70.1 rotor). The clear supernatant was 
filtered by injecting through a 0.45 pm pore size filters (Aero LC 13, Gelman sciences). It 
was then immediately frozen at -19°C. Samples were kept frozen for no longer than 16 
days. The results obtained with aged aqueous standards suggested that 5-HTP underwent 
little degradation over several weeks, if stored at 4°C. Prior to injection each sample 
was defrosted to room temperature and whirlimixed. Three injections of 100pl each were 
made using a Hamilton syringe to first clean the loop, the fourth 100pl injection was then 
allowed to warm up in the loop prior to injection onto the column.
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An aqueous standard was injected after every third brain sample to check that the 
efficiency of the column had not changed. Sometimes, the standard was injected twice 
consecutively, this was only done if the peak produced by the first injection was ± 5% 
different from the pre-sampie value.
4.2.8 E fficiency of the column
An estimate of percentage recovery for 5-HTP and 5-HIAA was calculated by first 
injecting an aqueous standard then an actual brain sample which contained 5-HTP or 5- 
HIAA, and finally a brain sample spiked with aqueous standard (see Table 21).
Table 21.
Efficiency of the column for detecting 5-HTP and 5-HIAA 
Peak Height ( mm ) 5-HTP (n=2) 5-HIAA (n=2 )
50% of standard 78±1.5 48±1.0
50% of brain sample 47±0 11 ±0.5
(50% of brain sample + 124±2.0 49±2.0
50% of standard)  ;__________  '
Recovery % 99.2 83
The results are expressed meansts.e.m. of two separate experiments. Reproducibility 
was very good.
Since the percentage recovery for 5-HTP is approaching 100%, no further 
correction to its values was necessary, while those of 5-HIAA were adjusted accordingly.
The peaks of interest were susceptible to displacement by varying the mobile phase 
composition. Untreated brain samples produced little or no peaks at the retention time of 
5-HTP. The peaks produced by a spiked brain sample were superimposed on and additive to 
those of treated brain samples. Furthermore, the injection of an unspiked sample of Milli Q 
water failed to produce any peaks, confirming that no impurity was present in the water. 
These findings corroborate and add credence to the idea that the peaks being measured truly 
belonged to 5-HTP and 5-HIAA.
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4.2.9 Estimation of Protein content
In order to obtain an estimation of the protein content of cerebral cortex tissue, the 
Lowry et al. (1951), protein assay was employed, using bovine serum albumin as standard 
(Table 22).
Table 22.
Estimation of protein content of rat cerebral cortex 
Protein Conc. Absorbance 
20 pg 0.097 (Unknown-1 0.589
60 pg 0.324 (Unknown-2  0.598
100 pg 0.565 (Unknown-3 0.598
120 pg 0.658
Unknown 1-3 contain 0.84 mg cerebral cortex tissue *  109.5 pg protein, or 1 mg 
of cerebral cortex contains 0.13 mg protein.
The mean weight of cerebral cortex tissue obtained from each rat was 382 mg. 
This means that the mean protein obtained from each rat was approximately 50 mg.
4.2.10 Calculations and Statistics
The effect of 8 -OH-DPAT on 5-HTP concentrations is expressed as percentage 
formation, with respect to control values. They were calculated assuming a maximum 
effect at 300 pg/kg of 8 -OH-DPAT. Basal 5-HTP values being first deducted from mid­
dark control and drug treated values.
Each set of data was first analysed by means of one-way analysis of variance 
followed by Dunnett's t-test to assess the differences in the means of the treatments as 
compared to control. Student's t-test was then applied to compare for statistical 
differences between mid-light and mid-dark at each dose of 8 -OH-DPAT.
4.2.11 Drugs
m-hydroxybenzylhydrazine dihydrochloride (Sigma, St. Louis, MO, USA), 8 - 
hydroxy-2-(di-n-propylamino) tetralin (Semat Technical Ltd., St. Albans, England), 5 -
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= 108.5 pg} 
-  110  pg}
*  110 pg}
hydroxyindole acetic acid (Sigma), 5-hydroxytryptophan (Sigma).
4.3 RESULTS
The sensitivity for detecting 5-HTP was set at a peak/noise ratio of 2 (i.e. a peak 
whose height is double the baseline noise), in the present case this was 35 pg/100 p.l 
sample (i.e.3.5 ng/g 5-HTP). Experiments to determine endogenous, basal concentrations 
of 5-HTP (i.e. in untreated rats) revealed that very little was actually present. Indeed, 
concentrations observed at mid-light were below the level of detection. However, 
concentrations at mid-dark were slightly higher, approximating to a mean of about 50 
pg/100 pi sample (i.e. 5.0 ng/g 5-HTP). This finding is rather surprising since 5-HTP is 
considered to be decarboxylated almost immediately after synthesis. These results 
suggest that the difference in 5-HTP concentrations may be the consequence of a variation 
in tryptophan hydroxylase or 5-HTP decarboxylase activity.
Earlier studies carried out in our laboratory (Sinei, 1987) to monitor 5-HTP 
concentrations, 60 min after 5-HTP decarboxylase inhibition, have shown the rate of 
formation of 5-HTP to depend on the dose of NSD 1015 used. This rate of formation of 5- 
HTP was linear up to a dose of 50 mg/kg; higher doses of 75 and 100 mg/kg did not result 
in any further increases in 5-HTP. A dose of 100 mg/kg was therefore considered 
suitable to achieve adequate decarboxylase inhibition. Using this dose it was shown that 
the accumulation of 5-HTP was linear with time for about 60 min, after which it was 
observed to fall. This fall was attributed to either the recovery of the enzyme or the 
redistribution of the accumulated 5-HTP away from the brain. The work of Hjorth et ai. 
(1982) using similar doses has shown that the optimum time to observe 5-HTP 
concentrations is 60 min after 8 -OH-DPAT or 30 min after NSD 1015, as 5-HTP 
concentrations begin to recover after that time.
Fig. 39, represents a typical chromatogram obtained with samples from rats given 
NSD 1015, 30 minutes before death. Each sample took approximately 70 min to elute and 
for the baseline to return to normal. Although, 5-HTP, 5-HIAA and 5-HT were all 
detectable and well resolved from each other, only 5-HTP and 5-HIAA were quantified, 
because the 5-HT peaks were regularly off scale.
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F igure 39. M easu rem e n t o f 5 -H T P . 5-H IA A  and 5-H T  c o n c e n tra tio n s  
using HPLC
This is a typical chromatogram of the rat cortical extracts following a dose of NSD 1015 
(100 mg/kg i.p.), 30 minutes before death. The detector potential was set at +0.6 V and 
sensitivity 0.5 nA f.s.d. The mobile phase and other conditions are described more fully in 
section 4.2.1. Peak 1 (5-HTP) tR =19.15 min/sec, Peak 2 (5-HIAA) tR =21.40and Peak 
3 (5-HT) tR =27.10.
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The administration of NSD 1015 (100 mg/kg i.p.), 30 min prior to death caused the 
accumulation of 5-HTP concentrations in the cerebral cortex of the rat. The amount of 5- 
HTP accumulated at mid-dark, following NSD 1015, was corrected by taking into account 
the higher basal concentrations of 5-HTP at this time point. The accumulation of 5-HTP at 
mid-light and mid-dark was very similar.
8-OH-DPAT (10-300 pg/kg s.c.) when administered 30 min prior to NSD 1015 
caused a dose-related inhibition of 5-HTP synthesis at both mid-light and at mid-dark (Fig. 
40 and Fig. 41). The maximum inhibition achieved was approximately 53%; this value is 
very similar to the 52% reported by Hjorth et al. (1982). Analysis of variance (ANOVA) 
indicated a significant effect of 8-OH-DPAT on 5-HTP concentrations at mid-light (F=64.9 
for 4/17 DF; p<0.001) and at mid-dark (F=30.9 for 4/25 DF; p<0.001). This test was 
followed by Dunnett's t-test to identify the 8-OH-DPAT-treated groups that were 
significantly different from control. The inhibitory effect of 8-OH-DPAT was highly 
significant at all doses above 10 pg/kg (p<0.01) at mid-light and at mid-dark. Student's t- 
test was then used for comparison of mid-light and mid-dark values. No statistical 
differences were seen when each dose of 8-OH-DPAT was compared at the two time points.
Endogenous concentrations of 5-HIAA were significantly higher at mid-light as 
compared to mid-dark {mid-light=192.4±19.2 ng/g tissue, n=3 ; mid-dark=97.0±10.3, n=5 
(mean±s.e.m.)}. This difference may be due to the inability of synaptic vesicles to store 
large amounts of 5-HT, following synthesis, as tissue concentrations of 5-HT are highest 
during the light phase. As a result of which the newly-synthesized 5-HT spills out into the 
cytoplasm of terminals where it is susceptible to attack by monoamine oxidase.
NSD 1015 produced a significant reduction in the basal concentrations of 5-HIAA, 
30 minutes after injection, both at mid-light and at mid-dark. Moreover, 8-OH-DPAT 
produced a similar effect which was additive to that produced by NSD 1015. This effect of 
8-OH-DPAT was statistically significant when tested by ANOVA at mid-light (F=6.8 for 
4/17 DF; p<0.01) and at mid-dark (F=12.5 for 4/25 DF; p<0.01). Further analysis using 
Dunnett's t-test suggested that while only the highest dose of 8-OH-DPAT produced a 
significant lowering of 5-HIAA concentrations at mid-light (Fig. 42), whereas all doses 
above 10 pg/kg caused a significant lowering of 5-HIAA concentrations, at mid-dark
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Figure 40.









0 10 30 100 300
8-OH-DPAT pg/kg s.c.
Effect of 8-OH-DPAT on the formation of 5-HTP in the cerebral cortex of the rat, at 
mid-light. 8-OH-DPAT (0-300 pg/kg s.c.) and NSD 1015 (100 mg/kg i.p.) 
were given 60 and 30 min, respectively, before death. The results are expressed as 
percentage inhibition of control value. The endogenous basal concentration of 5-HTP 
was below the level of detection (i.e. less than 3.5 ng/g 5-HTP). The mean ±  s.e.m. 
(n=4), control value was 104.5 ± 4.1 ng/g 5-HTP. ANOVA was used to compare 
control and increasing doses of 8-O H-DPAT, followed by Dunnett's t-test
( * * p < 0 . 0 1 ) .
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Figure 41.
5 - H T P  
formation, 
% of control
0 10 30 100 300
8-OH-DPAT p.g/kg s.c.
Effect of 8-OH-DPAT on the formation of 5-HTP in the cerebral cortex of the rat, at 
mid-dark. 8-O H-DPAT (0-300 pg/kg s.c.) and NSD 1015 (100 mg/kg i.p.) 
were given 60 and 30 min, respectively, before death. The results are expressed as 
percentage inhibition of control value. The endogenous basal concentration of 5-HTP 
was 5 ± 0.5 ng/g 5-HTP. The mean ±  s.e.m. (n=6), control value was 103.5 ± 3.7 
ng/g 5-HTP. ANOVA was used to compare control and increasing doses of 8-OH- 
DPAT, followed by Dunnett's t-test (**p<0 .01).
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(Fig. 43). No statistical differences were observed when comparisons were made between 
each doses of 8-OH-DPAT, at the two time points.
The results from this section show that 8-OH-DPAT reduces the rate of 5-HT 
synthesis (as measured by the inhibition of 5-HTP formation), to an extent which is the 
same at mid-light and mid-dark. NSD 1015 and 8-OH-DPAT both caused a significant
reduction in 5-HIAA concentrations; this effect is probably secondary to their effect on 5- 
HT synthesis.
Figure 42.
[ 5 -H IA A ] ,  
% control
o 10 30 100 300
8-OH-DPAT pg/kg s.c.
Effect of 8-OH-DPAT on the formation of 5-HIAA in the cerebral cortex of the rat, 
at mid-light. 8-OH-DPAT (0-300 pg/kg s.c.) and NSD 1015 (100 mg/kg i.p.) 
were given 60 and 30 min, respectively, before death. The results are expressed as 
percentage inhibition of control value. The mean ±  s.e.m. (n=4), control value was
49.7 ±  1.8 ng/g 5-HIAA. ANOVA was used to compare control and increasing doses of 
8-OH-DPAT, followed by Dunnett’s t-test (*p<0.05).
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Figure 43.









0 10 30 100 300
8-OH-DPAT pg/kg s.c.
Effect of 8-OH-DPAT on the formation of 5 -H IA A  in the cerebral cortex of the rat, 
at m i d - d a r k .  8-OH-DPAT (0-300 pg/kg s.c.) and NSD 1015 (100 mg/kg i.p.) 
were given 60 and 30 min, respectively, before death. The results are expressed as 
percentage inhibition of control value. The mean ±  s.e.m. (n=6), control value was
51.8 ±  2.1 ng/g 5-HIAA. ANOVA was used to compare control and increasing doses of 
8-OH-DPAT, followed by Dunnett's t-test (*p<0 .05 , **p < 0 .01 ).
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4.4 DISCUSSION
Circadian variations are reported in 5-HT concentrations in the brain stem (Semba 
et al., 1984 ; Agren et al., 1986) and terminal-containing regions (Quay, 1968 ; Hery 
eta/., 1972 ; Semba et al., 1984), with higher concentrations being observed during the 
light phase of the light : dark cycle. In contrast, extracellular concentrations of 5-HT, 
when measured by brain microdialysis, are higher during the dark period, suggesting that 
the release of 5-HT into the synaptic cleft is greater at this time (Martin and Marsden, 
1985 ; Kalen et al., 1988,1989). In support, electrophysiological studies have shown 
that the firing rate of 5-HT neurons in freely moving cats is increased during arousal and 
decreased during drowsiness and sleep (McGinty and Harper, 1976 ; Trulson and Jacobs, 
1979). These studies are consistent with the idea that the greater release of 5-HT during 
the dark phase, may result from the higher firing rate of 5-HT neurones associated with an 
increase in the arousal or vigilance of the animals (Kalen et al., 1989).
The firing rate of these neurones is controlled by many factors, including the 
activity of the somadendritic 5-HT autoreceptor, which when stimulated by 5-HT or 5- 
HT-j ^-selective agonists, inhibits 5-HT neuronal firing (Sprouse and Aghajanian, 
1986,1987), and, as a consequence, the synthesis (Hjorth et al., 1982) and the release 
(Garratt et al., 1988) of 5-HT. This somadendritic 5-HT autoreceptor is believed to be 
of the 5-HTja subtype (see section 1.4.9), although a pharmacological characterization can 
not be performed due to the lack of a suitable 5 -H T ^  antagonist. However, a recent 
report suggests that a fluoro analogue of 8-OH-DPAT may possess 5-HT-ja antagonist 
activity, and this compound may prove useful in the characterization of this receptor 
(Hillver et al., 1990).
The ability of the somadendritic 5-HT autoreceptor to control the firing rate of 5- 
HT neurones suggests that a variation in its sensitivity, or activity, may account for the 
observed circadian variation in synthesis and release of 5-HT. The aim of this study was 
to investigate the sensitivity of this autoreceptor at mid-light and at mid-dark, 
corresponding to time points when the firing rate of 5-HT neurones would be expected to be 
lowest and highest respectively.
The sensitivity of the somadendritic 5-HT autoreceptor was measured by the
ability of 8-OH-DPAT (which at low doses preferentially activates this receptor) to 
attenuate 5-HT synthesis (as measured by the accumulation of 5-HTP, after 5-HTP- 
decarboxylase inhibition) in the cerebral cortex, resulting from its inhibitory effect on 5- 
HT neuronal firing (Sprouse and Aghajanian, 1986, 1987 ; Blier and De Montigny, 1987).
The endogenous basal concentration of 5-HTP in the cerebral cortex was higher at 
mid-dark (about 50 pg/1Q0p.l) as compared to mid-light, when it was below the level of 
detection (i.e. less than 35 pg/100pl). This variation in 5-HTP concentrations is unlikely 
to result from a variation in 5-HTP-decarboxylase activity, since this enzyme is normally 
unsaturated with its substrate (Hillier and Redfern, 1976a). However, these authors 
observed a variation in 5-HTP-decarboxylase activity when using crude brain 
homogenates, but were unable to observe any differences after purification of the enzyme, 
suggesting that the variation in the activity of the enzyme was the result of other factors, 
such as substrate competition or co-factor availability. The greater 5-HTP concentrations 
observed during mid-dark may be caused by the higher rate of 5-HT synthesis, reported at 
this time point (Fernstrom and Wurtman, 1971 ; Sinei, 1987). It is also possible that this 
phenomena could be caused by the enzyme, 5-HTP-decarboxylase approaching saturation 
with its substrate or from co-factor limitation.
The administration of NSD 1015 (5-HTP decarboxylase inhibitor) was associated 
with an accumulation of 5-HTP in the cerebral cortex; the concentrations observed during 
the light and the dark phase were the same. Increasing doses of 8-OH-DPAT produced a 
dose-dependent inhibition of the accumulation of 5-HTP. The size of the inhibition was 
essentially identical at each dose, when its effect at mid-light was compared with that at 
mid-dark. In addition, 8-OH-DPAT caused a dose-dependent reduction of 5-HIAA 
concentrations, the magnitude of which was similar at each dose, during mid-light and mid­
dark. This reduction in 5-HIAA concentrations is likely to reflect either the decreased 
metabolism, resulting from a decrease in the release of 5-HT (Hjorth et al., 1982), or the 
decreased intraneuronal metabolism of 5-HT. These results demonstrate that the 
sensitivity of the somadendritic 5-HT autoreceptor to 8-OH-DPAT is unchanged when 
measured at mid-light or at mid-dark. These results also suggest that the diurnal 
variation in the 5-HT neuronal firing rate is not derived from an innate rhythm in the 
activity of this receptor, although the autoreceptor sensitivity would have to be
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determined at a greater number of time points, during the light : dark cycle, to be 
absolutely certain. The firing rate of 5-HT neurones is likely to be under the control of 
other neuronal inputs, such as the locus coeruleus (Baraban and Aghajanian, 1980) or the 
SCN (Bons et al., 1983).
The firing rate of 5-HT neurones and the release of 5-HT are greater during the 
dark phase, when the animals are most active (McGinty and Harper, 1976 ; Trulson and 
Jacobs, 1979 ; Kalen et al., 1989). In addition, 5-HT synthesis, as gauged by the 
activity of the enzyme tryptophan hydroxylase, is also highest during the dark phase 
(Redfern and Sinei, 1985). However, the rate of 5-HT synthesis in terminal-containing 
regions can be modulated by the 5-HT neuronal firing rate as well as by local mechanisms 
(Hjorth and Magnusson, 1988). Evidence for a role of local mechanisms has been provided 
by experiments where the rate of 5-HT synthesis, following unilateral axotomy, was not 
significantly different on the transected and the intact sides (Hjorth and Magnusson, 1988). 
These authors proposed two equally plausible explanations to account for their results: i) 
Transection impairs the propagation of nerve impulses in ascending 5-HT neurones, as well 
as other neurones, some of which may impinge on and interfere with the activity in 5-HT 
terminals. A disinhibition of these non-serotoninergic influences on terminal 5-HT 
synthesis and release may lead to an increase in the rate of 5-HT synthesis, ii) The 
decrease in 5-HT release following axonal transection would result in an attenuation of the 
(autoreceptor- and/or postsynaptic 5-HT receptor-mediated) negative feedback mechanism 
of terminal 5-HT synthesis. In turn, this might counterbalance the expected reduction in 
synthesis, following the inhibition of neuronal firing. In support of this hypothesis, Sharp 
et al. (1988) reported a small amount of 5-HT release to be still evident, following the 
administration of 8-OH-DPAT, at a dose which would be expected to produce its maximal 
effect. Furthermore, in the case of dopamine neurones, the reduced activation of the 
terminal dopamine autoreceptor, caused by axonal transection, enhances the activity of the 
enzyme tyrosine hydroxylase (an analogous situation might exist for 5-HT neurones) 
(Walters and Roth, 1976). Moreover, the highest dose of 8-OH-DPAT (300 pg/kg s.c.)
caused a reduction in the rate of 5-HTP synthesis on the transected side; this effect may 
stem from a loss of selectivity and probably reflects its action on the terminal 5-HT 
autoreceptor (Hjorth and Magnusson, 1988). In support of this explanation, an in vitro
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study has reported 8-OH-DPAT to be capable of activating the terminal 5-HT autoreceptor 
(Hamon et al., 1984).
Apart from local mechanisms, the rate of 5-HT synthesis can be modulated by the 
5-HT neuronal firing rate, which requires an intact 5-HT neurone (Hjorth and Magnusson, 
1988). However, doses of 8-OH-DPAT which totally inhibit 5-HT neuronal firing, as 
determined by electrophysiological techniques (Neale et al., 1987), produce a maximum 
inhibition of only about 53% of 5-HTP synthesis, in the cerebral cortex, and a number of 
other brain regions (Hjorth et al., 1982). The weaker effect of 8-OH-DPAT on 5-HT 
synthesis, as compared to its potent effect on the firing rate of 5-HT neurones, suggests 
that about 47% of 5-HT synthesis takes place independently of the firing rate. This firing- 
insensitive component of 5-HT synthesis is probably controlled by local mechanisms, 
similar to those responsible for the enhancement of 5-HT synthesis following neuronal 
transection. The results presented here confirm that a proportion of 5-HT synthesis can 
take place following the administration of 8-OH-DPAT, at doses which totally inhibit the 
firing rate of 5-HT neurones. This rate of 5-HT synthesis was the same, during mid-light 
and mid-dark. It is likely therefore that the firing rate of 5-HT neurones partially 
modulates the synthesis of 5-HT, and this component may be additive on the synthesis that 
takes place when the 5-HT neuronal firing is inhibited.
The firing rate of 5-HT neurones is reported to be dependent on the state of arousal 
or vigilance of the animals (McGinty and Harper, 1976 ; Trulson and Jacobs, 1979), which 
can in turn influence the rate of 5-HT synthesis (Hjorth and Magnusson, 1988). It is 
possible therefore that any factor/s that change the firing rate will produce an 
accompanying change in the rate of 5-HT synthesis. In the present study it was necessary 
to disturb the animals, from their normal sleep/wake cycle, for the administration of 
drugs. As a consequence, the animals in their active phase (dark phase) underwent 
handling and injections, while those in their rest phase (light phase) underwent the 
additional stress of being woken up, prior to handling and injection. Handling and injection 
are stressful stimuli which are reported to be associated with an increase in 5-HT release; 
handling (72% increase), tail pinch (48% increase) (Kalen et al., 1989). This increase in 
5-HT release is likely to result from a corresponding increase in the firing rate of their 5- 
HT neurones. In addition, the awakening of previously asleep animals is associated with an
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increase the firing rate of their 5-HT neurones (Trulson and Jacobs, 1979). it is likely 
that these unavoidable interferences caused a change of the rate of synthesis of 5-HT, in 
terminal containing regions. A higher level of change, in 5-HT synthesis, would be 
expected in animals that were at the mid-light point of their light : dark cycle, because the 
firing rate of their 5-HT neurones is generally low at this time (McGinty and Harper, 
1976). Furthermore, it is possible that the biochemical changes resulting from these 
interferences may have clouded the observation of a variation in somadendritic 5-HT 
autoreceptor sensitivity, which may exist under normal physiological conditions.
The somadendritic 5-HT autoreceptor is reported to be capable of undergoing 
desensitization following drug administration. This desensitization is not apparent in in 
vitro or in vivo electrophysiological studies, following acute administration of a 5-HT-j^ 
agonist, CM 57493 (Adrien et al., 1989), but can be produced by the long-term 
administration of gepirone (Blier and De Montigny, 1987). The firing rate of 5-HT 
neurones was depressed during the acute phase of the long-term administration of the 5-HT 
uptake inhibitors, indalpine or zimeldine (De Montigny et al., 1984), and also after 
gepirone (Blier and De Montigny, 1987), but recovered to normal levels after 14 days of 
their administration. This recovery of the firing rate, to normal levels, is likely to be 
caused by the desensitization of the somadendritic 5-HT autoreceptor (De Montigny et al., 
1984 ; Blier and De Montigny, 1987). However, the long term administration of 8-OH- 
DPAT was reported not to impair the ability of the somadendritic 5-HT autoreceptor to 
attenuate the synthesis of 5-HTP, in the rat hippocampus or hypothalamus (Larsson et al., 
1990); in support of this, the Kp and Bmax values of the 5 -H T ^ binding site in the medulla 
were unchanged. These findings are rather surprising, since this treatment would have 
been expected to produce a desensitization of the somadendritic 5-HT autoreceptor, but 
they add further credence to the idea that the measurement of 5-HTP synthesis, following 
5-HTP decarboxylase inhibition, gives a good indication of somadendritic 5-HT autoreceptor 
sensitivity.
The hyperphagic behavioural response in satiated rats is attributed to the selective 
activation of the somadendritic 5-HT autoreceptor, and exhibits rapid desensitization 
following the single, low dose injection of 8-OH-DPAT (Kennett et al., 1987). In addition, 
this hyperphagic response of 8-OH-DPAT is prevented by pretreatment with PCPA (Hutson
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et al., 1987), a treatment reported to cause desensitization of the somadendritic 5-HT 
autoreceptor (Chaput et al., 1987). However, a rapid desensitization of the 
somadendritic 5-HT autoreceptor is not observed in electrophysiologicai studies (Adrien 
et al., 1989). These authors proposed that the reduction in the hyperphagic response may 
depend on other mechanisms, rather than an adaptive change of the somadendritic 5-HT 
autoreceptor or that the autoreceptor involved in the behavioural effects of 5-HT-\ a 
agonists is different from that responsible for the inhibition of 5-HT neuronal firing. 
Furthermore, Sleight et al. (1988) demonstrated that 8-OH-DPAT was capable of 
producing both hyperphagia and hypophagia in freely feeding rats, depending on its time of 
administration. They attributed this mixed effect of 8-OH-DPAT to be caused by the 
existence of two distinct 5-HT systems modulating food intake, one mediating hyperphagia 
(central) and the other mediating hypophagia (peripheral).
In conclusion, it is clear that the somadendritic 5-HT autoreceptor, by its ability to 
modulate the firing rate of 5-HT neurones, regulates the synthesis and the release of 5-HT 
in terminal containing regions. The firing rate of these neurones and the release of 5-HT is 
greater during the dark phase, when the rats are more active. In addition, the rate of 5- 
HT synthesis is also at its highest during the dark phase. It is tempting to speculate that 
the greater 5-HT synthesis during the dark phase is caused by the higher firing rate at this 
time. The rate of 5-HT synthesis can be modulated partially by the firing rate and 
partially by local mechanisms (i.e. independent of 5-HT neuronal firing). The results 
presented in this study demonstrate that the sensitivity of the somadendritic 5-HT 
autoreceptor to 8-OH-DPAT, as measured by the ability of this compound to depress 5-HT 
synthesis, was the same at mid-dark and at mid-light. These findings suggest that factors 
other than any variation in the sensitivity of the somadendritic 5-HT autoreceptor are 
responsible for the observed circadian variation in the synthesis of 5-HT, although the 
sensitivity of the somadendritic 5-HT autoreceptor would have to be determined at several 
more time points before a definite conclusion could be drawn about any circadian changes in 
its sensitivity. Furthermore, these results imply that the changes observed in the firing 
rate of 5-HT neurones, during the light : dark cycle, are not caused by an altered 
sensitivity of the somadendritic 5-HT autoreceptor, however, it would be capable of 
passing on any fluctuations applied to it. Clearly, more studies are required to determine
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the underlying factors responsible for the firing rate of 5-HT neurones, and also for the 




The results presented in this thesis have already been extensively discussed in 
each of the relevant chapters. The purpose of this section is to provide general comment 
on the techniques used, and to suggest areas where further investigation would be 
particularly beneficial.
Biochemical techniques were employed in this thesis to determine the functional 
activity of 5-HT autoreceptors modulating the release and synthesis of 5-HT during the 12h 
light : 12h dark cycle.
From the results described in this thesis it can be concluded that the circadian 
variation in the release of 5-HT from central serotoninergic neurones, is not the result of a 
corresponding rhythm in the sensitivity of the terminal 5-HT-jq autoreceptor (rat), 
terminal 5-HT-jQ autoreceptor (guinea-pig) or the presynaptic a/p/?a2-adrenoceptor 
located on serotoninergic nerve terminals. In addition, the circadian rhythm in 5-HT 
synthesis is not derived from a corresponding rhythm in the sensitivity of the 
somadendritic 5 -H T ^  autoreceptor.
The superfusion technique employed in this thesis for the estimation of the 
sensitivity of receptors located on 5-HT terminals in regulating the release of 5-HT has a 
number of drawbacks. It primarily relies on the release of previously taken up [^H]5-HT 
as an indicator of the release of endogenous 5-HT, but it is not known how evenly this 
ligand mixes with the endogenous stores of 5-HT or if the release consists of [^H]5-HT. 
Furthermore, the method of stimulation used is rather unspecific in that the whole slice is 
stimulated, and not just the neurones containing 5-HT. This mode of stimulation is likely to 
cause the release not just of 5-HT but also of a host of other neurotransmitters, some of 
which may, by their receptors, or through other mechanism/s, be capable of regulating the 
release of 5-HT. It is likely therefore that the overall release of tritium evoked by this 
method of stimulation, and any drug-induced changes in the release rate, are the result of 
complex interactions between neurotransmitters. In addition, the use of an artificially 
high level of stimulation to evoke neurotransmitter release, when used in conjunction with 
a 5-HT uptake inhibitor, leads to an elevation in synaptic 5-HT concentrations. This
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condition is likely to cause a much greater (and prolonged) stimulation of the terminal 5-HT 
autoreceptor than would be expected under normal physiological conditions, and, probably 
accounts for the discrepancy between functional potencies obtained using this technique 
when compared with those of radio-ligand binding studies. Under such circumstances, it is 
not certain that all the systems usually operating to control the release of 
neurotransmitter are functioning normally. It is also possible that circadian variations 
that are important physiologically become obscured. For example, the in vivo release of 
5-HT is greater during the dark phase (Martin and Marsden, 1985 ; Kalen et al., 1989) but 
this variation was absent in the present in vitro studies. There is no way to control for 
all of these variables except by studying the 5-HT autoreceptor by a number of methods, 
each of which will have their own particular drawbacks.
The study of neurotransmitter release from synaptosomes is useful in that it 
allows the estimation of the sensitivity of the 5-HT autoreceptor in the absence of an 
endogenous inhibitory tone, but at the expense of the loss of structural integrity of the 
tissue. A more physiological technique, recently described (Blier et al., 1989b), uses a 
low frequency of stimulation to minimize feedback inhibition (see section 2.5), but it still 
relies on the measurement of the release of [3H]5-HT as an indicator of 5-HT release. A 
further advancement would be made if this technique could be applied to the measurement of 
the release of endogenous 5-HT.
In vitro superfusion techniques provide only a "snap shot” estimation of the 
receptor activity at one particular time point. It is possible that a rhythm could be missed 
if it was of a low amplitude or if the sampling times did not correspond to the zenith and 
nadir of its activity. A way of discounting this possibility would be to increase the number 
of sampling times during the light : dark cycle. However, this would still not be as good as 
a continuous in vivo technique which could provide information of the on-going changes in 
the activity of the terminal autoreceptor during the light : dark cycle. The development of 
such a technique is eagerly awaited.
The results of functional studies could not be correlated with those of radio-ligand 
binding studies because of the poor choice of displacing agent and also because the 5-HT^ g 
binding sites are located pre- and post-synaptically (Crino et al., 1990). The
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presynaptically located 5-HT-jb binding sites are considered to correspond to the terminal 
5-HT autoreceptor in the rat brain (Verge et al., 1986). These binding sites are likely to 
be present in small numbers, and this has hindered their quantification (Verge et al., 1985 
; Weissmann-Nanopoulos, 1985). In addition, an inherent limitation of radio-ligand binding 
studies is their inability to distinguish between functional and non-functional receptors. 
Furthermore, this technique would be incapable of detecting the decoupling of a receptor 
from its secondary messenger system. One possible approach to this problem would be to 
study the 5-HT receptor-stimulated secondary messenger system. However, this may 
pose a problem in brain regions which contain a mixed population of 5-HT receptor subtypes 
linked to the same secondary messenger system. The development of compounds with 
increased selectivity for the 5-HT^q and the 5-HT-jq autoreceptor will prove to be very 
useful in this respect. Experiments of this type will undoubtedly complement the results of 
this thesis, and shed further light on the mechanisms involved in the regulation of 5-HT 
release.
The rate of 5-HT synthesis in terminal containing regions is controlled partially by 
the firing rate of 5-HT neurones, and partially by local mechanism/s which become more 
prominent when the neuronal firing is impeded (i.e. following nerve transection) (Hjorth 
and Magnusson, 1988). The nature of these local mechanism/s controlling 5-HT synthesis 
is at present not known but it is thought that the terminal 5-HT autoreceptor may be 
involved, as is the case for the dopamine autoreceptor (Walters and Roth, 1976). Further 
studies in this area will serve to identify the factors that are able to control the rate of 5- 
HT synthesis, and of the mechanism/s involved. These studies, and many more, will serve 
to increase our understanding of the factors that are ultimately responsible for the 
circadian variation in 5-HT concentrations.
In the present study the sensitivity of the somadendritic 5-HT autoreceptor was 
assessed by its ability to modulate 5-HT synthesis, as a consequence of its effect on 
neuronal firing. A far superior, and probably more accurate method of estimating the in 
vivo sensitivity of this receptor would be to monitor directly the effect of the 
microiontophoretic application of compounds on the firing rate of 5-HT neurones, during the 
light : dark cycle. This method would also bypass any fluctuations which may be caused by
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diurnal differences in the pharmacokinetic handling of the compounds.
It would also be of interest to determine the factors that are responsible for 
initiating and controlling the firing rate of 5-HT neurones, since the firing rate is likely to 
be the major determinant of the release of 5-HT in terminal containing regions. It would be 
interesting to correlate the in vivo firing rate of 5-HT neurones with the simultaneous 
measurement of the reiease of 5-HT by microdialysis in terminal containing regions, during 
the light : dark cycle. However, an inherent problem with microdialysis is its poor 
recovery of neurotransmitters; as a consequence sampling times are long, and this would 
be expected to even out any circadian variations. A way around this problem would be to 
monitor extracellular 5-HT concentrations using in vivo voltammetry (Crespi et al., 
1988). This technique will provide for shorter sampling times and continuous recording, 
thus enabling better correlations of neurotransmitter release with on-going behaviour.
As reported here, many of the components involved in the synthesis of 5-HT 
display a variation in their function, during the light : dark cycle. In addition, the 
behavioural effects of 5-HT receptor stimulation also display a circadian variation. From 
the available evidence it is possible to propound a hypothesis to explain how the various 
components of 5-HT neuronal firing, release and synthesis interact to produce the circadian 
variation in 5-HT concentrations.
The circadian variation in the release of 5-HT can be explained by the 
corresponding variation in the firing rate of 5-HT neurones, both are greater during the 
dark phase. However, a similar relationship between the firing rate and the circadian 
variation in 5-HT concentrations in terminal containing regions is not so readily apparent. 
The firing rate of 5-HT neurones can modulate the rate of 5-HT synthesis. In addition, 5- 
HT synthesis can occur independently of the firing rate of 5-HT neurones, and is probably 
controlled by local mechanisms. It is tempting to speculate that the higher firing rate of 
5-HT neurones, during the dark phase, may be responsible for stimulating the "firing- 
dependent" component of 5-HT synthesis, while the lower firing rates observed during the 
light phase would produce a comparatively smaller rise in the rate of 5-HT synthesis. In 
contrast, the Tiring-insensitive” component of 5-HT synthesis would proceed at a steady 
pace during the light : dark cycle. These two components of 5-HT synthesis are probably
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additive, therefore it is possible that any changes observed in the 5-HT synthesis rate are 
the direct result of a variation in the "firing-sensitive" component. In support of a greater 
rate of 5-HT synthesis during the dark phase is the higher activity of tryptophan 
hydroxylase, higher brain concentrations of its precursor, tryptophan, and the observation 
that newly synthesized 5-HT is released preferentially to old. On this basis, the higher 
firing rate of 5-HT neurones during the dark phase accounts for the the greater release and 
synthesis of 5-HT. However, these parameters are 180° out of phase with 5-HT 
concentrations. It is possible that the lower firing rate and consequently the lower release 
rate observed during the light phase, enable the 5-HT synthesized by this "firing- 
insensitive" component to accumulate and thus account for the higher concentrations 
observed during the light phase.
This theory, like all theories, is based on the current knowledge in this area. It is 
hoped that this theory will stimulate further research, which will serve to modify and 
correct it.
In conclusion, the results presented in this thesis demonstrate that the circadian 
variation in the release and the synthesis of 5-HT is not due to an innate rhythm in the 
sensitivity of the terminal- or the somadendritic-5-HT autoreceptor respectively. In 
addition, there are as yet no suitable behavioural models for assessing the activity of the 
5-HT autoreceptor, but the development of such models in the future is likely to prove 
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